As confidentially submitted to the Securities and Exchange Commission on June 24, 2014
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Clearside Biomedical, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 45-2437375 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
1220 Old Alpharetta Road, Suite 300
Alpharetta, GA 30005
(678) 270-3631
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Daniel H. White
Chief Executive Officer
Clearside Biomedical, Inc.
1220 Old Alpharetta Road, Suite 300
Alpharetta, GA 30005
(678) 270-3631
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Brent B. Siler Darren K. DeStefano Brian F. Leaf Cooley LLP 11951 Freedom Drive Reston, VA 20190-5656 (703) 456-8000 |
Peter N. Handrinos Latham & Watkins LLP John Hancock Tower, 20th Floor 200 Clarendon Street Boston, MA 02116 (617) 948-6000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ¨
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ¨
CALCULATION OF REGISTRATION FEE
| ||||
Title of Securities being Registered | Proposed Maximum Aggregate Offering Price(1)(2) |
Amount of Registration Fee | ||
Common Stock, $0.001 par value per share |
$ | $ | ||
| ||||
|
(1) | In accordance with Rule 457(o) under the Securities Act of 1933, as amended, the number of shares being registered and the proposed maximum offering price per share are not included in this table. |
(2) | Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Includes offering price of additional shares that underwriters have the option to purchase. |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 under the Securities Exchange Act of 1934. (Check one):
Large Accelerated Filer ¨ |
Accelerated Filer ¨ | Non-accelerated Filer x | Smaller Reporting Company ¨ |
The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to Completion, dated June 24, 2014
Shares
COMMON STOCK
We are offering shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. We expect the initial public offering price to be between $ and $ per share.
We intend to apply to list our common stock on The NASDAQ Global Market under the symbol .
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, and will be subject to reduced public company reporting requirements.
Investing in our common stock involves a high degree of risk. See Risk Factors beginning on page 15.
PER SHARE | TOTAL | |||||||
Initial public offering price |
$ | $ | ||||||
Underwriting discount and commissions(1) |
$ | $ | ||||||
Proceeds, before expenses, to us |
$ | $ |
(1) | See Underwriting in this prospectus for a description of compensation payable to the underwriters. |
We have granted the underwriters an option to purchase up to additional shares of common stock, exercisable at any time until 30 days after the date of this prospectus. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $ and the total proceeds to us, before expenses, will be $ .
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares on or about , 2014.
RBC CAPITAL MARKETS | WELLS FARGO SECURITIES | |
NEEDHAM & COMPANY | OPPENHEIMER & CO. |
Prospectus dated , 2014
You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not authorized anyone to provide you with information that is different from that contained in such prospectuses. We are offering to sell shares of our common stock, and seeking offers to buy shares of our common stock, only in jurisdictions where such offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock.
Until and including , 2014, 25 days after the date of this prospectus, all dealers that buy, sell or trade our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions.
For investors outside of the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto and the information set forth under the sections Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations, in each case included in this prospectus. Unless the context otherwise requires, we use the terms Clearside, company, we, us and our in this prospectus to refer to Clearside Biomedical, Inc.
Overview of Clearside Biomedical
We are a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Our current product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space, or SCS, adjacent to the choroid, using our proprietary microinjector. With the SCS injection procedure, our product candidates are more directly administered to the retina and choroid as compared to currently used intravitreal injections, which we believe may provide a number of benefits, including lower frequency of necessary administration and faster onset of therapeutic effect. We hold the exclusive rights to develop and commercialize drugs for non-surgical administration into the SCS. Our most advanced product candidates, CLS-1001 and CLS-1003, are based on commonly used ophthalmic therapeutic agents, which we believe will allow us to more efficiently and predictably pursue the regulatory approval of these product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. CLS-1001, for macular edema associated with non-infectious uveitis, is in an ongoing Phase 1/2 clinical trial, from which we expect final results in the first half of 2015. We expect to be able to conduct a single pivotal Phase 3 clinical trial in approximately 150 patients beginning in the first half of 2015, the results of which we believe will be sufficient to support the filing of a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the first half of 2017. For CLS-1003, for macular edema associated with retinal vein occlusion, or RVO, we plan to initiate a Phase 2 clinical trial in the second half of 2014, with data expected in the second half of 2015. In our CLS-1002 program, for wet age-related macular degeneration, or wet AMD, we are evaluating drug compounds with anti-VEGF activity or dual anti-VEGF and anti-platelet-derived growth factor, or anti-PDGF, activity for SCS injection, and plan to file an investigational new drug application, or IND, by the end of 2015. We are also considering a development program for drug compounds to treat diabetic macular edema, or DME. We estimate that there are nearly five million people in the United States diagnosed with our target indications and that worldwide annual sales of drugs to treat these indications were approximately $6 billion in 2013.
Our current and planned development programs aim to restore or improve visual function primarily by reducing the macular edema associated with a number of diseases affecting the retina, the tissue that lines the inside of the eye and is the part of the eye primarily responsible for vision, and the choroid, the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. These diseases include uveitis, RVO, wet AMD and DME. Macular edema is the build-up of fluid that can cause abnormal swelling of the macula, the portion of the retina responsible for central vision and color perception. This swelling can rapidly result in deterioration of vision and can eventually lead to blindness.
1
The most common treatments for diseases of the retina and choroid are corticosteroids and drugs that inhibit vascular endothelial growth factor, or anti-VEGF drugs. These corticosteroids and anti-VEGF drugs are injected into the vitreous, a jelly-like substance that occupies the central portion of the eye. Intravitreal injections rely on drug to diffuse outward from the vitreous to the retina and choroid, which diffusion can result in lower concentrations of drug in these targeted areas. At the same time, this diffusion can result in drug spreading to unintended parts of the eye, where, for some drugs, it can cause significant side effects. By contrast, with our approach, drug is injected into and spreads within the SCS, which is the space located between the choroid and the outer protective layer of the eye known as the sclera, to reach the back of the eye. We believe SCS administration may provide improved bioavailability to the targeted retina and choroid, with drug remaining more localized and away from other parts of the eye, where the drug could cause side effects. Corticosteroids are effective both at treating the inflammation aspect of ocular disease and at reducing macular edema, but when delivered intravitreally, they have been associated with significant side effects, such as cataracts and elevated intraocular pressure, or IOP, which can lead to glaucoma. Anti-VEGF drugs, while highly effective in reducing macular edema, require frequent administration, in some cases as often as monthly. We believe that our differentiated approach of injecting ocular drugs into the SCS may result in fewer side effects and improved bioavailability of drug at the diseased retina and choroid, as compared to intravitreal administration, a faster onset of therapeutic effect, a similar efficacy profile with lower drug amounts required, and longer duration of therapeutic effect with less frequent required injections. The procedure for SCS injection with our microinjector is conducted in an in-office setting and is similar to the procedure for intravitreal injection, and we therefore expect that our products will be easily incorporated into retinal specialists standard medical practice.
We are developing CLS-1001 for the treatment of macular edema associated with non-infectious uveitis. CLS-1001 consists of an SCS injection of CLS-TA, our proprietary, preservative-free formulation of the corticosteroid triamcinolone acetonide, or TA, specifically designed to be administered through our SCS microinjector. We expect final results from our ongoing Phase 1/2 clinical trial with Triesence, a commonly used TA, in the first half of 2015, and we plan to initiate a Phase 2 clinical trial with CLS-TA in approximately 30 patients in the second half of 2014, with data expected in the first half of 2015. We also plan to initiate a single pivotal Phase 3 clinical trial in approximately 150 patients in the first half of 2015, with the goal of filing a Section 505(b)(2) NDA in the first half of 2017. Based on our discussions with the FDA, we believe we will be able to initiate our pivotal Phase 3 clinical trial of CLS-1001 before we have the final results from our planned Phase 2 clinical trial. We are developing CLS-1003 for the treatment of macular edema associated with RVO. CLS-1003 consists of an SCS injection of CLS-TA with our microinjector, for administration together with an intravitreal injection of an anti-VEGF drug. We plan to initiate a Phase 2 clinical trial in approximately 40 patients in the second half of 2014, with data expected in the second half of 2015. Under our CLS-1002 program, we are evaluating a number of compounds to develop as an SCS-injected therapy for the treatment of wet AMD, including compounds with anti-VEGF activity and compounds with dual anti-VEGF and anti-PDGF activity. We expect to select a lead drug candidate under this program for IND submission in 2015.
Our drug candidates, microinjector and method of non-surgical drug delivery into the SCS are protected by three issued U.S. patents and over 20 patent applications filed in the United States and major international markets. Our issued patents are broadly directed to methods of administering drugs of any type into the SCS by injection and are not scheduled to expire until between 2027 and 2029. Our patent applications relate to SCS delivery technology and methods, our current therapeutic drug candidates and
2
formulations, various therapeutic uses, including treatment of specific indications such as macular edema associated with non-infectious uveitis and RVO, as well as wet AMD and DME, and administration of specific classes of drugs to the SCS, including anti-inflammatory drugs and anti-VEGF drugs. Our pending patent applications are not projected to expire until between 2027 and 2034.
If our product candidates are approved, we plan to commercialize them with a specialty sales force of 30 to 40 representatives to target retinal specialists in the United States, and we may also pursue collaborations with third parties to commercialize any of our drugs approved for marketing outside the United States.
The members of our management team have held senior leadership positions at a number of pharmaceutical and biotechnology companies with approved ophthalmic drugs, including Alcon, Alimera Sciences, CIBA Vision and ISTA Pharmaceuticals. Members of our team have contributed to the development and commercialization of several retinal products, such as Triesence, Iluvien, Nevanac, Visudyne and Xibrom.
Anticipated Benefits from the Clearside Approach
We are developing drugs for back of the eye diseases to be administered to the retina and choroid through the SCS using our proprietary microinjector. We believe that our novel, patented approach of SCS drug administration provides a number of potential benefits, including:
| Improved bioavailability at the site of disease and faster onset of therapeutic effect. In preclinical studies, we observed higher amounts of drug present in the retina and choroid following SCS injection, as compared to the distribution of the same drug following intravitreal injection. We believe this suggests that SCS injection may have similar or better efficacy with a faster onset of therapeutic effect than intravitreal injection in diseases of the retina and choroid like uveitis, RVO, wet AMD and DME. |
| Similar efficacy profile with lower drug amounts required. In a preclinical study in a model of uveitis, SCS injection of TA achieved similar efficacy results with only 10% of the drug amount commonly administered through intravitreal injection. We believe this suggests our approach may allow us to develop ocular therapies with similar efficacy, but with lower amounts of active drug, compared to current therapies. |
| Less frequent injections. Current treatments for RVO require monthly intravitreal injections of anti-VEGF drugs, while current treatments for wet AMD require such injections as often as seven times per year. For RVO patients, we believe that a combination of a standard intravitreal injection of an anti-VEGF drug that addresses the vascular aspect of the disease, together with an SCS injection of CLS-TA, which addresses the inflammatory aspect of RVO, may have similar or better efficacy with a reduction in the frequency of required anti-VEGF treatments from 30 days to 90 days. In wet AMD, we believe that more direct application of drugs with anti-VEGF or dual anti-VEGF and anti-PDGF activity to the neovascularization in the choroid through SCS injection may block the process of additional new vascular growth within the choroid before the vessels break into the retina and create further damage through leakage. We believe that such SCS injection of treatment therefore has the potential to delay vision loss for a longer duration of time than the current standard intravitreal administration of anti-VEGF drugs and, accordingly, could require less frequent administration. |
3
| Enhanced safety profile. Intravitreal injections result in drugs diffusing throughout the eye, including into the lens, iris and ciliary body at the front of the eye, which for some drugs, has been associated with safety issues, such as cataracts and elevated IOP levels. Intravitreal administration of TA has been associated with cataracts and increases in IOP levels in 20% to 60% of patients. Because SCS injection of drugs appears to result in drug remaining localized in the retina and choroid without substantial diffusion to the vitreous or the front portion of the eye, we believe SCS injection has the potential to reduce the incidence of these side effects. Based on interim results from our ongoing Phase 1/2 clinical trial, none of the four patients for whom data is available have experienced cataracts, abnormally high levels of IOP or other treatment-related serious adverse events over the course of 16 to 26 weeks following a single SCS injection of TA. |
| Easily incorporated into standard medical practice. If approved, our drugs will be packaged together with our SCS microinjector for one-time use by retinal specialists in their offices. Our product candidates are designed to be administered using a procedure similar to that used for intravitreal injections, without the need for any capital equipment to be installed in the office. Accordingly, we expect our products, if approved, will be easily incorporated into retinal specialists standard medical practice. |
Strategy
Our goal is to be a leading biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and the retina. The key elements of our strategy are:
| Advancing CLS-1001 and CLS-1003 to FDA approval under the Section 505(b)(2) regulatory pathway. Our most advanced product candidates, CLS-1001 and CLS-1003, utilize CLS-TA, our proprietary formulation of TA, a corticosteroid that has been used for decades to treat ocular inflammatory conditions. We believe this approach will allow us to more efficiently and predictably pursue the regulatory approval of these product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. We plan to advance CLS-1001 into a single pivotal Phase 3 clinical trial for macular edema associated with non-infectious uveitis and, based on our discussions with the FDA, we expect this single trial to be sufficient to support a 505(b)(2) NDA filing. Our goal is to submit the 505(b)(2) NDA for CLS-1001 in the first half of 2017. Separately, we expect to initiate a Phase 2 clinical trial for CLS-1003 for macular edema associated with RVO in the second half of 2014, with data expected in the second half of 2015. |
| Maximizing the commercial potential of our product candidates. If either CLS-1001 or CLS-1003 is approved, we plan to build a specialized sales force of approximately 30 to 40 representatives to target the approximately 1,700 retinal specialists in the United States. We expect that this sales force would be able to effectively sell more than one of our products, in the event that multiple product candidates are approved for marketing. We have retained the worldwide commercialization rights to all of our product candidates, and we may pursue collaborations with third parties to commercialize any of our drugs approved for marketing outside the United States, either through territorial licenses or distributor relationships. |
4
| Developing therapies for other back of the eye diseases that can be treated more effectively with SCS injection. We believe that SCS injection of ocular therapies could have benefits in a variety of other back of the eye indications. Our initial areas of focus include: |
| Advancing our CLS-1002 wet AMD development program. We are investigating opportunities to improve the treatment of wet AMD through SCS injection of compounds that are commonly used for this disease, such as anti-VEGF drugs, or have shown clinical promise, such as anti-VEGF drugs in combination with anti-PDGF drugs. These therapies are commonly administered by intravitreal injection. We have completed an exploratory Phase 1 clinical trial using an anti-VEGF drug, Avastin, administered into the SCS, rather than intravitreally, in four patients with wet AMD, from which we observed encouraging safety and efficacy results. We are conducting preclinical studies evaluating other compounds with dual anti-VEGF and anti-PDGF activity, with the goal of selecting a lead drug candidate under this program for IND submission in 2015. |
| Developing a product candidate to treat DME. DME, like uveitis and RVO, is characterized by an inflammatory aspect. Once the data from the CLS-1003 Phase 2 clinical trial have been analyzed, we intend to initiate clinical trials to develop a product candidate to treat DME modeled after our approach for addressing macular edema associated with RVO. |
| Developing additional therapies through collaborations with third parties. We plan to explore collaborations with third parties to develop SCS-administered treatments for back of the eye diseases. These collaborations may take the form of in-licenses of the third parties drugs or drug candidates for our own development for SCS injection, or out-licenses for third parties to use our intellectual property covering SCS injection as part of the development of their own drugs. We are currently studying several compounds under a research collaboration with Santen Pharmaceutical Co., Ltd. |
| Maintaining and strengthening our intellectual property portfolio. Our intellectual property strategy aims to control the commercialization of SCS access, with patents and patent applications covering non-surgical SCS delivery methods, novel formulations of drugs, and microinjectors used to access the SCS. Our current patents and patent applications provide us with exclusivity in the United States and major international markets, and are not projected to expire until between 2027 and 2034. We will seek to broaden the scope of and increase the geographic reach of our patent protection throughout the world. |
5
Overview of our Product Candidates
The current development status of our product candidates is summarized in the chart below:
Development Program |
Indication |
Route of Administration and Active Ingredient |
Status and Upcoming Milestones | |||
CLS-1001 | Macular edema associated with non- |
SCS injection of CLS-TA | Final results from ongoing Phase 1/2 clinical trial with Triesence expected 1H 2015 Initiate ~30-patient Phase 2 clinical trial in 2H 2014 with CLS-TA, with data expected 1H 2015 Initiate ~150-patient single pivotal Phase 3 clinical trial in 1H 2015 with CLS-TA, with 505(b)(2) NDA filing expected 1H 2017
| |||
CLS-1003 |
Macular edema associated with RVO |
SCS injection of CLS-TA together with intravitreal injection of anti-VEGF compound
|
Initiate ~40-patient Phase 2 clinical trial in 2H 2014, with data expected 2H 2015 | |||
CLS-1002 |
Wet AMD | SCS injection of anti- VEGF compound or compound with dual anti-
|
Exploratory Phase 1 clinical trial with Avastin completed outside the U.S. Selection of lead drug candidate for IND submission expected in 2015 |
CLS-1001 Program Targeting Macular Edema Associated with Non-infectious Uveitis
The most common treatment for non-infectious uveitis, a condition characterized by inflammation of the choroid and surrounding tissues, involves the use of corticosteroids, such as TA. CLS-1001 consists of an SCS injection of CLS-TA with our microinjector. Under our CLS-1001 program, we are conducting a Phase 1/2 clinical trial in which we are evaluating the safety of SCS injection of Triesence, a TA formulation that is similar to CLS-TA and that has been approved by the FDA to treat non-infectious uveitis. While the trial is primarily a safety and tolerability study, we are also assessing efficacy measures. We intend to enroll approximately 10 patients in this trial. Interim data from the four patients for whom data is available indicate that SCS injection of the drug has generally been well tolerated, with none of the four patients having developed cataracts or experienced elevated IOP. The visual acuity of these four patients has improved by between five and 15 letters on a standard eye chart. Because CLS-1001 is based on our formulation of TA, and TA is known to be effective in treating uveitis, we believe that our product candidate will be at least as effective as commonly used formulations of TA in treating the disease, including the associated macular edema. Our preclinical studies suggest that SCS injection of TA may provide improved bioavailability of drug at the diseased retina and choroid, which may result in faster onset of therapeutic effect and a similar efficacy profile with lower drug amounts required. Our early clinical trial results suggest the potential for CLS-1001 to effectively treat uveitis for at least 90 days following a single SCS injection. Currently used ocular injections of TA are typically effective for approximately 90 days. In the second half of 2014, we plan to initiate a Phase 2 clinical trial in approximately 30 patients with macular edema associated with non-infectious uveitis to evaluate the safety and efficacy of our CLS-TA
6
administered into the SCS. In the first half of 2015, we also expect to initiate a single pivotal Phase 3 clinical trial with our CLS-TA administered into the SCS in approximately 150 patients with macular edema associated with non-infectious uveitis, with the goal of being able to submit an NDA to the FDA in the first half of 2017. Based on our discussions with the FDA, we believe this single pivotal clinical trial will be sufficient to support a 505(b)(2) NDA filing for CLS-1001 for macular edema associated with non-infectious uveitis. If approved, CLS-1001 would be the first drug specifically indicated for macular edema associated with non-infectious uveitis.
CLS-1003 Program Targeting Macular Edema Associated with Retinal Vein Occlusion
Under our CLS-1003 program, we are planning to initiate a Phase 2 clinical trial in the second half of 2014 in approximately 40 patients with macular edema associated with RVO, a sight-threatening disorder resulting from the blockage of a retinal vein. The current standard of care for RVO involves monthly intravitreal injections of an anti-VEGF drug, such as Lucentis (ranibizumab), Eylea (aflibercept) or Avastin (bevacizumab). Although studies have shown that corticosteroids effectively address the inflammatory aspect of RVO, they are not used as first-line therapy because they are not considered to be as effective as anti-VEGF drugs and also have an unattractive side effect profile when injected intravitreally. In our Phase 2 clinical trial, we will evaluate the safety and efficacy of the injection of our CLS-TA into the SCS together with Eylea injected into the vitreous, as compared to an intravitreal injection of Eylea alone. We believe that SCS administration of our CLS-TA, by addressing the inflammatory aspect of RVO, in combination with intravitreal anti-VEGF treatment, addressing the vascular aspect of RVO, may result in faster onset of therapeutic effect and may be able to improve visual acuity, compared to currently used intravitreal anti-VEGF treatment alone, while also potentially reducing the frequency of necessary anti-VEGF treatments from 30 days to 90 days. In addition, we believe that the side effect profile of CLS-1003
will be similar to that of current intravitreal anti-VEGF treatments alone, as SCS injections of CLS-TA should allow the corticosteroid to remain substantially localized in the retina and choroid without introducing the side effects that are commonly observed with other routes of administration of corticosteroids.
CLS-1002 Program Targeting Wet Age-Related Macular Degeneration
Under our CLS-1002 program, we are evaluating a number of compounds as potential therapies for the treatment of wet AMD by SCS injection, including compounds with anti-VEGF activity and compounds with dual anti-VEGF and anti-PDGF activity. Wet AMD is a condition involving the abnormal formation and growth of new blood vessels in the choroid, their intrusion into the outer layers of the retina and the leakage of blood and fluid into the retina. The current standard of care for the treatment of wet AMD is intravitreal injection of anti-VEGF drugs as a standalone therapy, as often as seven times per year. We have completed a Phase 1 clinical trial evaluating the safety and efficacy of SCS injection of Avastin, an anti-VEGF drug, in four patients with wet AMD. In this trial, SCS injection of Avastin was observed to be well tolerated, with no treatment-related serious adverse events. In addition, the four patients showed an average improvement in visual acuity of nine letters on a standard eye chart at the end of the eight-week post-treatment observation period. Two of the four patients showed an improvement in visual acuity of at least 13 letters. Because wet AMD manifests in the retina and choroid, we believe that SCS injection of drug more directly to the retina and choroid may result in faster onset of therapeutic effect as compared to intravitreal injection, and could reduce the necessary frequency of treatment to once every 90 days.
7
Future Potential Product Candidates
We believe that our SCS-focused approach has the potential to become more broadly used for the treatment of other back of the eye diseases, and we intend to develop additional product candidates for SCS injection based on the results of our current and planned clinical trials. In addition to uveitis, RVO and wet AMD, there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need for which SCS injection of therapy may be beneficial. These indications include DME, a common ocular complication of diabetes that results in swelling in the macula and is the primary cause of vision loss associated with diabetes, polypoidal choroidal vasculopathy, or PCV, a disorder resulting from the abnormal growth of new blood vessels in the choroid adjacent to the macula, and geographic atrophy, an advanced form of AMD.
Risks Associated with Our Business
Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are discussed more fully in the Risk Factors section of this prospectus. These risks include the following:
| We have incurred significant losses since our inception, expect to incur losses over the next several years and may never achieve or maintain profitability. |
| We are very early in our development efforts and none of our product candidates have completed a clinical trial. |
| Clinical drug development involves a lengthy and expensive process, with an uncertain outcome, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. |
| We rely, and expect to continue to rely, on third parties to conduct our clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. |
| If the FDA does not conclude that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements under Section 505(b)(2) are not as we expect, the approval pathway for our product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. |
| Our research and development efforts are focused on the development of product candidates for SCS administration, which is a novel approach and may fail to achieve and sustain market acceptance. |
| If we are unable to establish sales, marketing and distribution capabilities for our product candidates, we may not be successful in commercializing those product candidates, if and when they are approved. |
| If we are unable to obtain and maintain patent protection for our technology and product candidates, or if our licensors are unable to obtain and maintain patent protection for the technology or product candidates that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired. |
8
| An active trading market for our common stock may not develop and you may not be able to resell your shares of our common stock at or above the initial offering price, if at all. |
| We are an emerging growth company and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors. |
Corporate Information
We were incorporated under the laws of the State of Delaware in May 2011. Our principal executive offices are located at 1220 Old Alpharetta Road, Suite 300, Alpharetta, Georgia 30005 and our telephone number is (678) 270-3631. Our website address is www.clearsidebio.com. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.
We have proprietary rights to a number of trademarks used in this prospectus which are important to our business, including Clearside® and the Clearside logo. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.
Implications of Being an Emerging Growth Company
As a company with less than $1 billion in revenue during our last fiscal year, we qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from some of the reporting requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:
| being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced Managements Discussion and Analysis of Financial Condition and Results of Operations disclosure; |
| not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; |
| not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors report providing additional information about the audit and the financial statements; |
| reduced disclosure obligations regarding executive compensation; and |
| not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved. |
We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross
9
revenue of at least $1 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (2) the date on which we have issued more than $1 billion in non-convertible debt during the prior three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of some reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.
In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
10
THE OFFERING
Common stock offered by us |
shares |
Common stock to be outstanding immediately after this offering |
shares |
Option to purchase additional shares |
We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to additional shares of our common stock. |
Use of proceeds |
We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $ million, assuming the shares are offered at $ per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus. |
We anticipate that the majority of the net proceeds from this offering will be used to fund Phase 2 and Phase 3 clinical trials for CLS-1001, as well as a Phase 2 clinical trial for CLS-1003. The remaining proceeds will be used for further development of CLS-1003 and continued research and development of our earlier-stage programs, and for working capital and general corporate purposes. See Use of Proceeds for additional information. |
Risk factors |
You should read the Risk Factors section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. |
Proposed NASDAQ Global Market symbol |
The number of shares of our common stock that will be outstanding after this offering is based on 13,791,119 shares of common stock outstanding as of March 31, 2014, after giving effect to the automatic conversion of 9,555,757 shares of our convertible preferred stock outstanding as of March 31, 2014 and the exercise of warrants to purchase an aggregate of 248,175 shares of common stock that would otherwise expire upon the closing of this offering, and excludes:
| 1,657,159 shares of our common stock issuable upon the exercise of stock options outstanding under our 2011 stock incentive plan as of March 31, 2014, at a weighted average exercise price of $0.16 per share; |
| 16,550 shares of our common stock issuable upon exercise of a warrant outstanding as of March 31, 2014, at an exercise price of $1.81 per share; and |
| shares of our common stock reserved for future issuance under our equity incentive plans following this offering. |
11
Except as otherwise indicated herein, all information in this prospectus, including the number of shares that will be outstanding after this offering, assumes or gives effect to:
| -for- reverse stock split of our common stock expected to be completed prior to the completion of this offering; |
| the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 9,555,757 shares of our common stock, which will occur automatically upon the closing of this offering; |
| the exercise of all outstanding warrants to purchase shares of common stock that will otherwise expire upon the closing of this offering for an aggregate of 248,175 shares of common stock; |
| the conversion of an outstanding warrant to purchase shares of Series A-1 convertible preferred stock into a warrant to purchase 16,550 shares of common stock upon the closing of this offering; and |
| no exercise of the underwriters option to purchase additional shares of common stock. |
12
Summary Financial Data
In the tables below, we provide you with our summary financial data for the periods indicated. We have derived the following summary of our statement of operations data for the years ended December 31, 2012 and 2013 from our audited financial statements appearing elsewhere in this prospectus. We have derived the following summary of our statement of operations data for the three months ended March 31, 2013 and 2014 and for the period from May 26, 2011 (date of inception) through March 31, 2014 and our balance sheet data as of March 31, 2014 from our unaudited interim financial statements appearing elsewhere in this prospectus.
The financial data for the three months ended March 31, 2013 and 2014, for the period from May 26, 2011 (date of inception) through March 31, 2014 and as of March 31, 2014 includes, in the opinion of our management, all adjustments, consisting only of normal recurring adjustments that are necessary for a fair presentation of our financial position and results of operations for these periods. Our historical results are not necessarily indicative of the results to be expected in the future, and our operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the entire year ending December 31, 2014 or any other future period.
You should read this summary financial data together with the historical financial statements and related notes to those statements, as well as Managements Discussion and Analysis of Financial Condition and Results of Operations, which are included elsewhere in this prospectus.
Year Ended December 31, |
Three Months Ended March 31, |
Period From May 26, 2011 (Date of Inception) to March 31, 2014 |
||||||||||||||||||
2012 | 2013 | 2013 | 2014 | |||||||||||||||||
(in thousands, except share and per share data) | ||||||||||||||||||||
Statement of Operations Data: |
||||||||||||||||||||
Costs and expenses: |
||||||||||||||||||||
Research and development |
$ | 2,354 | $ | 5,045 | $ | 878 | $ | 1,250 | $ | 8,856 | ||||||||||
General and administrative |
1,575 | 2,193 | 465 | 520 | 4,429 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total costs and expenses |
3,929 | 7,238 | 1,343 | 1,770 | 13,285 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Loss from operations |
(3,929 | ) | (7,238 | ) | (1,343 | ) | (1,770 | ) | (13,285 | ) | ||||||||||
Other income (expense): |
||||||||||||||||||||
Interest expense |
(3 | ) | (23 | ) | (3 | ) | (5 | ) | (33 | ) | ||||||||||
Interest income |
1 | 7 | 3 | | 8 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total other expense |
(2 | ) | (16 | ) | | (5 | ) | (25 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (3,931 | ) | $ | (7,254 | ) | $ | (1,343 | ) | $ | (1,775 | ) | $ | (13,310 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net loss per share of common stock basic and diluted |
$ | (2.12 | ) | $ | (2.45 | ) | $ | (0.51 | ) | $ | (0.50 | ) | $ | (5.98 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Weighted average shares outstanding, basic and diluted |
1,853,423 | 2,956,285 | 2,620,868 | 3,559,263 | 2,224,229 | |||||||||||||||
Pro forma net loss per share basic and diluted |
$ | (0.58 | ) | $ | (0.14 | ) | ||||||||||||||
|
|
|
|
|||||||||||||||||
Pro forma weighted average shares outstanding basic and diluted |
12,512,042 | 13,115,020 |
13
The following table presents our summary balance sheet data:
| on an actual basis as of March 31, 2014; |
| on a pro forma basis to give effect to: |
| the conversion of all then outstanding shares of our convertible preferred stock into an aggregate of 9,555,757 shares of our common stock, which will occur automatically upon the closing of this offering; |
| our issuance of an aggregate of $3.0 million in 7% convertible promissory notes in April and May 2014; and |
| the exercise of all outstanding warrants to purchase shares of common stock that will otherwise expire upon the closing of this offering for an aggregate of 248,175 shares of common stock; and |
| on a pro forma as adjusted basis to give further effect to our sale of shares of common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. |
As of March 31, 2014 | ||||||||||||
Actual | Pro forma | Pro forma as adjusted |
||||||||||
(in thousands) | ||||||||||||
Balance Sheet Data: |
||||||||||||
Cash and cash equivalents |
$ | 525 | $ | $ | ||||||||
Total assets |
710 | |||||||||||
Total liabilities |
1,242 | |||||||||||
Total convertible preferred stock |
11,877 | |||||||||||
Total stockholders equity (deficit) |
(12,409 | ) |
The pro forma as adjusted information presented in the summary balance sheet data is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease each of cash and cash equivalents, total assets and total stockholders equity on a pro forma as adjusted basis by $ million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Similarly, each increase or decrease of 1.0 million shares offered by us at the assumed initial public offering price would increase or decrease each of cash and cash equivalents, total assets and total stockholders equity on a pro forma as adjusted basis by $ million.
14
Investing in our common stock involves a high degree of risk. Before you invest in our common stock, you should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this prospectus. Any of the following risks could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline, which would cause you to lose all or part of your investment. When determining whether to invest, you should also refer to the other information contained in this prospectus, including our financial statements and the related notes thereto.
Risks Related to Our Financial Position and Capital Needs
We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
Since our inception through March 31, 2014, we have incurred net losses of $13.3 million. We incurred net losses of $3.9 million, $7.3 million and $1.8 million for the years ended December 31, 2012 and 2013 and the three months ended March 31, 2014, respectively. As of March 31, 2014, we had a deficit accumulated during the development stage of $13.3 million. Through March 31, 2014, we had financed our operations to date with approximately $11.7 million of net cash proceeds raised in private placements of convertible preferred stock.
We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials. We are still in the early stages of development of our product candidates, and we have not completed development of any drugs. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:
| continue our ongoing Phase 1/2 clinical trial evaluating the safety of SCS administration of a commercially available formulation of TA with our microinjector, and initiate clinical trials using CLS-TA in our CLS-1001 and CLS-1003 drug programs; |
| continue the research and development of our other product candidates; |
| seek to discover and develop additional product candidates; |
| seek regulatory approvals for any product candidates that successfully complete clinical trials; |
| ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drugs for which we may obtain regulatory approval; |
| maintain, expand and protect our intellectual property portfolio; |
| hire additional clinical, manufacturing and scientific personnel; |
| add operational, financial and management information systems and personnel, including personnel to support our drug development and planned future commercialization efforts; and |
| incur additional legal, accounting and other expenses in operating as a public company. |
To become and remain profitable, we must succeed in developing and eventually commercializing drugs that generate significant revenue. This will require us to be successful in a range of challenging
15
activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval and manufacturing, marketing and selling any products for which we may obtain regulatory approval, as well as discovering and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.
Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.
Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations. A decline in our value could also cause you to lose all or part of your investment.
We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or altogether cease our drug development programs or commercialization efforts.
We believe that the net proceeds from this offering, together with our existing cash and cash equivalents as of March 31, 2014, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, we will need to obtain substantial additional funding in connection with our continuing operations. Our future capital requirements will depend on many factors, including:
| the progress and results of our planned Phase 2 and Phase 3 clinical trials, both for CLS-1001 and for CLS-1003; |
| the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates; |
| the number and development requirements of other product candidates that we may pursue; |
| the costs, timing and outcome of regulatory review of our product candidates; |
| the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; |
| the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; |
| the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and |
| the extent to which we acquire or in-license other product candidates and technologies. |
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our
16
product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts.
Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Our operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
We commenced active operations in 2012, and our operations to date have been largely focused on raising capital, identifying potential product candidates, broadening our expertise in the development of our product candidates and our microinjector, undertaking preclinical studies and conducting early clinical trials. We have not yet demonstrated an ability to successfully complete later-stage clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.
We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.
17
We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.
Risks Related to the Development of Our Product Candidates
Our research and development efforts are focused on the development of product candidates for SCS administration, which is a novel approach and may fail to achieve and sustain market acceptance.
Administering drugs into the SCS is a novel approach for ophthalmic therapies, and there is no guarantee this approach will be accepted by physicians, patients or third-party payors. We believe we are the first and only company developing drugs specifically for non-surgical SCS administration. The scientific evidence to support the feasibility of developing drugs based on this approach is both preliminary and limited. Although preclinical studies suggest that SCS administration of drugs, such as CLS-1001, may be effective at treating back of the eye diseases, to date no company has developed a drug for administration through the SCS that has received marketing approval.
Additionally, we have very limited clinical experience in SCS drug administration. Our most advanced clinical development program, CLS-1001 for the treatment of macular edema associated with non-infectious uveitis, is currently in a Phase 1/2 clinical trial in which we have dosed four patients to date with a commercially available formulation of the active ingredient in CLS-TA, only two of which have completed the 26 week post-treatment observation period. In addition to the preliminary data from the four patients in this trial, our only other human data involving SCS drug administration is from an exploratory Phase 1 clinical trial in four patients with wet AMD, which was conducted in Mexico without an IND from the FDA. To date, between these two trials, we have only dosed a total of eight humans using our proprietary SCS injection method. Therefore, we cannot guarantee that SCS administration of drugs will prove in clinical trials to be a safe or effective approach for treating back of the eye diseases in humans.
Even if we are able to achieve marketing approval for one of our product candidates, the novelty of SCS injection may make it difficult to demonstrate to physicians and third-party payors that SCS administration of our drugs is the appropriate approach for treating diseases such as non-infectious uveitis, RVO and wet AMD and is superior to the current standard of care. Further, if we are not successful in conveying to physicians, patients and third-party payors that the administration of our drug candidates with our proprietary microinjector improves patient outcomes, we may experience reluctance, or refusal, on the part of physicians to order and use, and third-party payors to cover and provide adequate payment for, our product candidates. Additionally, in some cases, our product candidates will complement the current standard of care, rather than serve as a replacement for the current standard of care. Therefore, we may encounter significant difficulty in gaining broad market acceptance by physicians, third-party payors and potential patients using CLS-1001, CLS-1003 and our other product candidates.
18
We are very early in our development efforts and none of our product candidates have completed a clinical trial. Our most advanced program, CLS-1001, is currently in a Phase 1/2 clinical trial. For our second program, CLS-1003, we plan to initiate our first clinical trial, a Phase 2 trial, in the second half of 2014. All of our other product candidates are still in preclinical development. If we are unable to commercialize our product candidates or if we experience significant delays in doing so, our business may be harmed.
We are very early in our development efforts. For our most advanced clinical development program, CLS-1001 for the treatment of macular edema associated with non-infectious uveitis, we are currently conducting a Phase 1/2 clinical trial in which we have dosed four patients to date with a commercially available formulation of the active ingredient in CLS-TA, only two of whom have completed the 26 week post-treatment observation period, and we plan to initiate a Phase 2 trial administering CLS-TA with our microinjector in the second half of 2014. For our second clinical development program, CLS-1003 for the treatment of macular edema associated with RVO, we also plan to initiate our first clinical trial administering CLS-TA to patients in the second half of 2014. In addition to the preliminary data from the four patients in our ongoing Phase 1/2 clinical trial, our only other human data is from an exploratory Phase 1 clinical trial conducted in Mexico without an IND from the FDA. Given our limited human experience with our clinical programs, the successful development of any of our product candidates is extremely uncertain, and we cannot guarantee that we will be successful in developing any of our product candidates.
We have not completed the development of any product candidates, we currently generate no revenues from sales of any products and we may never be able to develop a marketable product. We have invested substantially all of our efforts and financial resources in the development of our proprietary microinjector for SCS administration of drugs and the identification of potential drug candidates using that technology. Our ability to generate revenue from our product candidates, which we do not expect will occur for several years, if ever, will depend heavily on their successful development and eventual commercialization. The success of those product candidates will depend on several factors, including the following:
| successful completion of preclinical studies and requisite clinical trials; |
| receipt of marketing approvals from applicable regulatory authorities; |
| obtaining marketing approvals with labeling for sufficiently broad patient populations and indications, without unduly restrictive distribution limitations or safety warnings; |
| obtaining and maintaining patent, trademark and trade secret protection and regulatory exclusivity for our product candidates; |
| making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities; |
| launching commercial sales of products, if and when approved, whether alone or in collaboration with others; |
| successful training of physicians in the proper use of our microinjector to administer drugs into the SCS; |
| acceptance of the therapies and of the concept of SCS administration of drugs, if and when approved, by physicians, patients and third-party payors; |
| competing effectively with other therapies; |
| obtaining and maintaining healthcare coverage and adequate reimbursement; |
19
| protecting our rights in our intellectual property portfolio; and |
| maintaining a continued acceptable safety profile of the drugs and microinjector following approval. |
If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.
We have not yet dosed any patients using CLS-TA, our proprietary drug formulation of TA, for our two most advanced clinical programs.
To date, our clinical trial experience has involved the SCS injection of commercially available therapeutic agents. In our ongoing Phase 1/2 trial in our uveitis program, we are administering Triesence, a commercially available TA formulation, via SCS injection. However, in future clinical trials of our most advanced product candidates, including our planned Phase 2 clinical trials of CLS-1001 and CLS-1003, we intend to treat patients with CLS-TA, our proprietary drug formulation of TA. Although we have completed preclinical studies comparing CLS-TA to Triesence, we have never dosed this formulation in a human patient. Therefore, in addition to the risks associated with advancing our uveitis program from smaller scale to larger scale clinical trials and initiating our clinical trial program in RVO, there is also a risk that CLS-TA may have different pharmacokinetic or safety profiles in human subjects than the TA formulations that we have administered to date in animals. If CLS-TA does not exhibit similar safety and efficacy profiles to that of TA in humans, our ability to develop CLS-1001 and CLS-1003 may be harmed. Additionally, if the safety and efficacy profile of CLS-TA is not sufficiently comparable to that of previously commercialized TA formulations, we may be unable to rely on the Section 505(b)(2) regulatory approval pathway for CLS-1001 and CLS-1003, which would significantly lengthen our development process and the cost of developing and commercializing our product candidates.
The administration of CLS-1003 as a therapy together with anti-VEGF drugs for the treatment of macular edema associated with RVO is a novel approach and may fail to be successful.
We are developing our second drug program, CLS-1003, as a therapy to complement the current standard of care in the treatment of patients experiencing macular edema associated with RVO, with the goal of reducing current required monthly anti-vascular endothelial growth factor, or anti-VEGF, injections to quarterly injections. The scientific evidence to support the potential efficacy of this treatment approach is limited and based on third party clinical trials studying intravitreal injections of steroids in patients with RVO, which, although effective in reducing edema, has been associated with side effects. While our preliminary clinical trial experience involving the SCS injection of steroids suggest that these adverse side effects may be avoided using SCS injection, to date no company has explored this concomitant treatment approach in clinical trials or preclinical studies.
Even if we are able to successfully develop, and achieve marketing approval of, CLS-1003, it may be difficult to demonstrate to physicians and third-party payors that the administration of CLS-1003 concomitantly with anti-VEGF drugs, and the reduction in frequency of anti-VEGF treatments, is the appropriate approach for treating RVO and is superior to the current standard of care. Further, if we are not successful in conveying to physicians, patients and third-party payors that the administration of CLS-1003 concomitantly with anti-VEGF drugs improves patient outcomes, we may experience reluctance, or refusal, on the part of physicians to order and use, and third-party payors to pay for, CLS-1003. Therefore, we may encounter significant difficulty in gaining broad market acceptance by physicians, third-party payors and potential patients using CLS-1003.
20
We have recently finalized the design of our microinjector that we intend to utilize with any product candidate for which we ultimately seek marketing approval, but we do not yet have significant experience with this microinjector in humans.
To date, we have used a prototype of our microinjector in our preclinical studies and clinical trials, including in our ongoing Phase 1/2 clinical trial. However, we have recently completed the design of a modified microinjector that we intend to use in our planned pivotal Phase 3 clinical trial of CLS-1001 and, if successful, ultimately include in the NDA of any drug for which we seek marketing approval. We intend to use this design of our microinjector for the remainder of our ongoing Phase 1/2 clinical trial, but we have not yet dosed any patients using this design. Accordingly, in addition to the risks associated with drug development, we are also subject to the risks associated with developing the microinjector. For example, in our ongoing Phase 1/2 clinical trial, the needle of our prototype microinjector was not long enough to penetrate the scleras of two patients enrolled in the trial. If we encounter similar limitations with this design, or if it does not function properly in any way, we could be required to expend significant additional time and resources to redesign our microinjector, which would delay or compromise our drug development efforts. Additionally, our ability to successfully commercialize our product candidates will depend on retinal specialists being comfortable with the design and functionality of our microinjector. If, for any reason, retinal specialists were unsatisfied with the form or function of our microinjector, it would harm the market acceptance and potential commercial success of our product candidates, if any, that receive marketing approval.
We may not be successful in our efforts to build a pipeline of product candidates.
A key element of our strategy is to build a pipeline of product candidates for SCS administration and to progress these product candidates through clinical development for the treatment of a variety of diseases of the back of the eye. We may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have significant side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which could significantly harm our financial position and adversely affect our stock price.
Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
The risk of failure for our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. For example, the preliminary data obtained from our Phase 1/2 clinical trial for our CLS-1001 program is based on only four patients and might not be achieved in any other patients
21
treated with CLS-1001. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.
We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:
| regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; |
| we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; |
| clinical trials of our product candidates may produce negative or inconclusive results, including failure to demonstrate statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; |
| the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; |
| our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; |
| regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; |
| the cost of clinical trials of our product candidates may be greater than we anticipate; |
| the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and |
| our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials. |
If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:
| be delayed in obtaining marketing approval for our product candidates; |
| not obtain marketing approval at all; |
| obtain approval for indications or patient populations that are not as broad as intended or desired; |
| obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; |
| be subject to additional post-marketing testing requirements; or |
| have the product removed from the market after obtaining marketing approval. |
22
Our drug development costs may also increase if we experience delays in testing or marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. For example, our Phase 1/2 uveitis trial has been enrolling patients since July 2013, but has only treated four subjects to date. We have very little experience enrolling patients in our clinical trials, and cannot predict how successful we will be at enrolling patients in future clinical trials. If we are not successful at enrolling patients in one clinical trial, it may effect when we are able to initiate our next clinical trial, which could result in significant delays in our efforts to pursue regulatory approval of and commercialize our product candidates. In addition, some of our competitors have ongoing clinical trials to treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors. Patient enrollment is affected by other factors including:
| the severity of the disease under investigation; |
| the eligibility criteria for the study in question; |
| the perceived risks and benefits of the product candidate under study; |
| the availability of drugs approved to treat the diseases under study; |
| the efforts to facilitate timely enrollment in clinical trials; |
| the patient referral practices of physicians; |
| the ability to monitor patients adequately during and after treatment; and |
| the proximity and availability of clinical trial sites for prospective patients. |
Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which could cause our value to decline and limit our ability to obtain additional financing.
If serious adverse or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.
If our product candidates are associated with side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate.
23
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and management resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.
Risks Related to Our Dependence on Third Parties
We expect to rely on third parties to conduct our clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
We expect to engage clinical research organizations, or CROs, for our planned Phase 2 and Phase 3 clinical trials for CLS-1001 and CLS-1003. We also expect to engage CROs for any of our other product candidates that may progress to clinical development. We expect to rely on CROs, as well as other third parties, such as clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our drug development activities.
Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in FDA refusal to approve applications based on the clinical data, fines, adverse publicity and civil and criminal sanctions.
Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.
In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If
24
these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any new drug application, or NDA, we submit by the FDA. Any such delay or rejection could prevent us from commercializing CLS-1001, CLS-1003 or our other future product candidates.
We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.
We contract with third parties for the manufacture of CLS-TA and our microinjector for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of CLS-TA and our microinjector or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
We do not have any manufacturing facilities or personnel. We currently procure the active pharmaceutical ingredient in CLS-TA on a purchase order basis from a third-party manufacturer, and we anticipate entering into commercial supply agreements with this or another manufacturer at a later date. In addition, we obtain each of the components of our SCS microinjector on a purchase order basis from third-party suppliers. Some of our current suppliers are based outside of the United States. We expect to continue to rely on third parties as we proceed with preclinical and clinical testing using CLS-TA with our microinjector, as well as for commercial manufacture, if any of our product candidates receives marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of CLS-TA and our microinjector or such quantities at an acceptable cost or quality, which could delay, prevent or impair our ability to timely conduct our clinical trials or our other development or commercialization efforts.
We also expect to rely on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of any other product candidates for which we obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:
| reliance on the third party for regulatory compliance and quality assurance; |
| the possible breach of the manufacturing agreement by the third party; |
| the possible misappropriation of our proprietary information, including our trade secrets and know-how; and |
| the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. |
Our product candidates, including our proprietary drug formulations packaged together with our microinjector, are drug/device combination products that will be regulated under the drug regulations of the Federal Food, Drug, and Cosmetic Act, or FDCA, based on their primary mode of action as drugs. Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP,
25
regulations, regulations applicable to drug/device combination products, including applicable provisions of the FDAs drug cGMP regulations, device cGMP requirements embodied in the Quality System Regulation, or QSR, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates.
Our product candidates that we may develop may compete with other drugs and devices for access to manufacturing facilities. There are a limited number of manufacturers that operate under the drug and device cGMP regulations applicable to our product candidates and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance or our microinjector. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our drugs and the components of our microinjector, we may incur added costs and delays in identifying and qualifying any such replacement. For example, the FDA could require supplemental data if a new supplier is relied upon for the active pharmaceutical ingredient used in our products. Any interruption or delay in the supply of components and materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders.
Our current and anticipated future dependence upon others for the manufacture of our product candidates may compromise our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.
We may seek collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.
We may seek third-party collaborators for the development and commercialization of our product candidates, particularly for the commercialization of any of our product candidates that are approved for marketing outside the United States or for product candidates targeted at larger indications in the United States such as wet AMD and DME. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators abilities to successfully perform the functions assigned to them in these arrangements.
Collaborations involving our product candidates would pose the following risks to us:
| collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; |
| collaborators may not perform their obligations as expected; |
26
| collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; |
| collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; |
| collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized on terms that are more economically attractive than ours; |
| product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; |
| a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products; |
| disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; |
| collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation; |
| collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and |
| collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. |
Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.
If we are not able to establish collaborations, we may have to alter some of our future development and commercialization plans.
Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the future development and potential commercialization of those product candidates.
27
We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborators resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborators evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under existing license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.
We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.
Risks Related to the Commercialization of Our Product Candidates
If we are unable to establish sales, marketing and distribution capabilities for our product candidates, we may not be successful in commercializing those product candidates, if and when they are approved.
We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical drugs or medical devices. To achieve commercial success for any product candidate for which we may obtain marketing approval in the United States, we will need to establish a sales and marketing organization. In the future, we expect to build a focused sales and marketing infrastructure to target the approximately 1,700 retinal specialists in the United States for any of our product candidates that receive marketing approval. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.
Factors that may inhibit our efforts to commercialize our drugs on our own include:
| our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; |
28
| the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs; |
| the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage compared to companies with more extensive product lines; and |
| unforeseen costs and expenses associated with creating an independent sales and marketing organization. |
If we are unable to establish our own sales, marketing and distribution capabilities and, instead, enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to sell, market and distribute any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.
Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. SCS administration of drugs is a novel approach and physicians, patients or third-party payors may be hesitant to deviate from or change the current standard of care. If our product candidates do not achieve an adequate level of market acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:
| the efficacy and potential advantages compared to alternative treatments; |
| our ability to offer our drugs for sale at competitive prices; |
| the convenience and ease of administration compared to alternative treatments; |
| the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; |
| the willingness of the healthcare community and patients to adopt new technologies and our novel approach of SCS administration of drugs; |
| the willingness of retinal specialists to expend the time necessary to receive proper training on administering drugs into the SCS using our microinjector; |
| the ability to manufacture our product in sufficient quantities and yields; |
| the strength of marketing and distribution support; |
| the availability of third-party coverage and adequate reimbursement; |
| the prevalence and severity of any side effects; and |
| any restrictions on the use of our drugs together with other medications. |
29
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
The development and commercialization of new products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.
With respect to CLS-TA, we face competition from other commercially available forms of TA and other injectable and implantable corticosteroids. Bristol-Myers Squibb markets TA under the brand name Kenalog. Kenalog is indicated only for intramuscular or intraarticular injection, although it is commonly used off-label for intraocular inflammation. There are also a number of generic equivalents of Kenalog. In addition, Alcons injectable TA, Triesence, is approved in the United States for the treatment of uveitis and other inflammatory conditions unresponsive to topical corticosteroids, although it is not indicated for the treatment of macular edema associated with uveitis or RVO or for the treatment of DME. Ozurdex, marketed by Allergan, is a bioerodable extended release implant that delivers the corticosteroid dexamethasone and is approved for the treatment of macular edema following RVO and non-infectious uveitis in both the United States and in the European Union, and has been submitted to the FDA to treat DME. Bausch + Lomb markets Retisert, an intravitreal implant of the corticosteroid fluocinolone acetonide, for the treatment of non-infectious uveitis. Alimera Sciences is developing Iluvien, an injectable form of fluocinolone acetonide, as a therapy for DME in the United States. Iluvien has been approved in the European Union for the treatment of DME.
Our product candidates will also compete with anti-VEGF drugs, which are the current standard of care for RVO and wet AMD and have also been approved for DME. Genentechs products Lucentis and Avastin are both anti-VEGF antibodies. Lucentis is currently approved in the United States and European Union for the treatment of wet AMD and the treatment of macular edema following RVO. Lucentis is the only ophthalmic drug therapy approved to treat DME. Avastin is an anti-VEGF drug used by retinal specialists off-label in both the United States and in certain countries of the European Union in the treatment of numerous retinal diseases, but it is not indicated for ophthalmic use. Regenerons anti-VEGF product, Eylea, is approved for the treatment of wet AMD in the United States and in the European Union and has been submitted to the FDA for approval to treat DME and a form of RVO.
Ophthotechs drug candidate, Fovista, an anti-PDGF agent, is in Phase 3 clinical trials as a potential treatment for wet AMD to be administered together with an anti-VEGF drug. We are also aware of several other drug candidates in earlier stages of development as potential treatments for the diseases that we intend to target.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. For some of the indications that we are pursuing, drugs used off-label, such as Kenalog and Avastin, serve as a cheaper alternatives to our product candidates. Their lower prices could result in significant pricing pressure, even if our product candidates are otherwise viewed as a preferable therapy. Additional drugs may become available on a
30
generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.
Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Even if we are able to commercialize any product candidates, our product candidates may be subject to unfavorable pricing regulations, third-party coverage and reimbursement policies or healthcare reform initiatives.
Our ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and adequate reimbursement for our product candidates will be available from government payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers, managed care plans and other third-party payors. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medical products they will pay for and establish reimbursement levels. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs and products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Inadequate reimbursement levels may adversely affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our drugs may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement compared to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidates for which marketing approval is obtained.
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. By way of example, the Medicare Prescription Drug Improvement and Modernization Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for outpatient drug purchases by those covered by Medicare under a new Part D and introduced a new reimbursement methodology based on average sales prices for Medicare Part B physician-administered drugs, including drugs currently on the market used by physicians to treat the clinical indications for which we are currently seeking FDA approval and likely our product candidates, if approved. As a result of this legislation and the expansion of federal coverage of drug products, there is additional pressure to contain and reduce costs. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. These cost
31
reduction initiatives and other provisions of the MMA could decrease the coverage and reimbursement that we receive for any approved products, and could seriously harm our business.
Further, from time to time, typically on an annual basis, payment amounts are updated and revised by third-party payors. Because we expect that customers who use our product candidates, if approved, will be separately reimbursed for the procedure administering our products, these updates could directly impact the demand for our products. An example of payment updates is the Medicare program updates to physician payments, which is done on an annual basis using a prescribed statutory formula. In the past, when the application of the formula resulted in lower payment, Congress has passed interim legislation to prevent the reductions. Most recently, the Protecting Access to Medicare Act of 2014, signed into law in April 2014, provided for a 0.5% increase from 2013 payment rates under the Medicare Physician Fee Schedule through 2014 and a 0% increase from January 1 until April 1, 2015. If Congress fails to intervene to prevent the negative update factor in future years, the resulting decrease in payment may adversely affect our revenue and results of operations. In addition, the Medicare physician fee schedule has been adapted by some private payors into their plan-specific physician payment schedule. We cannot predict how pending and future healthcare legislation will impact our business, and any changes in coverage and reimbursement that further restricts coverage of our products or lowers reimbursement for procedures using our products could materially affect our business.
There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the product is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained at all. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved drugs that we develop could significantly harm our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition.
The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after
32
initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues able to be generated from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.
There can be no assurance that our product candidates, if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that third-party payors reimbursement policies will not adversely affect our ability to sell our product candidates profitably if they are approved for sale.
Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
| decreased demand for any product candidates or products that we may develop; |
| injury to our reputation and significant negative media attention; |
| withdrawal of clinical trial participants; |
| significant costs to defend the related litigation; |
| substantial monetary awards paid to trial participants or patients; |
| loss of revenue; |
| reduced resources of our management to pursue our business strategy; and |
| the inability to commercialize any drugs that we may develop. |
We currently hold $5.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $5.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.
33
Risks Related to Employee Matters and Managing Our Growth
Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
We are highly dependent on the management, research and development, clinical, financial and business development expertise of Daniel White, our Chief Executive Officer, Charlie Deignan, our Chief Financial Officer, and Glenn Noronha, our Executive Vice President of Research and Development, as well as the other members of our scientific and clinical teams. Although we intend to enter into new employment agreements with our executive officers that will be effective upon the closing of this offering, each of them may currently terminate their employment with us at any time and will continue to be able to do so after the closing of this offering. We do not maintain key person insurance for any of our executives or employees.
Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our product pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.
We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
As of March 31, 2014, we had 17 employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, drug development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.
34
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain patent protection for our technology and product candidates, or if our licensors are unable to obtain and maintain patent protection for the technology or product candidates that we license from them, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired.
Our success depends in large part on our and our licensors ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We and our licensors seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and product candidates.
The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. For example, we do not control the prosecution of the patent applications licensed to us under the Emory/GT License described below. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States or visa-versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.
Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and may also affect patent litigation. The United States Patent and Trademark Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16,
35
2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could significantly harm our business and financial condition. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our owned and licensed patents and patent applications.
Moreover, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.
Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, and may not be of sufficient scope or strength to provide us with any commercial advantage. Our competitors may be able to design around our owned or licensed patents by developing similar or alternative technologies or drugs without infringing on our intellectual property rights.
In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours, and our business will suffer.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patents claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which would undermine our competitive position.
36
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm business.
Our commercial success depends upon our ability, and the ability of any collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. In particular, we are focused on developing product candidates based on widely used therapeutic agents, many of which are protected by proprietary rights of third parties, and we are developing proprietary formulations of these therapeutic agents specifically for SCS administration using our proprietary microinjector. Although we seek to develop our proprietary drug formulations that dont infringe the intellectual property rights of others, we may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drugs or other aspects of our technology, including interference or derivation proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future.
If we are found to infringe a third partys intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our technology and drugs. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations.
Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit alleging our infringement of a competitors patent, we could be prevented from marketing our products in one or more foreign countries. As a result, our ability to grow our business and compete in the market may be harmed.
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could hurt the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.
37
If we fail to comply with our obligations under our existing intellectual property licenses with third parties, we could lose license rights that are important to our business.
We are a party to a license agreement with Emory University and Georgia Tech Research Corporation, or the Emory/GT License, and may enter into additional license agreements in the future. Our existing license agreement imposes, and we expect that future license agreements would impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, under the Emory/GT License, we are required to use commercially reasonable efforts to develop and commercialize licensed products under the agreement and to satisfy other specified obligations, including the payment of license fees and minimum royalty payments. If we fail to comply with our obligations under our license agreements, our licensors may have the right to terminate these license agreements, in which event we might not be able to market any product that is covered by these agreements, or to convert the license to a non-exclusive license, which could impair the value of the product candidate being developed under the license agreement. Termination of these license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms. If our licensors under the Emory/GT License were to terminate their license agreement with us for any reason, we would lose access to critical technology related to our microinjector.
We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed.
We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employees former employer. We may also in the future be subject to claims that we have caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these potential claims.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A court could prohibit us from using technologies or
38
features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and could be a distraction to management. In addition, any litigation or threat thereof may adversely affect our ability to hire employees or contract with independent service providers. Moreover, a loss of key personnel or their work product could hamper or prevent our ability to commercialize our products.
Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for our product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.
39
Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.
Our product candidates and the activities associated with their development and commercialization, including their design, research, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, export, and reporting of safety and other post-market information, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidates safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. If any of our product candidates receives marketing approval, the accompanying label may limit its approved use, which could limit sales of the product.
The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.
If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.
40
If the FDA does not conclude that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements under Section 505(b)(2) are not as we expect, the approval pathway for our product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.
We intend to seek FDA approval through the Section 505(b)(2) regulatory pathway for our product candidates, such as CLS-1001. Our product candidates, including our proprietary drug formulations packaged together with our microinjector, are drug/device combination products that will be regulated under the drug provisions of the FDCA, enabling us to submit NDAs for approval of our product candidates. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference.
If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for our product candidates, and complications and risks associated with our product candidates, would likely substantially increase. We may need to obtain additional funding, which could result in significant dilution to the ownership interests of our then existing stockholders to the extent we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain such additional financing on terms acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in competitive products reaching the market before our product candidates, which could impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure you that our product candidates will receive the requisite approvals for commercialization.
In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, some pharmaceutical companies and others have objected to the FDAs interpretation of Section 505(b)(2). If the FDAs interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its Section 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2).
Additional time may be required to obtain regulatory approval for our product candidates because they are combination products.
Our product candidates are drug/device combination products that require coordination within the FDA and similar foreign regulatory agencies for review of their device and drug components. Although the FDA and similar foreign regulatory agencies have systems in place for the review and approval of combination products such as ours, we may experience delays in the development and commercialization of our product candidates due to regulatory timing constraints and uncertainties in the product development and approval process.
41
Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.
In order to market and sell our products in the European Union and any other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, failure to obtain approval in one jurisdiction may impact our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.
A variety of risks associated with marketing our product candidates internationally could affect our business.
We may seek regulatory approval for our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:
| differing regulatory requirements in foreign countries; |
| the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally; |
| unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; |
| economic weakness, including inflation, or political instability in particular foreign economies and markets; |
| compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; |
| foreign taxes, including withholding of payroll taxes; |
| foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; |
| difficulties staffing and managing foreign operations; |
| workforce uncertainty in countries where labor unrest is more common than in the United States; |
| potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations; |
| challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; |
42
| production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and |
| business interruptions resulting from geo-political actions, including war and terrorism. |
These and other risks associated with our international operations may compromise our ability to achieve or maintain profitability.
Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.
Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy, which could involve requirements for, among other things, a medication guide, special training for prescribers and dispensers, and patient registries. If any of our product candidates receives marketing approval, the accompanying label may limit its approved uses, which could limit sales of the product.
The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of products to ensure products are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers communications regarding off-label use and if we do not market our drugs for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.
In addition, later discovery of previously unknown adverse events or other problems with our drugs, including device malfunctions, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have negative consequences, including:
| restrictions on such drugs, manufacturers or manufacturing processes; |
| restrictions on the labeling or marketing of a drug; |
| restrictions on drug distribution or use; |
| requirements to conduct post-marketing studies or clinical trials; |
| warning letters; |
| recall or withdrawal of the drugs from the market; |
| refusal to approve pending applications or supplements to approved applications that we submit; |
| clinical holds; |
43
| fines, restitution or disgorgement of profits or revenues; |
| suspension or withdrawal of marketing approvals; |
| refusal to permit the import or export of our drugs; |
| product seizure; or |
| injunctions or the imposition of civil or criminal penalties. |
Non-compliance with European Union requirements regarding safety monitoring, or pharmacovigilance, and with requirements related to the development of drugs for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Unions requirements regarding the protection of personal information can also lead to significant penalties and sanctions.
Even if we receive orphan drug designation for our most advanced product candidate, CLS-1001, we may not be able to obtain orphan drug marketing exclusivity for this product candidate or any of our future product candidates.
Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We have applied for orphan drug designation from the FDA, and intend to apply for orphan drug designation from the European Medicines Agency, or EMA, for CLS-1001 for the treatment of non-infectious uveitis, and we may seek orphan drug designation for our future drug candidates. However, we have not yet obtained orphan drug designation from either the FDA or the EMA, and there can be no assurance that we will receive this designation from either regulatory authority.
Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven years in the United States and 10 years in the European Union. The European Union exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Even if we obtain orphan drug exclusivity for CLS-1001, that exclusivity may not effectively protect the drug candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.
Our employees, independent contractors, principal investigators, CROs, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, CROs, consultants, commercial partners and
44
vendors, could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. In addition, federal procurement laws impose substantial penalties for misconduct in connection with government contracts and require certain contractors to maintain a code of business ethics and conduct. It is not always possible to identify and deter employee and independent contractor misconduct, and any precautions we take to detect and prevent improper activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.
Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to penalties.
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws that may affect our ability to operate include the following:
| the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid; |
45
| federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; |
| the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent; |
| the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; |
| HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; |
| the federal Open Payments program, created under Section 6002 of Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations, imposed new annual reporting requirements for manufacturers of drugs, devices, biologicals and medical supplies for certain payments and transfers of value provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1.0 million per year for knowing failures. Applicable manufacturers were required to begin collecting data on August 1, 2013 and submit reports on aggregate payment data to the government for the first reporting period by March 31, 2014, and will be required to report detailed payment data for the first reporting period and submit legal attestation to the completeness and accuracy of such data during Phase 2 of the program, which began on June 1, 2014 and will extend until June 30, 2014. Thereafter, manufacturers must submit reports by the 90th day of each subsequent calendar year. CMS will release the data on a public website by September 30, 2014; and |
46
| analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industrys voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. |
Further, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.
Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could significantly harm our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also affect our business.
Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.
Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, President Obama signed into law the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.
47
Among the provisions of the ACA of importance to our potential product candidates are the following:
| an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; |
| a 2.3% medical device excise tax on certain transactions, including many U.S. sales of medical devices, which currently includes, and we expect will continue to include, U.S. sales of drug and device combination products; |
| an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; |
| expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance; |
| addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; |
| a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers outpatient drugs to be covered under Medicare Part D; |
| extension of manufacturers Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; |
| expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing manufacturers Medicaid rebate liability; |
| expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; |
| the new requirements under the federal Open Payments program and its implementing regulations; |
| a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and |
| a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. |
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will stay in effect through 2024 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could negatively impact customers for our product candidates, if approved, and, accordingly, our financial operations.
48
We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDAs approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.
Governments outside the United States tend to impose strict price controls, which may affect our revenue, if any.
In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.
Although we maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
49
Risks Related to this Offering, Ownership of Our Common Stock and Our Status as a Public Company
An active trading market for our common stock may not develop and you may not be able to resell your shares of our common stock at or above the initial offering price, if at all.
Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be determined through negotiations with the underwriters and may not be indicative of the price at which our common stock will trade upon completion of this offering. Although we intend to apply to list our common stock on The NASDAQ Global Market, an active trading market for our shares may never develop or be sustained following this offering. If an active market for our common stock does not develop or is not sustained, it may be difficult for you to sell shares you purchased in this offering at an attractive price or at all.
The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.
Our stock price may be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:
| actual or anticipated variations in our operating results; |
| changes in financial estimates by us or by any securities analysts who might cover our stock; |
| conditions or trends in our industry; |
| stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry; |
| announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; |
| announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; |
| capital commitments; |
| investors general perception of us and our business; |
| recruitment or departure of key personnel; and |
| sales of our common stock, including sales by our directors and officers or specific stockholders. |
In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert managements attention and resources from our business.
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. We do not currently have and may never obtain
50
research coverage by equity research analysts. Equity research analysts may elect not to provide research coverage of our common stock after the completion of this offering, and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.
If you purchase shares of our common stock in this offering, you will suffer immediate dilution of your investment.
We expect the initial public offering price of our common stock to be substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value per share after this offering. Based on an assumed initial public offering price of $ per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $ per share, representing the difference between our pro forma as adjusted net tangible book value per share after this offering and the assumed initial public offering price. After this offering, we will also have outstanding options and warrants to purchase common stock with exercise prices lower than the initial public offering price. To the extent these outstanding options and warrants are exercised, there will be further dilution to investors in this offering.
A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market following this offering, the market price of our common stock could decline significantly.
Upon completion of this offering, we will have outstanding shares of common stock, assuming no exercise of outstanding options or warrants. Of these shares, the shares sold in this offering and additional shares will be freely tradable, additional shares of common stock will be eligible for sale in the public market beginning 90 days after the date of this prospectus under Rule 144 and Rule 701, and additional shares of common stock will be available for sale in the public market beginning 180 days after the date of this prospectus following the expiration of lock-up agreements between some of our stockholders and the underwriters. The representatives of the underwriters may release these stockholders from their lock-up agreements with the underwriters at any time and without notice, which would allow for earlier sales of shares in the public market.
In addition, promptly following the completion of this offering, we intend to file one or more registration statements on Form S-8 registering the issuance of approximately shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements on Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options, the lock-up agreements described above and, in the case of our affiliates, the restrictions of Rule 144.
51
Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result.
There are provisions in our certificate of incorporation and bylaws as they will be in effect following this offering that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors will have the authority to issue up to shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.
Our charter documents will also contain other provisions that could have an anti-takeover effect, including:
| only one of our three classes of directors will be elected each year; |
| stockholders will not be entitled to remove directors other than by a 66 2⁄3% vote and only for cause; |
| stockholders will not be permitted to take actions by written consent; |
| stockholders cannot call a special meeting of stockholders; and |
| stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings. |
In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.
Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.
Upon completion of this offering, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates will, in the aggregate, beneficially own approximately % of our outstanding common stock. As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions.
Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the price at which shares are being sold in this offering and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders.
52
We are an emerging growth company and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.
We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:
| being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced Managements Discussion and Analysis of Financial Condition and Results of Operations disclosure; |
| not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; |
| not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors report providing additional information about the audit and the financial statements; |
| reduced disclosure obligations regarding executive compensation; and |
| not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. |
We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.
Under Section 107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
After the completion of this offering, we will be subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act and the rules and regulations of The NASDAQ Stock Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Commencing with our fiscal year ending December 31, 2015, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Form 10-K filing for that year, as required by Section 404 of the Sarbanes-
53
Oxley Act. This will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. Prior to this offering, we have never been required to test our internal controls within a specified period, and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.
We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.
If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by The NASDAQ Stock Market, the Securities and Exchange Commission or other regulatory authorities.
We will have broad discretion in the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.
We will have broad discretion over the use of proceeds from this offering. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. We expect to use the net proceeds to us from this offering to advance the development of CLS-1001 into Phase 2 and Phase 3 clinical trials and CLS-1003 into a Phase 2 clinical trial, to fund the research and development of our earlier-stage programs, including drug discovery, and for working capital and general corporate purposes. Our failure to apply the net proceeds of this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering.
Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.
You should not rely on an investment in our common stock to provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock.
54
We plan to use potential future operating losses and our federal and state NOL carryforwards to offset future taxable income, if any. However, our ability to use existing NOL carryforwards could be limited as a result of issuances of equity securities.
As of December 31, 2013, we had approximately $10.4 million of federal and $12.4 million of state net operating loss, or NOL, carryforwards. If not utilized, these federal NOL carryforwards will begin to expire at various dates beginning in 2031, and these state NOL carryforwards will begin to expire at various dates beginning in 2027. To the extent we generate taxable income in the future, we plan to use our existing NOL carryforwards and future losses to offset income that would otherwise be taxable. However, under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, as interpreted by the U.S. Internal Revenue Service, the amount of benefits from our NOL carryforwards may be impaired or limited if we incur a cumulative ownership change of more than 50% over a three-year period. The completion of this offering, private placements and other transactions that have occurred, and future offerings of our securities may trigger, or may have already triggered, such an ownership change. In addition, since we will need to raise substantial additional funding to finance our operations, we may undergo further ownership changes in the future. We have not conducted an analysis as to whether such a change of ownership has occurred, but if such a change has occurred or occurs in the future, we will be limited regarding the amount of NOL carryforwards that can be utilized annually in the future to offset taxable income. Any such annual limitation may significantly reduce the value of our NOL carryforwards before they expire, which could result in greater tax liabilities than we would incur in the absence of such a limitation.
We will incur increased costs and demands upon management as a result of being a public company.
As a public company listed in the United States, we will incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and The NASDAQ Stock Market, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of managements time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.
Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.
55
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA
This prospectus contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the sections entitled Prospectus Summary, Risk Factors, Managements Discussion and Analysis of Financial Condition and Results of Operations and Business, but are also contained elsewhere in this prospectus. In some cases, you can identify forward-looking statements by the words may, might, will, could, would, should, expect, intend, plan, objective, anticipate, believe, estimate, predict, project, potential, continue and ongoing, or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about:
| our plans to develop and commercialize our product candidates; |
| our planned clinical trials for CLS-1001 and CLS-1003; |
| the timing of the availability of data from our clinical trials; |
| the timing of our selection of a lead drug candidate for our CLS-1002 program; |
| the timing of our planned regulatory filings; |
| the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; |
| our expectation that CLS-1001, if approved, would be the first drug specifically indicated for macular edema associated with non-infectious uveitis; |
| the clinical utility of our product candidates; |
| our commercialization, marketing and manufacturing capabilities and strategy; |
| our intellectual property position; |
| our ability to identify additional drug candidates with significant commercial potential that are compatible with SCS administration and which are consistent with our commercial objectives; and |
| our estimates regarding future revenues, expenses and needs for additional financing. |
You should refer to the Risk Factors section of this prospectus for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
56
This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
57
We estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be approximately $ million, or approximately $ million if the underwriters exercise their option to purchase additional shares in full, based upon an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease the net proceeds to us from this offering by $ million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0 million in the number of shares we are offering at the assumed initial public offering price would increase or decrease the net proceeds to us from this offering by $ million.
We currently estimate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:
| approximately $ million to complete our planned Phase 2 and Phase 3 clinical trials of CLS-1001 in uveitis patients; |
| approximately $ million to complete our planned Phase 2 clinical trial of CLS-1003 in RVO patients; and |
| the remainder to fund further development of CLS-1003 and continued research and development of our earlier-stage programs, including drug discovery for potential new applications for our SCS microinjection technology, and for working capital and other general corporate purposes. |
In the ordinary course of our business, we expect to from time to time evaluate the acquisition of, investment in or in-license of complementary products, technologies or businesses, and we could use a portion of the net proceeds from this offering for such activities. We currently do not have any agreements, arrangements or commitments with respect to any potential acquisition, investment or license.
This expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status of and results from clinical trials, as well as any collaborations that we may enter into with third parties for our product candidates, and any unforeseen cash needs.
Our management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds of this offering. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending these uses, we plan to invest these net proceeds in short-term, interest bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the United States. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are readily available to fund our operations.
58
We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.
59
The following table sets forth our cash and cash equivalents and our capitalization as of March 31, 2014:
| on an actual basis; |
| on a pro forma basis to give effect to: |
| the conversion of all then outstanding shares of our convertible preferred stock into an aggregate of 9,555,757 shares of our common stock, which will occur automatically upon the closing of this offering, and the filing of our amended and restated certificate of incorporation upon the closing of this offering; |
| our issuance of an aggregate of $3.0 million in 7% convertible promissory notes in April and May 2014; and |
| the exercise of all outstanding warrants to purchase shares of common stock that will otherwise expire upon the closing of this offering for an aggregate of 248,175 shares of common stock; and |
| on a pro forma as adjusted basis to give further effect to our sale of shares of common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. |
60
The following information is illustrative only of our cash and cash equivalents and capitalization following the completion of this offering and will change based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this table together with Managements Discussion and Analysis of Financial Condition and Results of Operations and our financial statements and the related notes appearing elsewhere in this prospectus.
As of March 31, 2014 | ||||||||||||
Actual | Pro forma | Pro forma as adjusted |
||||||||||
(in thousands) | ||||||||||||
Cash and cash equivalents |
$ | 525 | $ | $ | ||||||||
|
|
|
|
|
|
|||||||
Long-term debt, including current portion |
$ | 268 | $ | $ | ||||||||
Convertible promissory notes |
| |||||||||||
Convertible preferred stock: |
||||||||||||
Series A convertible preferred stock, $0.001 par value; 5,200,000 shares authorized, 5,198,826 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted |
4,043 | |||||||||||
Series A-1 convertible preferred stock, $0.001 par value; 4,800,000 shares authorized, 4,356,931 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted |
7,834 | |||||||||||
Stockholders equity (deficit): |
||||||||||||
Common stock, $0.001 par value; 17,000,000 shares authorized, 3,704,569 shares issued and outstanding, actual; shares authorized, shares issued and outstanding, pro forma; shares authorized, shares issued and outstanding, pro forma as adjusted |
3 | |||||||||||
Preferred stock, $0.001 par value; no shares authorized, issued or outstanding, actual; shares authorized, no shares issued or outstanding, pro forma or pro forma as adjusted |
| |||||||||||
Additional paid-in-capital |
898 | |||||||||||
Deficit accumulated during the development stage |
(13,310 | ) | ||||||||||
|
|
|
|
|
|
|||||||
Total stockholders equity (deficit) |
(12,409 | ) | ||||||||||
|
|
|
|
|
|
|||||||
Total capitalization |
$ | (264 | ) | $ | $ | |||||||
|
|
|
|
|
|
Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total stockholders equity and total capitalization by $ million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Each increase or decrease of 1.0 million in the number of shares we are offering at the assumed initial public offering price would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total stockholders equity and total capitalization by $ million.
61
The number of shares of common stock outstanding in the table above does not include:
| 1,657,159 shares of our common stock issuable upon the exercise of stock options outstanding under our 2011 stock incentive plan as of March 31, 2014, at a weighted average exercise price of $0.16 per share; |
| 16,550 shares of our common stock issuable upon exercise of a warrant outstanding as of March 31, 2014, at an exercise price of $1.81 per share; and |
| shares of our common stock reserved for future issuance under our equity incentive plans following this offering. |
62
If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. Net tangible book value per share is determined by dividing our total tangible assets less total liabilities and convertible preferred stock by the number of outstanding shares of our common stock.
As of March 31, 2014, we had a net tangible book deficit of $(12.4) million, or $(3.11) per share of common stock. On a pro forma basis, after giving effect to the conversion of the outstanding shares of our convertible preferred stock into 9,555,757 shares of our common stock upon the completion of this offering, the issuance by us of an aggregate of $3.0 million in 7% convertible promissory notes in April and May 2014, and the exercise of all outstanding warrants to purchase shares of common stock that will otherwise expire upon the closing of this offering for 248,175 shares of common stock, our pro forma net tangible book value would have been $ million, or $ per share of common stock.
After giving effect to the issuance and sale of shares of our common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of March 31, 2014 would have been $ million, or $ per share of common stock. This represents an immediate increase in the pro forma net tangible book value of $ per share to existing stockholders, and an immediate dilution in the pro forma net tangible book value of $ per share to investors purchasing shares of our common stock in this offering. The following table illustrates this per share dilution:
Assumed initial public offering price per share |
$ | |||||||
Actual net tangible book deficit per share as of March 31, 2014 |
$ | (3.11 | ) | |||||
Increase per share attributable to assumed conversion of convertible preferred stock, issuance of convertible promissory notes and exercise of warrants |
||||||||
|
|
|||||||
Pro forma net tangible book value per share before this offering |
||||||||
Increase in pro forma net tangible book value per share attributable to this offering |
||||||||
|
|
|||||||
Pro forma as adjusted net tangible book value per share after this offering |
||||||||
|
|
|||||||
Dilution per share to investors participating in this offering |
$ | |||||||
|
|
The dilution information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease our pro forma as adjusted net tangible book value by $ million, or $ per share, and the dilution per share to investors participating in this offering by $ per share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. Each increase or decrease of 1.0 million shares in the number of shares offered by us at the assumed initial public offering price would increase or decrease our pro forma as adjusted net tangible book value per share after this offering by $ per share and decrease or increase the dilution to investors participating in this offering by $ per share.
63
If the underwriters exercise their option in full to purchase additional shares of common stock in this offering, the pro forma as adjusted net tangible book value per share after the offering would be $ per share, the increase in the pro forma net tangible book value per share to existing stockholders would be $ per share and the dilution to new investors purchasing common stock in this offering would be $ per share.
The following table sets forth as of March 31, 2014, on the pro forma basis described above, the differences between the number of shares of common stock purchased from us, the total consideration paid and the weighted average price per share paid by existing stockholders and by investors purchasing shares of our common stock in this offering at an assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page on this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us:
Shares purchased | Total consideration | Weighted average price per share |
||||||||||||||||
Number | Percent | Amount | Percent | |||||||||||||||
Existing stockholders |
% | $ | % | $ | ||||||||||||||
New investors |
||||||||||||||||||
|
|
|
|
|
|
|
||||||||||||
Total |
100 | % | $ | 100 | % | |||||||||||||
|
|
|
|
|
|
|
Each $1.00 increase or decrease in the assumed initial public offering price of $ per share, which is the midpoint of the range set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $ million, and increase or decrease the percent of total consideration paid by new investors by percentage points, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same.
The table above also excludes:
| 1,657,159 shares of our common stock issuable upon the exercise of stock options outstanding under our 2011 stock incentive plan as of March 31, 2014, at a weighted average exercise price of $0.16 per share; |
| 16,550 shares of our common stock issuable upon exercise of a warrant outstanding as of March 31, 2014, at an exercise price of $1.81 per share; and |
| shares of our common stock reserved for future issuance under our equity incentive plans following this offering. |
The shares of our common stock reserved for future issuance under our equity benefit plans may be subject to automatic annual increases in accordance with the terms of the plans. To the extent that options or warrants are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.
64
The following tables set forth our selected financial data for the periods indicated. The following selected statement of operations data for the years ended December 31, 2012 and 2013 and the selected balance sheet data as of December 31, 2012 and 2013 are derived from our audited financial statements appearing elsewhere in this prospectus. The selected statement of operations data for the three-month periods ended March 31, 2013 and 2014 and for the period from May 26, 2011 (date of inception) through March 31, 2014 and the selected balance sheet data as of March 31, 2014 are derived from unaudited condensed financial statements appearing elsewhere in this prospectus. The data should be read together with Managements Discussion and Analysis of Financial Condition and Results of Operations and in conjunction with the financial statements, related notes, and other financial information included elsewhere in this prospectus.
The unaudited condensed financial statements include all adjustments, consisting of normal recurring accruals, which management considers necessary for a fair presentation of the financial position and the results of operations for these periods. Our historical results are not necessarily indicative of the results to be expected in the future, and our operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the entire year ending December 31, 2014.
Year Ended December 31, |
Three Months Ended March 31, |
Period From May 26, 2011 (Date of Inception) to March 31, 2014 |
||||||||||||||||||
2012 | 2013 | 2013 | 2014 | |||||||||||||||||
(in thousands, except share and per share data) | ||||||||||||||||||||
Statement of Operations Data: |
||||||||||||||||||||
Costs and expenses: |
||||||||||||||||||||
Research and development |
$ | 2,354 | $ | 5,045 | $ | 878 | $ | 1,250 | $ | 8,856 | ||||||||||
General and administrative |
1,575 | 2,193 | 465 | 520 | 4,429 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total costs and expenses |
3,929 | 7,238 | 1,343 | 1,770 | 13,285 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Loss from operations |
(3,929 | ) | (7,238 | ) | (1,343 | ) | (1,770 | ) | (13,285 | ) | ||||||||||
Other income (expense): |
||||||||||||||||||||
Interest expense |
(3 | ) | (23 | ) | (3 | ) | (5 | ) | (33 | ) | ||||||||||
Interest income |
1 | 7 | 3 | | 8 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total other expense |
(2 | ) | (16 | ) | | (5 | ) | (25 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (3,931 | ) | $ | (7,254 | ) | $ | (1,343 | ) | $ | (1,775 | ) | $ | (13,310 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net loss per share of common stock basic and diluted |
$ | (2.12 | ) | $ | (2.45 | ) | $ | (0.51 | ) | $ | (0.50 | ) | $ | (5.98 | ) | |||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Weighted average shares outstanding, basic and diluted |
1,853,423 | 2,956,285 | 2,620,868 | 3,559,263 | 2,224,229 | |||||||||||||||
Pro forma net loss per share basic and diluted |
$ | (0.58 | ) | $ | (0.14 | ) | ||||||||||||||
|
|
|
|
|||||||||||||||||
Pro forma weighted average shares outstanding basic and diluted |
12,512,042 | 13,115,020 |
65
As of December 31, | As of March 31, 2014 |
|||||||||||
2012 | 2013 | |||||||||||
(in thousands) |
||||||||||||
Balance Sheet Data: |
||||||||||||
Cash and cash equivalents |
$ | 856 | $ | 1,909 | $ | 525 | ||||||
Total assets |
948 | 2,137 | 710 | |||||||||
Long-term debt |
150 | 268 | 268 | |||||||||
Total liabilities |
709 | 1,004 | 1,242 | |||||||||
Total convertible preferred stock |
4,029 | 11,871 | 11,877 | |||||||||
Total stockholders deficit |
(3,790 | ) | (10,738 | ) | (12,409 | ) |
66
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the Risk Factors section of this prospectus for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Our current product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space, or SCS, using our proprietary microinjector. With the SCS injection procedure, our product candidates are more directly administered to the retina and choroid as compared to currently used intravitreal injections, which we believe may provide a number of benefits, including lower frequency of necessary administration and faster onset of therapeutic effect. We hold the exclusive rights to develop and commercialize drugs for non-surgical administration into the SCS. Our most advanced product candidates, CLS-1001 and CLS-1003, are based on commonly used ophthalmic therapeutic agents, which we believe will allow us to more efficiently and predictably pursue the regulatory approval of these product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
CLS-1001 is in an ongoing Phase 1/2 clinical trial of patients with non-infectious uveitis for which we expect final results in the first half of 2015. In the second half of 2014, we plan to initiate a Phase 2 clinical trial in approximately 30 patients with macular edema associated with non-infectious uveitis to evaluate the safety and efficacy of our CLS-1001 administered into the SCS. In the first half of 2015, we also expect to initiate a single pivotal Phase 3 clinical trial with our CLS-1001 administered into the SCS in approximately 150 patients with macular edema associated with non-infectious uveitis, with the goal of being able to submit a Section 505(b)(2) NDA to the FDA in the first half of 2017. Under our CLS-1003 program, we are planning to initiate a Phase 2 clinical trial in the second half of 2014 in approximately 40 patients with macular edema associated with RVO, a sight-threatening disorder resulting from the blockage of a retinal vein. Under our CLS-1002 program, we are evaluating a number of compounds for the treatment of wet AMD by SCS injection, including compounds with anti-VEGF activity and compounds with dual anti-VEGF and anti-PDGF activity. We plan to file an IND for this CLS-1002 program by the end of 2015. We also intend to evaluate treatments for DME. If our product candidates are approved, we plan to commercialize them with a specialty sales force of 30 to 40 representatives to target retinal specialists in the United States, and we may also pursue collaborations with third parties to commercialize any of our drugs approved for marketing outside the United States.
We are a development-stage company and have incurred net losses since our inception in May 2011. Our operations to date have been limited to organizing and staffing our company, raising capital, undertaking preclinical studies and other research and development initiatives and, beginning in 2013, conducting a clinical trial of our most advance product candidate. To date, we have not generated any revenue and have primarily financed our operations through the private placement of our equity securities
67
and issuance of convertible promissory notes. Through March 31, 2014, we have raised net cash proceeds of $11.7 million from the sale of convertible preferred stock. As of March 31, 2014, we had a deficit accumulated during the development stage of $13.3 million. We recorded net losses of $3.9 million and $7.3 million for the years ended December 31, 2012 and 2013, respectively, and $1.3 million and $1.8 million for the three months ended March 31, 2013 and 2014, respectively. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and obtaining regulatory approval and preparing for potential commercialization of our product candidates.
We expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we:
| initiate our planned Phase 2 clinical trial of CLS-1001 in the second half of 2014 and our planned pivotal Phase 3 clinical trial of CLS-1001 in the first half of 2015; |
| initiate our planned Phase 2 clinical trial of CLS-1003 in the second half of 2014; |
| continue the research and development of our other product candidates; |
| seek to evaluate and develop additional product candidates; |
| seek regulatory approvals for any product candidates that successfully complete clinical trials; |
| ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any product candidates for which we may obtain regulatory approval; |
| maintain, expand and protect our intellectual property portfolio; |
| hire additional clinical, manufacturing and scientific personnel; |
| add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts; and |
| begin to operate as a public company. |
We anticipate that we will use approximately $ million of the net proceeds from this offering for clinical and non-clinical costs associated with the initiation and completion of planned Phase 2 and Phase 3 clinical trials for CLS-1001 and approximately $ million for clinical and non-clinical costs associated with the initiation and completion of the planned Phase 2 clinical trial for CLS-1003. We intend to use the remainder of the proceeds of this offering to fund the research and development of our earlier-stage programs, including drug discovery and for working capital and general corporate purposes. We expect that these funds will not be sufficient to enable us to complete all necessary development and commercially launch both of these product candidates. Accordingly, we will be required to obtain further funding through other public or private offerings of our capital stock, debt financing, collaboration and licensing arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts. Although it is difficult to predict
68
future liquidity requirements, we believe that the net proceeds of this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operations for at least the next 12 months. However, our ability to successfully transition to profitability will be dependent upon achieving a level of revenues adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from our operating activities.
Components of Operating Results
Revenue
We have not generated any revenue from the sale of any drugs, and we do not expect to generate any revenue unless or until we obtain regulatory approval of and commercialize our product candidates. Over time, we may also seek to earn revenue by out-licensing our proprietary microinjection technology for SCS drug administration to third-party strategic collaborators.
Research and Development
Since our inception, we have focused on our development programs. Research and development expenses consist primarily of costs incurred for the research and development of our preclinical and clinical product candidates, which include:
| employee-related expenses, including salaries, benefits, travel and stock-based compensation expense for research and development personnel; |
| expenses incurred under agreements with contract research organizations, or CROs, as well as contract manufacturing organizations and consultants that conduct clinical trials and preclinical studies; |
| costs associated with preclinical activities and development activities; |
| costs associated with technology and intellectual property licenses; |
| costs for our research and development facility; and |
| depreciation expense for assets used in research and development activities. |
We expense research and development costs to operations as incurred. The costs for some of our development activities, such as clinical trials, are recognized based on the terms of underlying agreements, as well as an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations and additional information provided to us by our vendors about their actual costs occurred.
Expenses related to activities, such as manufacturing and stability and toxicology studies, that are supportive of a product candidate itself, are classified as direct non-clinical costs. Expenses related to clinical trials and similar activities, including costs associated with CROs, are classified as direct clinical costs. Expenses related to activities that support more than one development program or activity, such as salaries, stock-based compensation and depreciation, are not classified as direct clinical costs or non-clinical costs and are separately classified as unallocated.
For the year ended December 31, 2012, substantially all of our research and development expenses related to the non-clinical development of CLS-1001. For the year ended December 31, 2013 and the three months ended March 31, 2013 and 2014, substantially all of our research and development expenses related to the non-clinical and clinical development of CLS-1001. From inception through March 31, 2014, we have incurred $8.9 million in research and development expenses, of which only $0.2 million was expended
69
prior to January 1, 2012. Prior to January 1, 2012, we did not allocate any research and development expenses to any specific product candidate.
Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended under contracts with research institutions, consultants and CROs that conduct and manage clinical trials on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the protocol. If future timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been material.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as we progress CLS-1001 and our other product candidates through clinical development. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.
The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:
| number of trials required for approval and any requirement for extension trials; |
| per patient trial costs; |
| the number of patients that participate in the trials; |
| the number of sites included in the trials; |
| the countries in which the trial is conducted; |
| the length of time required to enroll eligible patients; |
| the number of doses that patients receive; |
| the drop-out or discontinuation rates of patients; |
| potential additional safety monitoring or other studies requested by regulatory agencies; |
| the duration of patient follow-up; and |
| the efficacy and safety profile of the product candidate. |
In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each candidates commercial potential.
General and Administrative
General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development, and
70
human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to intellectual property and corporate matters and fees for accounting and consulting services.
We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization of our product candidates and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company including expenses related to services associated with maintaining compliance with NASDAQ listing rules and SEC requirements, insurance, and investor relations costs. In addition, if CLS-1001 or any of our other product candidates obtains regulatory approval for marketing, we expect to incur expenses associated with building a sales and marketing team. However, we do not expect to receive any such regulatory approval for at least the next several years.
Other Income (Expense)
Other income consists of interest income earned on our cash and cash equivalents. Interest income is not considered significant to our financial statements, but we expect our interest income to increase following this offering as we invest the net proceeds from this offering pending their use in operations.
Other expense consists of interest accrued under promissory notes and amortization of debt discounts arising from the preferred stock purchase warrant described in the footnotes to our financial statements appearing elsewhere in this prospectus.
Critical Accounting Policies and Significant Judgments and Estimates
Our managements discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of expenses during the reporting periods. In accordance with GAAP, we evaluate our estimates and judgments on an ongoing basis. Significant estimates include assumptions used in the determination of stock-based compensation and some of our research and development expenses. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We define our critical accounting policies as those accounting principles generally accepted in the United States of America that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 2 to our financial statements appearing elsewhere in this prospectus, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments.
71
Accrued Expenses
As part of the process of preparing our financial statements, we are required to estimate accrued expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable vendor personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include fees paid to CROs and investigative sites in connection with clinical trials.
We accrue our expenses related to clinical trials based on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct research activities or manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the level of effort varies from our estimate, we will adjust the accrual accordingly. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. Although we do not currently anticipate the future settlement of existing accruals to differ materially from our estimates, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low for any period. There have been no material changes in estimates for the periods presented in our financial statements.
Fair Value Measurements
We record some of our financial assets and liabilities at fair value in accordance with the provisions of Accounting Standards Codification, or ASC, Topic 820 on fair value measurements. As defined in the guidance, fair value, defined as an exit price, represents the amount that would be received to sell an asset or pay to transfer a liability in an orderly transaction between market participants. As a result, fair value is a market-based approach that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering these assumptions, the guidance defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value.
| Level 1 Unadjusted quoted prices in active, accessible markets for identical assets or liabilities. |
| Level 2 Other inputs that are directly or indirectly observable in the marketplace. |
| Level 3 Unobservable inputs that are supported by little or no market activity. |
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Our material financial instruments at December 31, 2012, December 31, 2013 and March 31, 2014 consisted primarily of cash and cash equivalents, long-term debt and stock purchase warrant liabilities. The fair value of cash and cash equivalents and long-term debt approximate their respective carrying values
72
due to the short-term nature of these instruments. We have determined the preferred stock purchase warrant, the value of which is recorded as an adjustment to long-term debt, to be valued under Level 3.
Stock-Based Compensation
We recognize compensation costs related to stock options and restricted stock granted to employees, directors and consultants ratably over the requisite service period, which in most cases is the vesting period of the award for employees, based on the estimated fair value of the awards on the date of grant. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of the awards granted to non-employees is re-measured each period until the related service is complete.
Stock-based compensation expense was $0.3 million for each of the years ended December 31, 2012 and 2013 and $64,000 and $0.1 million for the three months ended March 31, 2013 and 2014, respectively.
Significant Factors, Assumptions and Methodologies Used in Determining Fair Value
Determining the appropriate fair value measurement of stock-based awards requires the use of subjective assumptions. In the absence of a public trading market for our common stock, and in preparation for this offering, we conducted retrospective assessments of the valuation of our common stock as of December 31, 2012 and 2013, as described below in Common Stock Valuations. The determination of the fair value measurement of options using the Black-Scholes option pricing model is affected by our estimated common stock fair values as well as assumptions regarding a number of other subjective variables. These other variables include the expected term of the options, our expected stock price volatility over the expected term of the options, stock option exercise and cancellation behaviors, risk-free interest rates and expected dividends.
We estimated the fair value of stock options at the grant date using the following assumptions:
| Fair Value of our Common Stock. Since no public market exists for our stock, we must estimate its fair value, as discussed in Common Stock Valuations below. |
| Volatility. As we do not have a trading history for our common stock, we utilize data from a representative group of publicly traded companies to estimate expected stock price volatility. We selected representative companies from the pharmaceutical industry with similar characteristics to us, including stage of product development and therapeutic focus. |
| Expected Term. We used the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, as we do not have sufficient historical exercise and post-vesting termination data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees. |
| Risk-Free Rate. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected time to liquidity. |
| Forfeitures. Forfeitures are estimated such that we only recognize expense for the shares expected to vest, and adjustments are made if actual forfeitures differ from those estimates. We estimated our annual forfeiture rates to be zero for 2012 and 2013. |
| Dividend Yield. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. |
73
The table below lists the weighted average assumptions utilized in the Black-Scholes option pricing model for the years ended December 31, 2012 and 2013 and for the three months ended March 31, 2013. We did not grant any stock options during the three months ended March 31, 2014.
Year Ended December 31, |
Three Months Ended March 31, 2013 |
|||||||||||
2012 | 2013 | |||||||||||
Expected term (years) |
7.00 | 7.00 | 7.00 | |||||||||
Expected stock price volatility |
156.84 | % | 97.02 | % | 100.28 | % | ||||||
Risk-free interest rate |
1.07 | % | 1.69 | % | 1.23 | % | ||||||
Dividend yield |
0.00 | % | 0.00 | % | 0.00 | % |
The estimation of the number of stock awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period in which estimates are revised.
Common Stock Valuations
We are a private company with no active public market for our common stock. Our common stock valuations are determined by our board of directors in its sole discretion based on recommendations from management and, beginning in 2014, taking into account advice and assistance provided by a third-party valuation consultant engaged to assist us in connection with such valuations. The valuations of our common stock were determined utilizing guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, referred to as the Practice Aid. The methodologies used to determine fair value of our common stock included estimating the fair value of the enterprise and then allocating this value to all classes of equity securities using a combination of the option pricing method and, beginning with our retrospective valuation as of December 31, 2013, the initial public offering scenario within the probability-weighted expected return method, described in more detail below.
The assumptions used in the valuation models that ultimately determine the fair value of our common stock as of the valuation date are based on numerous objective and subjective factors combined with management judgment, including the following:
| our results of operations, financial position and the status of our research and development efforts; |
| the composition of, and changes to, our management team and board of directors; |
| the lack of liquidity of our common stock as a private company; |
| our stage of development and business strategy and the material risks related to our business and industry; |
| our discounted future cash flows, based on our projected operating results; |
| the potential impact on our common stock of liquidation preference rights of our convertible preferred stock; |
| the valuation of publicly traded companies in the life sciences and pharmaceutical industry sectors, as well as recently completed mergers and acquisitions of peer companies; |
| any external market conditions affecting the life sciences and pharmaceutical industry sectors; |
74
| the likelihood of achieving a liquidity event for the holders of our common stock and stock options, such as an initial public offering, or IPO, or a sale of our company, given prevailing market conditions; |
| the state of the IPO market for similarly situated privately held biotechnology companies; and |
| any recent contemporaneous valuations prepared in accordance with methodologies outlined in the Practice Aid. |
The following table presents the grant dates and related exercise prices of stock options that we granted from January 1, 2013 through the date of this prospectus, along with the corresponding exercise price for each option grant and the fair values per share utilized to calculate stock-based compensation expense. Refer to Estimate of Fair Value for Option Grants During Six Months Ended June 30, 2013 and Retrospective Valuation as of December 31, 2013 for additional information.
Date of Grant |
Number of Shares Underlying Options |
Exercise Price Per Option |
Common Stock Fair Value Per Share on Grant Date |
|||||||||
3/1/2013 |
585,500 | $ | 0.18 | $ | 0.50 | (1) | ||||||
5/21/2013 |
5,000 | 0.18 | 0.50 | (1) | ||||||||
6/17/2013 |
100,000 | 0.18 | 0.50 | (1) | ||||||||
8/7/2013 |
165,000 | 0.18 | 0.66 | (1) | ||||||||
10/16/2013 |
50,000 | 0.18 | 0.66 | (1) | ||||||||
11/25/2013 |
500,000 | 0.18 | 0.66 | (1) | ||||||||
12/17/2013 |
30,000 | 0.18 | 0.66 | (1) |
(1) | We assessed the fair value of our common stock subsequent to the grant date of these awards, as described below. |
Based on an assumed initial public offering price of $ per share, the midpoint of the price range set forth on the cover page of this prospectus, the intrinsic value of all stock options outstanding as of March 31, 2014 was $ million, of which $ million and $ million related to stock options that were vested and unvested, respectively, at that date.
Common Stock Valuation Methodologies
The Practice Aid describes market, income and cost approaches to valuing equity securities, each of which approaches is summarized below.
Market Approach. The market approach uses similar companies or transactions in the marketplace. When using the guideline company method of the market approach in determining the fair value of common stock, a company identifies companies similar to its business and uses these guideline companies to develop relevant market multiples and ratios, which are then applied to its financial forecasts to create an indication of total equity value. When using the similar transaction methodology of the market approach in determining the fair value of common stock, a company uses publicly disclosed data from arms-length transactions involving similar companies to develop relationships or value measures between the prices paid for the target companies and the underlying financial performance of those companies. These value measures are then applied to a companys applicable operating data to create an indication of total equity value.
Income Approach. For the income approach, a company uses the discounted free cash flow method, which is based on the premise that equity value as of the respective valuation date is equal to the projected future free cash flows and expected terminal value of the business, discounted by a required rate of return that
75
investors would demand given the risks of ownership and the risks associated with achieving the stream of projected future free cash flows.
Cost Approach. The cost approach involves identifying a companys significant tangible assets, estimating the individual current market values of each and then totaling them to derive the value of the business as a whole. A company can use the cost approach to value its adjusted net assets available to common stockholders if it were forced to liquidate its assets if its business model failed and the company was unable to raise additional financing.
Methods Used to Allocate Our Enterprise Value to Classes of Securities
In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at the valuation date. The methods we considered consisted of the following:
Current Value Method. Under the current value method, once the fair value of the enterprise is established, the value is allocated to the various series of preferred and common stock based on their respective seniority, liquidation preferences or conversion values, whichever is greatest.
Option Pricing Method, or OPM. Under the option pricing method, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options.
Probability-Weighted Expected Return Method, or PWERM. The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.
Retrospective Valuation as of December 31, 2012
In view of our relatively early stage of development as of December 31, 2012, as well as the state of the market for biopharmaceutical initial public offerings at that time, we conducted a retrospective valuation of our common stock as of December 31, 2012 using the OPM. In conducting this valuation, we used a market approach to backsolve for an estimate of our enterprise value based on our Series A-1 convertible preferred stock financing, which occurred shortly thereafter in January 2013. Although we did not rely on the guideline company or similar transaction methodologies to determine our enterprise value as part of the market approach, we did review them to gain a deeper insight into the companies in the ophthalmic therapeutics market and to evaluate prevailing market conditions.
Once we determined an estimate of our enterprise value, we then allocated the estimated enterprise value to the various classes of our equity securities using the OPM, which analyzes the rights of the common stock relative to those of the preferred stock by assessing the break points, or the points at which it is economically viable for the holders of preferred stock to convert their preferred stock into common stock. At the December 31, 2012 valuation date, the model incorporated an assumed time to a liquidity event of 2.5 years. After applying a 40% discount for lack of marketability, the fair value per share of common stock on a non-marketable interest basis under the OPM was $0.30 as of December 31, 2012. We used basic put option and Finnerty put option analyses to estimate the discount for lack of marketability. These models are commonly used for estimating illiquidity discounts for securities.
76
Estimate of Fair Value for Option Grants During Six Months Ended June 30, 2013
In January 2013, we completed our Series A-1 preferred stock financing, raising gross proceeds of $7.9 million, which we believe resulted in an increased value of our company and our common stock. Also in January 2013, we received approval of our IND from the FDA to initiate our Phase 1/2 clinical trial in our CLS-1001 program. Therefore, for purposes of our retrospective assessment of the fair value of our common stock as of dates after January 2013, we believed that it was appropriate to increase our estimate of the fair value of our common stock from the December 31, 2012 estimated fair value of $0.30 per share. In deriving this estimate, we interpolated between $0.30 per share and the $0.66 per share estimated fair value that we utilized for our grants made in the second half of 2013, as described below. Based on this interpolation, we estimated the fair value per share of common stock to be $0.50 per share, which we have applied retrospectively to all of our stock option grants made during the first half of 2013.
Retrospective Valuation as of December 31, 2013
By the end of 2013, based on our board of directors review of overall market conditions, the improving market for biopharmaceutical initial public offerings and the progress of our clinical and preclinical development, our board of directors determined that a shift was occurring with respect to the potential valuation of our common stock in a liquidity event scenario, and we therefore performed a valuation for our common stock as of December 31, 2013.
In conducting this valuation, we used a market approach to backsolve for an estimate of our enterprise value based upon anticipated transactions involving convertible preferred stock. Specifically, based on our capital plan at the valuation date, we estimated that we would need additional funding during 2014. At the valuation date, we expected that such a new investment, a Series B preferred stock financing, would be completed at the same price as our prior Series A-1 convertible preferred stock, issued in January and February 2013, but would be senior to it in terms of liquidation preference. Although we did not rely on the guideline company or similar transaction methodologies to determine our enterprise value as part of the market approach, we did review them to gain a deeper insight into the companies in the ophthalmic therapeutics market and to evaluate prevailing market conditions.
Once we determined an estimate of our enterprise value, we then allocated the estimated enterprise value to the various classes of our equity securities using the OPM, which analyzes the rights of the common stock relative to those of the preferred stock by assessing the break points, or the points at which it is economically viable for the holders of preferred stock to convert their preferred stock into common stock. At the December 31, 2013 valuation date, the model incorporated an assumed time to a liquidity event of two years. After applying a 30% discount for lack of marketability, the fair value per share of common stock on a non-marketable interest basis under the OPM was $0.32 as of December 31, 2013. We used basic put option and Finnerty put option analyses to estimate the discount for lack of marketability. These models are commonly used for estimating illiquidity discounts for securities.
As of December 31, 2013, our board of directors had authorized management to begin preparing for a potential initial public offering, or IPO, of our common stock, although we did not select underwriters for this offering until April 2014. Because an IPO scenario was considered to be a possible liquidity event, we also used the PWERM to estimate our enterprise value under this scenario and to estimate the fair value of our common stock in such a scenario. For this scenario, we assumed an IPO at the end of 2014. We reviewed a number of IPOs completed by life sciences and biopharmaceutical companies during 2013 and estimated an enterprise value for our company that would have been somewhat below the first quartile of the enterprise values of recent IPOs, after taking into account our stage of development as compared to the
77
reviewed companies. After applying a 20% discount rate to the estimated future enterprise value at the time of an IPO, and after applying a 20% discount for lack of marketability using basic put option and Finnerty put option analyses, the fair value per share of common stock on a non-marketable basis under the PWERM was $2.01 as of December 31, 2013.
Based upon our estimates of the probabilities of the future outcomes, we then attributed an 80% weighting to the OPM and a 20% weighting to the IPO scenario within the PWERM. This resulted in a weighted per share value of $0.66 for our common stock as of December 31, 2013. For financial reporting purposes in determining the estimated fair value of the stock options, this value has been applied retrospectively to all of our stock option grants made during the six months ended December 31, 2013.
Determination of Estimated Offering Price
In April 2014, we selected underwriters for this offering. The midpoint of the preliminary range for the initial public offering as determined by us and the underwriters was $ per share. In comparison, our estimate of the fair value of our common stock was $0.66 per share as of the December 31, 2013 valuation. We note that, as is typical in IPOs, the preliminary range was not derived using a formal determination of fair value, but was determined based upon discussions between us and the underwriters. Among the factors that were considered in setting this range were our prospects and the history of and prospects for our industry, the general condition of the securities markets and the recent market prices of, and the demand for, publicly traded common stock of generally comparable companies. We believe that the difference between the fair value of our common stock as of December 31, 2013 and the midpoint of the price range for this offering is the result of these factors as well as the fact that the estimated IPO price range necessarily assumes that the initial public offering has occurred, a public market for our common stock has been created and that our preferred stock converted into common stock in connection with the IPO, and therefore excludes any discount for lack of marketability of our common stock, which was factored into the December 31, 2013 retrospective valuation.
Results of Valuation Models May Vary
Valuation models require the input of highly subjective assumptions and estimates. These judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event and the determinations of the appropriate valuation methods. Because our common stock has characteristics significantly different from that of publicly traded common stock and because changes in the subjective input assumptions can materially affect our fair value estimates, the existing models do not necessarily provide a reliable, single measure of the fair value of our common stock. If we had made different assumptions, our stock-based compensation expense, our net loss and net loss per share could have been significantly different. The foregoing valuation methodologies are not the only valuation methodologies available and will not be used to value our common stock once this offering is complete. We cannot make assurances as to any particular valuation for our stock. Accordingly, investors are cautioned not to place undue reliance on the foregoing valuation methodologies as an indicator of future stock prices.
Tax Valuation Allowance
We recorded deferred tax assets of $4.3 million as of December 31, 2013, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. We record a valuation allowance if it is more likely than not that a deferred tax asset will not be realized. We provided a
78
full valuation allowance on our deferred tax assets that primarily consist of cumulative net operating losses, or NOLs, of $10.4 million for the period from our inception on May 26, 2011 to December 31, 2013. We incurred a net loss of $1.8 million for the three months ended March 31, 2014. Due to our three-year cumulative loss position, history of operating losses and losses expected to be incurred in the foreseeable future, we considered it necessary to provide for a full valuation allowance against our net deferred tax assets.
Our deferred tax assets are primarily composed of federal and state tax NOL carryforwards. As of December 31, 2013, we had federal NOL carryforwards of $10.4 million and state NOL carryforwards of $12.4 million available to reduce future taxable income, if any. These federal NOL carryforwards will begin to expire at various dates starting in 2031. The state NOL carryforwards will begin to expire at various dates starting in 2027. In general, if we experience a greater than 50 percentage point aggregate change in ownership of specified significant stockholders over a three-year period, utilization of our pre-change NOL carryforwards will be subject to an annual limitation under Section 382 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, and similar state laws. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization and may be substantial. If we experience a Section 382 ownership change in connection with this offering or as a result of future changes in our stock ownership, some of which changes are outside our control, the tax benefits related to the NOL carryforwards may be further limited or lost.
Results of Operations for the Three Months Ended March 31, 2013 and 2014
The following table sets forth our results of operations for the three months ended March 31, 2013 and 2014.
Three Months Ended March 31, |
Period-to-Period Change |
|||||||||||
2013 | 2014 | |||||||||||
(in thousands) | ||||||||||||
Costs and expenses: |
||||||||||||
Research and development |
$ | 878 | $ | 1,250 | $ | 372 | ||||||
General and administrative |
465 | 520 | 55 | |||||||||
|
|
|
|
|
|
|||||||
Total costs and expenses |
1,343 | 1,770 | 427 | |||||||||
|
|
|
|
|
|
|||||||
Loss from operations |
(1,343 | ) | (1,770 | ) | (427 | ) | ||||||
Other income (expense): |
||||||||||||
Interest expense |
(3 | ) | (5 | ) | 2 | |||||||
Interest income |
3 | | 3 | |||||||||
|
|
|
|
|
|
|||||||
Total other expense |
| (5 | ) | 5 | ||||||||
|
|
|
|
|
|
|||||||
Net loss |
$ | (1,343 | ) | $ | (1,775 | ) | $ | (432 | ) | |||
|
|
|
|
|
|
Research and development. Research and development expense increased by $0.4 million, from $0.9 million for the three months ended March 31, 2013 to $1.3 million for the three months ended March 31, 2014, an increase of 42%. The increase was primarily attributable to a $0.1 million increase in costs related to the design and testing or our microinjector, as well as an increase of $0.1 million in direct clinical expenses for our CLS-1001 program, for which a Phase 1/2 clinical trial was initiated in the second half of 2013. We also incurred an additional $0.1 million in non-clinical expenses during the three months ended March 31, 2014 related to the other product candidates in our pipeline, including CLS-1003, for which we are planning to begin a Phase 2 clinical trial in RVO patients in the second half of 2014. We hired a new
79
executive vice president of research and development in the second half of 2013, and therefore we incurred increased personnel costs during the three months ended March 31, 2014 as compared to the prior year.
General and administrative. General and administrative expense increased by $48,000, from $0.5 million for the three months ended March 31, 2013 to $0.5 million for the three months ended March 31, 2014, an increase of 10%. The increase was primarily attributable to increases in personnel costs, including stock-based compensation.
Results of Operations for the Years Ended December 31, 2012 and 2013
The following table sets forth our results of operations for the years ended December 31, 2012 and 2013.
Year Ended December 31, |
Period-to-Period Change |
|||||||||||
2012 | 2013 | |||||||||||
(in thousands) | ||||||||||||
Costs and expenses: |
||||||||||||
Research and development |
$ | 2,354 | $ | 5,045 | $ | 2,691 | ||||||
General and administrative |
1,575 | 2,193 | 618 | |||||||||
|
|
|
|
|
|
|||||||
Total costs and expenses |
3,929 | 7,238 | 3,309 | |||||||||
|
|
|
|
|
|
|||||||
Loss from operations |
(3,929 | ) | (7,238 | ) | (3,309 | ) | ||||||
Other income (expense): |
||||||||||||
Interest expense |
(3 | ) | (23 | ) | (20 | ) | ||||||
Interest income |
1 | 7 | 6 | |||||||||
|
|
|
|
|
|
|||||||
Total other expense |
(2 | ) | (16 | ) | (14 | ) | ||||||
|
|
|
|
|
|
|||||||
Net loss |
$ | (3,931 | ) | $ | (7,254 | ) | $ | (3,323 | ) | |||
|
|
|
|
|
|
Research and development. Research and development expense increased by $2.6 million, from $2.4 million for the year ended December 31, 2012 to $5.0 million for the year ended December 31, 2013, an increase of 114%. The increase was primarily attributable to higher compensation, travel and facilities costs of $1.4 million resulting from new hires in 2013, as well as an increase of $0.6 million in direct clinical expenses for our CLS-1001 program, which began clinical development in the second half of 2013, and an increase of $0.7 million in preclinical expenses related to our other programs, including our earlier-stage RVO and wet AMD programs, during the year ended December 31, 2013.
General and administrative. General and administrative expense increased by $0.6 million, from $1.6 million for the year ended December 31, 2012 to $2.2 million for the year ended December 31, 2013, an increase of 39%. The increase was primarily attributable to an increase of $0.5 million in costs related to new hires in our general and administrative functions, including compensation and travel costs. Additionally, we had an increase of $0.1 million in professional fees as compared to the prior year.
Liquidity and Capital Resources
Sources of Liquidity
We have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development and general and administrative expenses will increase over historical levels and,
80
as a result, we will need additional capital to fund our operations, which we may obtain from additional public offerings, debt financing, collaboration and licensing arrangements or other sources.
For the period from our inception on May 26, 2011 to March 31, 2014, we have cumulative net cash used by operating activities of $11.5 million and cumulative net losses of $13.3 million. Since our inception, we have funded operations primarily through the sale of convertible preferred stock and the issuance of convertible promissory notes. Through March 31, 2014, we have raised net cash proceeds of $11.7 million from the sale of convertible preferred stock. As of December 31, 2013 and March 31, 2014, we had cash and cash equivalents of $1.9 million and $525,000, respectively. We invest any cash in excess of our immediate requirements primarily with a view to liquidity and capital preservation. As of December 31, 2013 and March 31, 2014, our funds were held in cash and money market funds.
In April 2014, we authorized the sale of convertible promissory notes, or the bridge notes, to our existing stockholders, including two of our executive officers and one of our directors in their individual capacities, in the aggregate principal amount of $6.0 million. In April 2014, we issued $3.0 million in aggregate principal amount of bridge notes, and we expect to issue the remaining $3.0 million in aggregate principal amount of bridge notes in June 2014. The outstanding notes accrue interest at an annual rate of 7%, with principal plus interest due upon maturity in April 2015 unless earlier converted. The bridge notes are convertible upon the occurrence of a qualified financing, as defined in the bridge notes, or, upon the consent of the lenders, may be converted into shares of Series A-1 convertible preferred stock. We expect that all outstanding bridge notes, including accrued interest, will be converted into shares of our convertible preferred stock prior to the completion of this offering, which shares of convertible preferred stock will then be converted into shares of our common stock upon the completion of this offering. In connection with the issuance of the bridge notes, we also issued warrants to the lenders to purchase an aggregate of 248,175 shares of our common stock at an exercise price of $0.01 per share. These warrants expire upon the closing of this offering, and therefore we expect that these warrants will be exercised in connection with the completion of this offering and that we will issue 248,175 shares of our common stock upon their exercise.
In April 2013, we entered into a loan agreement with an entity affiliated with the State of North Carolina under which we borrowed an aggregate of $125,000. The outstanding balance bore interest at an annual rate of 4.25%. All unpaid principal, together with unpaid and accrued interest, were due and payable in February 2016 or, if earlier, upon the occurrence of specified events. We repaid this note in full in May 2014. In connection with the initial loan, we also issued this lender a warrant to purchase 16,550 shares of our Series A-1 convertible preferred stock, which will become a warrant to purchase 16,550 shares of our common stock following the completion of this offering.
In December 2012, we entered into a $150,000 unsecured promissory note with a lender, which bears interest at an annual rate of 5%. All unpaid principal, together with unpaid and accrued interest, will be due and payable prior to the completion of this offering or, if earlier, upon an event of default as defined in the note.
Between June 2011 and December 2011, we borrowed an aggregate of $100,000 from Daniel White, our chief executive officer. These advanced amounts, plus accrued interest of approximately $5,000, were converted into shares of our Series A convertible preferred stock during the year ended December 31, 2012.
81
Funding Requirements
Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.
The successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of CLS-1001, CLS-1003 or any of our other product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from product sales. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:
| successful enrollment in, and completion of clinical trials; |
| receipt of marketing approvals from applicable regulatory authorities; |
| establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; |
| obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; and |
| launching commercial sales of the products, if and when approved, whether alone or in collaboration with others. |
A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that candidate.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings and potential collaboration, license and development agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
We will also incur costs as a public company that we have not previously incurred or have previously incurred at lower rates, including but not limited to, increased costs and expenses for fees to members of our board of directors, increased personnel costs, increased directors and officers insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with reporting requirements under the Exchange Act and rules implemented by the SEC and NASDAQ. We estimate that we will annually incur approximately $1.0 million to $2.0 million in expenses to ensure compliance with these requirements.
82
Outlook
Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that the net proceeds from this offering, together with our existing cash and cash equivalents as of March 31, 2014, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress in these trials is uncertain.
Cash Flows
During each of the three months ended March 31, 2013 and 2014, our operating activities used net cash of $1.4 million. The use of net cash in each period primarily resulted from our net losses. The increase in net loss for the three months ended March 31, 2014 as compared to the three months ended March 31, 2013 was primarily attributable to higher research and development expenses. The other changes from operating activities were caused primarily by changes in our accounts payable and other accrued liabilities. During the three months ended March 31, 2013 and 2014, we did not engage in any material investing activities. The net cash provided by financing activities during the three months ended March 31, 2013 related to $7.8 million from the sale of our Series A-1 convertible preferred stock, net of issuance costs.
During the years ended December 31, 2012 and 2013, our operating activities used net cash of $3.2 million and $6.8 million, respectively. The use of net cash in each year primarily resulted from our net losses. The increase in net loss for the year ended December 31, 2013 as compared to the year ended December 31, 2012 was due primarily to the increase in research and development expenses and, to a lesser extent, an increase in general and administrative expenses. The other changes from operating activities were caused primarily by changes in our accounts payable and other accrued liabilities. During the years ended December 31, 2012 and 2013, our investing activities included primarily purchases of office furnishings and equipment to facilitate our increased research and development activities and headcount. During the years ended December 31, 2012 and 2013, our financing activities provided net cash of $4.1 million and $8.0 million, respectively. The net cash provided by financing activities during the year ended December 31, 2012 was primarily the result of $3.9 million in net proceeds from the sale of our Series A convertible preferred stock and $150,000 from the issuance of debt, while net cash provided by financing activities during the year ended December 31, 2013 was the result of $7.8 million from the sale of our Series A-1 convertible preferred stock as well as $125,000 from the issuance of debt.
Contractual Obligations
The following table summarizes our significant contractual obligations as of December 31, 2013, all of which consisted of obligations under leases for our corporate headquarters in Alpharetta, Georgia and our research facility in Durham, North Carolina.
Payment due by period (in thousands) | ||||||||||||||||||||
Total | Less than 1 year |
1-3 years | 3-5 years | More than 5 years |
||||||||||||||||
Operating lease obligations |
$ | 547 | $ | 254 | $ | 270 | $ | 23 | $ | | ||||||||||
Long-term debt obligations |
275 | | 125 | 150 | | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total |
$ | 822 | $ | 254 | $ | 395 | $ | 173 | $ | | ||||||||||
|
|
|
|
|
|
|
|
|
|
We have no material non-cancelable purchase commitments with contract manufacturers or service providers, as we have generally contracted on a cancelable purchase order basis.
83
Subsequent to December 31, 2013, we issued an aggregate of $3.0 million in principal amount of convertible promissory notes. If not converted in connection with a future financing, the principal and interest on such notes is due and payable in April 2015.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.
Recent Accounting Pronouncements
We have considered all recently issued accounting pronouncements and do not believe the adoption of such pronouncements will have a material impact on our financial statements.
JOBS Act
In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.
Quantitative and Qualitative Disclosures about Market Risk
The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December 31, 2012 and 2013 and March 31, 2014, we had cash and cash equivalents of $0.9 million, $1.9 million and $0.5 million, respectively. We generally hold our cash in interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.
We do not engage in any hedging activities against changes in interest rates. Our outstanding debt instruments carry a fixed interest rate and, as such, are not subject to interest rate risk.
We do not have any foreign currency or other derivative financial instruments.
84
Overview
We are a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Our current product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space, or SCS, adjacent to the choroid, using our proprietary microinjector. With the SCS injection procedure, our product candidates are more directly administered to the retina and choroid as compared to currently used intravitreal injections, which we believe may provide a number of benefits, including lower frequency of necessary administration and faster onset of therapeutic effect. We hold the exclusive rights to develop and commercialize drugs for non-surgical administration into the SCS. Our most advanced product candidates, CLS-1001 and CLS-1003, are based on commonly used ophthalmic therapeutic agents, which we believe will allow us to more efficiently and predictably pursue the regulatory approval of these product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. CLS-1001, for macular edema associated with non-infectious uveitis, is in an ongoing Phase 1/2 clinical trial, from which we expect final results in the first half of 2015. We expect to be able to conduct a single pivotal Phase 3 clinical trial in approximately 150 patients beginning in the first half of 2015, the results of which we believe will be sufficient to support the filing of a New Drug Application, or NDA, to the FDA in the first half of 2017. For CLS-1003, for macular edema associated with retinal vein occlusion, or RVO, we plan to initiate a Phase 2 clinical trial in the second half of 2014, with data expected in the second half of 2015. In our CLS-1002 program, for wet age-related macular degeneration, or wet AMD, we are evaluating drug compounds with anti-VEGF activity or dual anti-VEGF and anti-PDGF activity for SCS injection, and plan to file an investigational new drug application, or IND, by the end of 2015. We are also considering a development program for drug compounds that may be able to treat diabetic macular edema, or DME. We estimate that there are nearly five million people in the United States diagnosed with our target indications and that worldwide annual sales of drugs to treat these indications were approximately $6 billion in 2013.
Our current and planned development programs aim to restore or improve visual function primarily by reducing the macular edema associated with a number of diseases affecting the retina, the tissue that lines the inside of the eye and is the part of the eye primarily responsible for vision, and the choroid, the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. These diseases include uveitis, RVO, wet AMD and DME. Macular edema is the build-up of fluid that can cause abnormal swelling of the macula, the portion of the retina responsible for central vision and color perception. This swelling can rapidly result in deterioration of vision and can eventually lead to blindness.
The most common treatments for diseases of the retina and choroid are corticosteroids and drugs that inhibit vascular endothelial growth factor, or anti-VEGF drugs. These corticosteroids and anti-VEGF drugs are injected into the vitreous, a jelly-like substance that occupies the central portion of the eye. Intravitreal injections rely on drug to diffuse outward from the vitreous to the retina and choroid, which diffusion can result in lower concentrations of drug in these targeted areas. At the same time, this diffusion can result in drug spreading to unintended parts of the eye, where, for some drugs, it can cause significant side effects. By contrast, with our approach, drug is injected into and spreads within the SCS, which is the space located between the choroid and the outer protective layer of the eye known as the sclera, to reach the back of the eye. We believe SCS administration may provide improved bioavailability to the targeted retina and choroid, with drug remaining more localized and away from other parts of the eye, where the drug could cause side effects. Corticosteroids are effective both at treating the inflammatory aspect of ocular disease
85
and at reducing macular edema, but when delivered intravitreally, they have been associated with significant side effects, such as cataracts and elevated intraocular pressure, or IOP, which can lead to glaucoma. Anti-VEGF drugs, while highly effective in reducing macular edema, require frequent administration, in some cases as often as monthly. We believe that our differentiated approach of injecting ocular drugs into the SCS may result in fewer side effects and improved bioavailability of drug at the diseased retina and choroid, as compared to intravitreal administration, a faster onset of therapeutic effect, a similar efficacy profile with lower drug amounts required, and longer duration of therapeutic effect with less frequent required injections. The procedure for SCS injection with our microinjector is conducted in an in-office setting and is similar to the procedure for intravitreal injection, and we therefore expect that our products will be easily incorporated into retinal specialists standard medical practice.
Under our CLS-1001 program, we are conducting a Phase 1/2 clinical trial in patients with non-infectious uveitis, a condition characterized by inflammation of the choroid and surrounding tissues. The most common treatment for non-infectious uveitis involves the use of corticosteroids, such as triamcinolone acetonide, or TA. CLS-1001 consists of an SCS injection of CLS-TA, our proprietary, preservative-free formulation of TA, specifically designed to be administered through our SCS microinjector. In this ongoing Phase 1/2 clinical trial, we are evaluating the safety of SCS injection of Triesence, a TA formulation that is similar to CLS-TA and that has been approved by the U.S. Food and Drug Administration, or FDA, to treat non-infectious uveitis. While the trial is primarily a safety and tolerability study, we are also assessing efficacy measures. We intend to enroll approximately 10 patients in this trial. Interim data from the four patients for whom data is available indicate that SCS injection of the drug has generally been well tolerated, with none of the four patients having developed cataracts or experienced elevated IOP. The visual acuity of these four patients has improved by between five and 15 letters on a standard eye chart. Because CLS-1001 is based on our formulation of TA, and TA is known to be effective in treating uveitis, we believe that our product candidate will be at least as effective as commonly used formulations of TA in treating the disease, including the associated macular edema. Our preclinical studies suggest that SCS injection of TA may provide improved bioavailability of drug at the diseased retina and choroid, which may result in faster onset of therapeutic effect and a similar efficacy profile with lower drug amounts required. Our early clinical trial results suggest the potential for CLS-1001 to effectively treat uveitis for at least 90 days following a single SCS injection. Currently used ocular injections of TA are typically effective for approximately 90 days. In the second half of 2014, we plan to initiate a Phase 2 clinical trial in approximately 30 patients with macular edema associated with non-infectious uveitis to evaluate the safety and efficacy of our CLS-TA administered into the SCS. In the first half of 2015, we also expect to initiate a single pivotal Phase 3 clinical trial with our CLS-TA administered into the SCS in approximately 150 patients with macular edema associated with non-infectious uveitis, with the goal of being able to submit an NDA to the FDA in the first half of 2017. Based on our discussions with the FDA, we believe this single pivotal clinical trial will be sufficient to support a 505(b)(2) NDA filing for CLS-1001 for macular edema associated with non-infectious uveitis. If approved, CLS-1001 would be the first drug specifically indicated for macular edema associated with non-infectious uveitis.
Under our CLS-1003 program, we are planning to initiate a Phase 2 clinical trial in the second half of 2014 in approximately 40 patients with macular edema associated with RVO, a sight-threatening disorder resulting from the blockage of a retinal vein. The current standard of care for RVO involves monthly intravitreal injections of an anti-VEGF drug, such as Lucentis (ranibizumab), Eylea (aflibercept) or Avastin (bevacizumab). Although studies have shown that corticosteroids effectively address the inflammatory aspect of RVO, they are not used as first-line therapy because they are not considered to be as effective as anti-VEGF drugs and also have an unattractive side effect profile when injected intravitreally. In our
86
Phase 2 clinical trial, we will evaluate the safety and efficacy of the injection of our CLS-TA into the SCS together with Eylea injected into the vitreous, as compared to an intravitreal injection of Eylea alone. We believe that SCS administration of our CLS-TA, by addressing the inflammatory aspect of RVO, in combination with intravitreal anti-VEGF treatment, addressing the vascular aspect of RVO, may result in faster onset of therapeutic effect compared to currently used intravitreal anti-VEGF treatment alone, while also potentially reducing the frequency of necessary anti-VEGF treatments from 30 days to 90 days. In addition, we believe that the side effect profile of CLS-1003 will be similar to that of current intravitreal anti-VEGF treatments alone, as SCS injections of CLS-TA should allow the corticosteroid to remain substantially localized in the retina and choroid without introducing the side effects that are commonly observed with other routes of administration of corticosteroids.
Under our CLS-1002 program, we are evaluating a number of compounds as potential therapies for the treatment of wet AMD by SCS injection, including compounds with anti-VEGF activity and compounds with dual anti-VEGF and anti-platelet-derived growth factor, or anti-PDGF, activity. Wet AMD is a condition involving the abnormal formation and growth of new blood vessels in the choroid, their intrusion into the outer layers of the retina and the leakage of blood and fluid into the retina. The current standard of care for the treatment of wet AMD is intravitreal injection of anti-VEGF drugs as a standalone therapy, as often as seven times per year. We have completed a Phase 1 clinical trial evaluating the safety and efficacy of SCS injection of Avastin, an anti-VEGF drug, in four patients with wet AMD. In this trial, SCS injection of Avastin was observed to be well tolerated, with no treatment-related serious adverse events. In addition, the four patients showed an average improvement in visual acuity of nine letters on a standard eye chart at the end of the eight-week post-treatment observation period. Two of the four patients showed an improvement in visual acuity of at least 13 letters. Because wet AMD manifests in the retina and choroid, we believe that SCS injection of drug more directly to the retina and choroid may result in faster onset of therapeutic effect as compared to intravitreal injection, and could reduce the necessary frequency of treatment to once every 90 days.
Our drug candidates, microinjector, and method of non-surgical drug delivery into the SCS are protected by three issued U.S. patents and over 20 patent applications filed in the United States and major international markets. Our issued patents are broadly directed to methods of administering drugs of any type into the SCS by injection and are not scheduled to expire until between 2027 and 2029. Our patent applications relate to SCS delivery technology and methods, our current therapeutic drug candidates and formulations, various therapeutic uses, including treatment of specific indications such as macular edema associated with non-infectious uveitis and RVO, as well as wet AMD and DME, and administration of specific classes of drugs to the SCS, including anti-inflammatory drugs and anti-VEGF drugs. Our pending patent applications are not projected to expire until between 2027 and 2034.
If our product candidates are approved, we plan to commercialize them with a specialty sales force of 30 to 40 representatives to target retinal specialists in the United States, and we may also pursue collaborations with third parties to commercialize any of our drugs approved for marketing outside the United States.
The members of our management team have held senior leadership positions at a number of pharmaceutical and biotechnology companies with approved ophthalmic drugs, including Alcon, Alimera Sciences, CIBA Vision and ISTA Pharmaceuticals. Members of our team have contributed to the development and commercialization of several retinal products, such as Triesence, Iluvien, Nevanac, Visudyne and Xibrom.
87
Strategy
Our goal is to be a leading biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and the retina. The key elements of our strategy are:
| Advancing CLS-1001 and CLS-1003 to FDA approval under the Section 505(b)(2) regulatory pathway. Our most advanced product candidates, CLS-1001 and CLS-1003, utilize CLS-TA, our proprietary formulation of TA, a corticosteroid that has been used for decades to treat ocular inflammatory conditions. We believe this approach will allow us to more efficiently and predictably pursue the regulatory approval of these product candidates under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. We plan to advance CLS-1001 into a single pivotal Phase 3 clinical trial for macular edema associated with non-infectious uveitis and, based on our discussions with the FDA, we expect this single trial to be sufficient to support a 505(b)(2) NDA filing. Our goal is to submit the 505(b)(2) NDA for CLS-1001 in the first half of 2017. Separately, we expect to initiate a Phase 2 clinical trial for CLS-1003 for macular edema associated with RVO in the second half of 2014, with data expected in the second half of 2015. |
| Maximizing the commercial potential of our product candidates. If either CLS-1001 or CLS-1003 is approved, we plan to build a specialized sales force of approximately 30 to 40 representatives to target the approximately 1,700 retinal specialists in the United States. We expect that this sales force would be able to effectively sell more than one of our products, in the event that multiple product candidates are approved for marketing. We have retained the worldwide commercialization rights to all of our product candidates, and we may pursue collaborations with third parties to commercialize any of our drugs approved for marketing outside the United States, either through territorial licenses or distributor relationships. |
| Developing therapies for other back of the eye diseases that can be treated more effectively with SCS injection. We believe that SCS injection of ocular therapies could have benefits in a variety of other back of the eye indications. Our initial areas of focus include: |
| Advancing our CLS-1002 wet AMD development program. We are investigating opportunities to improve the treatment of wet AMD through SCS injection of compounds that are commonly used for this disease, such as anti-VEGF drugs, or have shown clinical promise, such as anti-VEGF drugs in combination with anti-PDGF drugs. These therapies are commonly administered by intravitreal injection. We have completed an exploratory Phase 1 clinical trial using an anti-VEGF drug, Avastin, administered into the SCS, rather than intravitreally, in four patients with wet AMD, from which we observed encouraging safety and efficacy results. We are conducting preclinical studies evaluating other compounds with dual anti-VEGF and anti-PDGF activity, with the goal of selecting a lead drug candidate under this program for IND submission in 2015. |
| Developing a product candidate to treat DME. DME, like uveitis and RVO, is characterized by an inflammatory aspect. Once the data from the CLS-1003 Phase 2 clinical trial have been analyzed, we intend to initiate clinical trials to develop a product candidate to treat DME modeled after our approach for addressing macular edema associated with RVO. |
| Developing additional therapies through collaborations with third parties. We plan to explore collaborations with third parties to develop SCS-administered treatments for back of the eye diseases. These collaborations may take the form of in-licenses of the third parties |
88
drugs or drug candidates for our own development for SCS injection, or out-licenses for third parties to use our intellectual property covering SCS injection as part of the development of their own drugs. We are currently studying several compounds under a research collaboration with Santen Pharmaceutical Co., Ltd. |
| Maintaining and strengthening our intellectual property portfolio. Our intellectual property strategy aims to control the commercialization of SCS access, with patents and patent applications covering non-surgical SCS delivery methods, novel formulations of drugs, and microinjectors used to access the SCS. Our current patents and patent applications provide us with exclusivity in the United States and major international markets, and are not projected to expire until between 2027 and 2034. We will seek to broaden the scope of and increase the geographic reach of our patent protection throughout the world. |
The Clearside Approach
We are developing drugs for back of the eye diseases to be administered to the retina and choroid through the SCS using our proprietary microinjector. We believe that our novel, patented approach of SCS drug administration provides a number of potential benefits, including:
| Improved bioavailability at the site of disease and faster onset of therapeutic effect. In preclinical studies, we observed higher amounts of drug present in the retina and choroid following SCS injection, as compared to the distribution of the same drug following intravitreal injection. We believe this suggests that SCS injection may have similar or better efficacy with a faster onset of therapeutic effect than intravitreal injection in diseases of the retina and choroid like uveitis, RVO, wet AMD and DME. |
| Similar efficacy profile with lower drug amounts required. In a preclinical study in a model of uveitis, SCS injection of TA achieved similar efficacy results with only 10% of the drug amount commonly administered through intravitreal injection. We believe this suggests our approach may allow us to develop ocular therapies with similar efficacy, but with lower amounts of active drug, compared to current therapies. |
| Less frequent injections. Current treatments for RVO require monthly intravitreal injections of anti-VEGF drugs, while current treatments for wet AMD require such injections as often as seven times per year. For RVO patients, we believe that a combination of a standard intravitreal injection of an anti-VEGF drug that addresses the vascular aspect of the disease, together with an SCS injection of CLS-TA, which addresses the inflammatory aspect of RVO, may have similar or better efficacy with a reduction in the frequency of required anti-VEGF treatments from 30 days to 90 days. In wet AMD, we believe that more direct application of drugs with anti-VEGF or dual anti-VEGF and anti-PDGF activity to the neovascularization in the choroid through SCS injection may block the process of additional new vascular growth within the choroid before the vessels break into the retina and create further damage through leakage. We believe that such SCS injection of treatment therefore has the potential to delay vision loss for a longer duration of time than the current standard intravitreal administration of anti-VEGF drugs and, accordingly, could require less frequent administration. |
| Enhanced safety profile. Intravitreal injections result in drugs diffusing throughout the eye, including into the lens, iris and ciliary body at the front of the eye, which for some drugs, has been associated with safety issues, such as cataracts and elevated IOP levels. Intravitreal administration of |
89
TA has been associated with cataracts and increases in IOP levels in 20% to 60% of patients. Because SCS injection of drugs appears to result in drug remaining localized in the retina and choroid without substantial diffusion to the vitreous or the front portion of the eye, we believe SCS injection has the potential to reduce the incidence of these side effects. Based on interim results from our ongoing Phase 1/2 clinical trial, none of the four patients for whom data is available have experienced cataracts, abnormally high levels of IOP or other treatment-related serious adverse events over the course of 16 to 26 weeks following a single SCS injection of TA. |
| Easily incorporated into standard medical practice. If approved, our drugs will be packaged together with our SCS microinjector for one-time use by retinal specialists in their offices. Our product candidates are designed to be administered using a similar procedure as is used for intravitreal injections, and no capital equipment will be required. Accordingly, we expect our products, if approved, will be easily incorporated into retinal specialists standard medical practice. |
The current development status of our product candidates is summarized in the chart below:
Development Program |
Indication |
Route of Administration and Active Ingredient |
Status and Upcoming Milestones | |||
CLS-1001 | Macular edema associated with non- |
SCS injection of CLS-TA | Final results from ongoing Phase 1/2 clinical trial with Triesence expected 1H 2015 Initiate ~30-patient Phase 2 clinical trial in 2H 2014 with CLS-TA, with data expected 1H 2015 Initiate ~150-patient single pivotal Phase 3 clinical trial in 1H 2015 with CLS-TA, with 505(b)(2) NDA filing expected 1H 2017
| |||
CLS-1003 |
Macular edema associated with RVO |
SCS injection of CLS-TA together with intravitreal injection of anti-VEGF compound
|
Initiate ~40-patient Phase 2 clinical trial in 2H 2014, with data expected 2H 2015 | |||
CLS-1002 |
Wet AMD | SCS injection of anti- VEGF compound or compound with dual anti-
|
Exploratory Phase 1 clinical trial with Avastin completed outside the U.S. Selection of lead drug candidate for IND submission expected in 2015 |
CLS-1001 Program Targeting Macular Edema Associated with Non-infectious Uveitis
We are developing CLS-1001 for treatment of macular edema associated with non-infectious uveitis, a condition characterized by inflammation of the choroid and surrounding tissues. CLS-1001 consists of an SCS injection of CLS-TA, our proprietary formulation of TA specifically designed to be administered through our SCS microinjector. We expect final results from our ongoing Phase 1/2 clinical trial in the first half of 2015, plan to initiate a Phase 2 clinical trial with CLS-TA in approximately 30 patients in the second half of 2014, with expected data in the first half of 2015, and plan to initiate a single pivotal Phase 3 clinical trial in approximately 150 patients in the first half of 2015, with a Section 505(b)(2) NDA filing expected in the first half of 2017. Based on our discussions with the FDA, we believe we will be able to initiate our
90
single pivotal Phase 3 clinical trial of CLS-1001 before we have the final results from our planned Phase 2 clinical trial. We believe that CLS-1001 will be at least as effective in treating uveitis, including the associated macular edema, as commonly used treatments with corticosteroids, but has the potential to provide improved bioavailability of drug at the diseased retina and choroid, which may result in faster onset of therapeutic effect, a similar efficacy profile with lower drug amounts required, and longer duration of therapeutic effect, potentially resulting in a reduced frequency of necessary injections. We also believe that CLS-1001 may result in fewer side effects compared to commonly used corticosteroid treatments.
Market Opportunity for Treatment of Macular Edema Associated with Non-infectious Uveitis
Uveitis is one of the most frequent causes of blindness in the developed world. Based on prevalence data published in the journal Ophthalmology in 2004 and United States census data for 2010, we estimate approximately 350,000 individuals in the United States suffer from some form of uveitis. Typically diagnosed in individuals between the ages of 20 and 50, uveitis can occur in one or both eyes and accounts for approximately 10% of cases of blindness in the United States, according to a study published in Journal of Ophthalmology. Uveitis can be either infectious or non-infectious. Non-infectious uveitis accounts for approximately 80% of all uveitis cases. Macular edema related to uveitis is the predominant cause of blindness or visual impairment among patients with uveitis, accounting for approximately 30% of cases of blindness in uveitis patients. Because uveitis can become chronic or recurrent if not adequately treated, some patients may become refractory, or unresponsive, to treatment, leading to irreversible blindness.
Limitations of Currently Available Therapies for Macular Edema Associated with Non-Infectious Uveitis
Corticosteroids are the most commonly used treatments for non-infectious uveitis. Corticosteroids administered through eye drops, although used to treat some uveitis patients, are generally ineffective in treating patients with macular edema associated with non-infectious uveitis. Corticosteroids administered orally or systemically can be effective in treating patients with macular edema associated with non-infectious uveitis, but their long-term use is associated with significant side effects. As a result of the shortcomings associated with these methods of administering corticosteroids, the most common method for treating macular edema associated with non-infectious uveitis is intravitreal injection or implant of a corticosteroid, such as TA, dexamethasone or fluocinolone acetonide. Examples of intravitreal corticosteroid treatments include Ozurdex®, Retisert®, Kenalog® and Triesence. Ozurdex is a biodegradable dexamethasone implant that has been approved by the FDA as a treatment for non-infectious uveitis, but has been associated with increased IOP in 25% of patients, conjunctival hemorrhages in 22% of patients and cataracts in 5% of patients. Retisert, a non-biodegradable fluocinolone acetonide implant that requires surgical administration, has also been approved by the FDA as a treatment of non-infectious uveitis, but more than 75% of patients receiving Retisert require additional medications within three years of receiving Retisert therapy to effectively treat their uveitis, more than 35% of patients require surgical intervention in order to control increase in IOP levels, and nearly all patients develop cataracts and require cataract surgery following treatment.
Triesence and Kenalog are the main injectable formulations of TA that are used for the treatment of intraocular inflammatory conditions. Kenalog is used off-label because it has not been approved by the FDA to treat intraocular conditions. TA has been associated with increases in IOP or cataract progression in 20% to 60% of patients when injected intravitreally.
Immunosuppressive agents are also sometimes used to control the inflammation associated with non-infectious uveitis, but due to their ability to systemically impair the bodys immune system and their
91
association with additional side effects, physicians are cautious in using these agents. Anti-VEGF therapies are also used to treat macular edema in a variety of diseases, but are generally not used in uveitis patients because they do not treat the inflammation inherent in uveitis or most of the other complications associated with uveitis.
Benefits of CLS-1001
If approved, CLS-1001 would be the first treatment specifically indicated for macular edema associated with non-infectious uveitis. Because CLS-1001 is based on our CLS-TA formulation of TA, a corticosteroid known to be effective in treating uveitis, we believe that our product candidate will be at least as effective as TA in treating the disease, including the associated macular edema. Our preclinical studies suggest that SCS injection of TA provides improved bioavailability of drug at the retina and choroid, which may result in faster onset of therapeutic effect and a similar efficacy profile with lower drug amounts required. Our early clinical trial results suggest the potential for CLS-1001 to be effective at treating uveitis for at least 90 days following a single SCS injection. Currently used ocular injections of TA are typically effective for approximately 90 days. In contrast to intravitreal injections, based on our preclinical studies, we believe that SCS injection will allow the drug to remain more localized in the diseased retina and choroid. As a result of this localization, we believe that CLS-1001 may be effective in treating non-infectious uveitis, including the associated macular edema, without significant drug exposure to other eye tissues, thereby potentially reducing the incidence of side effects associated with commonly used corticosteroid treatments.
Initial Clinical Research on Surgical Administration of TA into the SCS
In 2011, two separate studies were published by researchers evaluating administration of TA together with the anti-VEGF drug Avastin in a total of 27 patients with severe retinal disease. In one study, six patients had RVO or DME, and in the other study, 21 patients had wet AMD. In both studies, a surgical procedure was used to cut open the eye to expose the choroidal tissue and insert a small tube into the SCS, through which both TA and Avastin were administered. The six RVO and DME patients were followed for one year and the 21 wet AMD patients were followed for six months. Of the 27 patients, only one patient had developed cataracts, and one other patient was in the initial stages of cataract formation at the end of the observation period. In addition, only one patient showed elevated IOP, which was controlled with a topical glaucoma medication. We believe these studies suggest that surgical administration of TA into the SCS might present a lower risk of increased IOP and cataracts than intravitreal injection of TA, which has been associated with increases in IOP or cataract progression in 20% to 60% of patients.
Our Clinical and Preclinical Development of CLS-1001 for Non-Surgical Administration
We have conducted or are conducting the following clinical trial and preclinical studies, in each case using TA injected non-surgically using a prototype of our microinjector, as part of our CLS-1001 development program:
| an ongoing Phase 1/2 clinical trial in non-infectious uveitis patients evaluating SCS injections of Triesence, a commercially available TA formulation, with our microinjector, from which we expect final safety and efficacy data in the first half of 2015; |
| a completed preclinical study comparing the pharmacokinetic effects of SCS and intravitreal injection of Triesence in rabbits; |
| a completed preclinical study comparing the pharmacokinetic effects of SCS injection of CLS-TA and Triesence in rabbits; |
92
| a completed preclinical study evaluating the pharmacodynamic effects of SCS and intravitreal injection of Triesence in a pig model of uveitis; and |
| completed preclinical studies evaluating the toxicology of SCS injection of CLS-TA and Triesence in rabbits. |
Details of this trial and these studies are summarized below.
Ongoing Phase 1/2 Clinical Trial
In July 2013, we initiated a Phase 1/2 multi-center, open-label clinical trial designed to evaluate the safety and tolerability of a single injection of Triesence into the SCS in patients diagnosed with non-infectious uveitis. The primary purpose of this trial is to demonstrate the overall safety of treating uveitis patients by administering a commercially available formulation of TA into the SCS, rather than intravitreally. We expect to use CLS-TA for all future clinical trials intended to support a 505(b)(2) NDA for CLS-1001.
Clinical Trial Design. We plan to enroll approximately 10 patients at three centers in this trial. Four patients have been treated in the trial to date. Eligibility criteria include adult patients with non-infectious uveitis experiencing either macular edema or vitreous haze, another common complication of uveitis. We are enrolling patients with either of these complications of uveitis in order to assess the safety and tolerability of SCS injection of TA and to determine whether SCS injection of TA can improve patient vision by reducing the effects of either of these conditions. For inclusion in the trial, patients must have IOP of no greater than 22 mmHg. Each patient enrolled receives a single SCS microinjection of 4.0 mg of Triesence, a common intravitreal dose of TA, at a location at the front of the eye similar to the location typically used for intravitreal injection. Patients return for a follow-up examination on the day after the injection and then for eight additional evaluations at weeks 1, 2, 4, 8, 12, 16, 20 and 26 following the treatment. Patients may receive other treatment for non-infectious uveitis at any time during the trial with any accepted therapy, if the patients condition deteriorates or if the treating physician otherwise determines it to be advisable. In the event a patient receives other treatment, we continue to follow the patient for the duration of the trial for safety purposes, but we thereafter no longer evaluate efficacy measures.
This Phase 1/2 clinical trial is not powered to show efficacy results with statistical significance. Statistical significance means that an effect is unlikely to have occurred by chance. Clinical trial results are considered statistically significant when the probability of the results occurring by chance, rather than from the efficacy of the product candidate, is sufficiently low. Since the trial is not powered to show results with statistical significance, the results from the trial may be attributable to chance and not the clinical efficacy of TA. This trial design is typical of Phase 1 and some Phase 2 clinical trials, the principal purpose of which is to provide the basis for the design of larger, definitive trials with the inclusion of more patients to show statistical significance.
Endpoints. Our Phase 1/2 clinical trial is primarily a safety and tolerability study, although we are also assessing efficacy measures. The main safety endpoint relates to changes from baseline in IOP. We are also assessing efficacy endpoints relating to changes in best-corrected visual acuity, or BCVA, and changes in retinal thickness, which is a common measurement of macular edema. BCVA is a common measurement of a patients ability to see at distances and is measured as the number of letters that the patient can read on the Early Treatment Diabetic Retinopathy Study, or ETDRS, eye chart. The ETDRS eye chart is a well-established standardized method of testing visual acuity.
93
Interim Safety Results. The chart below shows the mean change in IOP for the four patients treated to date in the trial, as measured at different time points post-treatment. Because the patients were treated at different dates, two have completed the full 26-week observation period, while the other two have been observed between 16 and 20 weeks post-treatment. No patient has experienced a clinically meaningful increase in IOP, defined as an increase in IOP from baseline of 10 millimeters of mercury, or mmHg, a common measure of pressure, or an absolute increase in IOP to a level above 25 mmHg, which symptoms are typically seen at four to 12 weeks after administration. Additionally, no patient has required medication to lower increased IOP during the course of the trial.
The number of patients included in the results for each time point in the chart below, indicated with the notation n=, varies because only two patients have progressed beyond the week 16 post-treatment observation period. In addition, at some time points up to week 4, a patient missed a follow-up visit, resulting in only three of the four patients being measured.
Mean Change in IOP
In addition to these IOP observations, the drug has been generally well tolerated in the trial to date. One patient with a history of pulmonary embolisms was hospitalized following an embolism 10 weeks after treatment. This serious adverse event was considered to be unrelated to the treatment and resolved after three days.
Interim Efficacy Results Visual Acuity. Data are available with respect to BCVA for all four patients who have received treatment to date. At each follow-up examination, the change in BCVA was measured as the difference from the patients baseline in the number of letters read on the ETDRS eye chart. To date, one patient has completed the entire 26-week observation period without receiving other treatment for non-infectious uveitis and one patient has completed 16 weeks of post-treatment observation without receiving other treatment for non-infectious uveitis. The remaining two patients received other treatment for non-infectious uveitis at weeks 8 and 16, respectively.
The chart below summarizes the mean improvement in BCVA observed to date in the trial for the four patients treated. All four patients showed improvement in BCVA within 24 hours following the SCS injection of Triesence. Improvements increased to between 5 and 15 letters from baseline by week 2. This observation generally continued through week 8. The two patients who did not receive other treatment for non-infectious uveitis and whose measurements, accordingly, have continued for 16 weeks and 26 weeks, respectively, have sustained BCVA improvements of between 5 and 15 letters, at every point at which they have been measured in the trial.
94
In addition to the number of patients varying at each time point as a result of being treated on different dates and missing follow-up visits, as described above under Interim Safety Results, the number of patients included in the results for the time points in the chart below also varies because efficacy observations for the two patients who received other treatment for their non-infectious uveitis during the follow-up observation period of the trial are only included up to the point that these patients received such other treatment.
Improvement in Best Corrected Visual Acuity (Number of Letters Read on ETDRS Chart)
Interim Efficacy Results Retinal Thickness. Of the four patients treated in the trial to date, three were experiencing macular edema at the time of treatment and were therefore also evaluated for change in retinal thickness after the injection. A reduction in retinal thickness in patients with macular edema occurs with the removal of excess fluid from the retina, reflecting a reduction of the swelling of the macula and other parts of the retina, affected by the edema. The fourth patient was experiencing vitreous haze associated with uveitis, an inflammatory symptom of uveitis where inflammatory cells cloud the vitreous, but in this case, the patient did not have macular edema, and change in retinal thickness is therefore not a relevant measurement for this patient.
The chart below summarizes the mean change in retinal thickness observed to date in the trial in the three evaluated patients. Each of the three evaluated patients achieved meaningful reductions in retinal thickness of approximately 50 microns from their respective baselines by week 2 following treatment. In addition, by week 2, two of the three evaluated patients experienced a reduction in retinal thickness to near or below 310 microns, which represents the maximum retinal thickness for 95% of the population with normal retinas. One micron is equal to one-thousandth of one millimeter. The reduction in retinal thickness experienced by one of these patients was over 20% from the patients baseline. Both of these measures are considered clinically meaningful improvements. For these two patients, these levels of reduction were generally sustained throughout the remainder of their measurement periods of 12 and 26 weeks, respectively.
95
The number of patients included in the results for the time points in the chart below varies because, of the three patients that were experiencing macular edema, one has completed the full 26-week follow-up period without requiring any other treatment and, for these other two patients, efficacy observations are only included up to the point that these patients received other treatment.
Mean Reduction in Retinal Thickness
We believe these interim results are encouraging because we observed a rapid and persistent effect in the back of the eye after the SCS injection procedure at a location at the front of the eye similar to the location typically used for intravitreal injection. It is important to note that the improvements in BCVA and reductions in retinal thickness were achieved only in a small patient population, with data from only four patients to date, in an open-label setting, were not statistically significant and might not be achieved by any additional patients observed in this trial or replicated in larger-scale trials.
Preclinical Study Comparing the Pharmacokinetic Effects of SCS and Intravitreal Injection of Triesence in Rabbits
We conducted a preclinical study in rabbits to compare the pharmacokinetic results of SCS injections and intravitreal injections of Triesence, a commercially available TA formulation. Pharmacokinetics refers to the process by which a drug is distributed and metabolized in the body, which provides information on drug levels in specific tissues and how these levels change over time. To compare these results, we observed the relative distributions of Triesence in the different tissues and areas of the eye for each method of administration.
In this study, each rabbit received a single dose of 4.0 mg of Triesence on day 1 of the study injected either intravitreally or into the SCS. The rabbits were then observed for periods of up to 90 days and the concentration of TA in various parts of the eye was measured at days 14, 28, 56 and 91.
The tables below illustrate the results of this study. For each tissue type or area of the eye, the values shown represent the average concentration of drug observed in the rabbits at the particular measurement points during the study, when comparing the two routes of injection. For clarity of presentation, the tables below include varying concentration scales.
96
Concentration of TA Following Either SCS or Intravitreal (IVT) Injection
![]() |
![]() | |
![]() |
![]() | |
![]() |
![]() |
In the inner sclera, choroid and outer retina, significantly higher concentrations of TA administered into the SCS were present throughout the 91-day period as compared to TA administered intravitreally. The opposite was the case in the iris, ciliary body, lens and aqueous humor, all of which are located at the front of the eye, as well as in the vitreous, with each of these tissues showing higher levels of TA throughout the 91-day period when administered intravitreally as compared to its administration into the SCS. Only minimal levels of TA were present in the iris, ciliary body, lens and aqueous humor when administered into the SCS. Although there was variability in the relative concentrations in the inner retina, which is the part of the retina adjacent to the vitreous, at different time points, the concentrations were generally comparable
97
across both administration methods. In this study, we also compared the drug levels in the blood plasma for each method of administration. Minimal levels of drug in the blood plasma were detected following each method of administration.
We believe these results suggest that drug administered through the SCS can remain substantially localized within the targeted retina and choroid, and away from other parts of the eye, where they could result in a higher incidence of side effects. We also believe these results suggest that SCS injection provides substantially better bioavailability for at least 90 days in the targeted retina and choroid than intravitreal injection.
Preclinical Study Comparing the Pharmacokinetic Effects of SCS Injection of CLS-TA and Triesence in Rabbits
In order to establish that our CLS-TA behaves in the same manner as Triesence despite the differences in formulation, we conducted a preclinical pharmacokinetic study in rabbits, comparing the pharmacokinetic profile of our CLS-TA with the profile of Triesence, each injected into the SCS. In the study, each rabbit received a single dose of 4.0 mg of either our CLS-TA or Triesence injected into the SCS on day 1. The rabbits were then observed for periods of up to 90 days and the resulting concentrations of each of the two TA formulations in various parts of the eye was measured at days 15, 29, 58, 63 and 91.
In this study, our CLS-TA and Triesence had comparable distributions throughout the eye over the 90-day period. As shown in the graphs below, both our CLS-TA and Triesence, administered through the SCS, remained present in the retina and choroid throughout the 90-day period following injection.
Concentration of Either CLS-TA or Triesence Following SCS Injection
|
![]() |
98
Preclinical Study Evaluating the Pharmacodynamic Effects of SCS and Intravitreal Injection of Triesence in a Pig Model of Uveitis
In this preclinical study, the results of which were published in the journal Investigative Ophthalmology and Vision Science, we studied the pharmacodynamics of Triesence injected into the SCS and injected intravitreally in a pig model of uveitis. Pharmacodynamics refers to the biochemical and physiological effects of a drug on the body. In this study, there were three drug treatment arms: two intravitreal and one SCS. The intravitreal injections were with doses of either 0.2 mg or 2.0 mg of Triesence and the SCS injection was with a dose of 0.2 mg of Triesence. The pigs were observed for three days after injection to measure their average change in inflammatory score, as measured by an established scale for measuring inflammation in the eye, the modified McDonald-Shadduck grading system. After three days, both the 2.0 mg intravitreal and the 0.2 mg SCS doses were observed to be more effective at reducing uveitic inflammation than the 0.2 mg intravitreal injection. Additionally, the 0.2 mg SCS dose and 2.0 mg intravitreal dose achieved similar reductions in inflammatory scores each day. Therefore, SCS injection of Triesence had a similar pharmacodynamic response to intravitreal administration at only 10% of the dose. The graph below illustrates these results.
Reduction in Inflammation Following Either SCS or Intravitreal Injection of Triesence in a Pig Model of Uveitis
Preclinical Studies Evaluating the Toxicology of SCS Injection of CLS-TA and Triesence in Rabbits
We have conducted toxicology studies in rabbits in which both our CLS-TA and Triesence were well tolerated when injected into the SCS. In one study, rabbits received a single SCS injection of either 3.2 mg or 5.2 mg of Triesence or of a vehicle control without active drug. The rabbits were then evaluated for the following 17 weeks. In the other study, rabbits received an initial SCS injection of either 4.0 mg of our CLS-TA or of vehicle control and were then evaluated for the following 13 weeks. A subgroup of the rabbits received a second SCS injection of our CLS-TA after the first 13 weeks and this subgroup was evaluated for an additional 13 weeks, resulting in a total observation period of 26 weeks. In both studies, the rabbits were observed for tolerability assessments as well as mortality and clinical observations, body weight and food and water consumption.
In these studies, all doses of our CLS-TA and Triesence were well-tolerated. In the study in which rabbits received our CLS-TA, a slight increase in IOP was observed. There were no other treatment-related or administration-related side effects, and in each case localization of TA in the back of the eye was observed, with minimal exposure in the front of the eye.
99
Planned Phase 2 Clinical Trial
We plan to conduct a Phase 2 randomized, controlled, multi-center clinical trial in the United States in approximately 30 patients with macular edema associated with non-infectious uveitis. We currently expect to initiate this trial in the second half of 2014 after we have completed dosing in the ongoing Phase 1/2 clinical trial. Of the approximately 30 patients to be enrolled, approximately equal numbers of patients will receive either a 4.0 mg dose of our CLS-TA, which is the standard dose of TA when administered intravitreally, or a lower dose of 0.8 mg of our CLS-TA, in both cases administered through the SCS with our microinjector. The trial will provide safety and efficacy information on SCS injection of our CLS-TA using the standard dose. We intend to explore the lower dose in this trial to assess whether efficacy may be observed at the lower dose. If the results of the Phase 2 clinical trial suggest that a lower dose is effective, we may seek to explore, and potentially seek approval of, the lower dose subsequent to the completion of our planned Phase 3 clinical trial using the standard 4.0 mg dose.
The primary efficacy endpoint will be the mean change from baseline in retinal thickness at two months after treatment. Secondary efficacy endpoints will include visual acuity improvements at one and two months post-treatment, measured by the mean change in BCVA from baseline. Safety measures will be monitored over the two-month observation period and will include the incidence of adverse events and serious adverse events, including cataracts and increases in IOP.
Planned Pivotal Phase 3 Clinical Trial
We intend to conduct a single pivotal Phase 3 randomized, controlled, multi-center clinical trial in patients with macular edema associated with non-infectious uveitis to support a Section 505(b)(2) NDA for this indication, which we expect to be able to file in the first half of 2017. We expect to commence this trial in the first half of 2015. Based on our discussions with the FDA, we do not expect to be required to wait for findings from our Phase 2 clinical trial to begin the single pivotal Phase 3 clinical trial and we expect that the single pivotal trial will be sufficient to support a potential Section 505(b)(2) NDA filing. We expect to enroll approximately 150 patients with macular edema associated with non-infectious uveitis, randomized 1:1 either to a treatment arm or to a sham injection arm. Based on discussions with the FDA, we expect to be able to use a sham injection as a comparator for CLS-1001, as opposed to an active drug, because there are no approved therapies for macular edema associated with non-infectious uveitis against which to compare CLS-1001. All of the approximately 75 patients in the treatment arm will receive a 4.0 mg dose of our CLS-TA injected into the SCS using our microinjector. In order to simulate an injection to maintain masking, the sham injection procedure will include all steps involved in the SCS injection procedure, except that an empty microinjector without a needle will be used to apply pressure to the eye. We anticipate that the treatment arm will receive an initial SCS injection of our CLS-TA at the beginning of the trial and a second SCS injection of our CLS-TA at week 12.
The primary efficacy endpoint of the trial will be mean change in BCVA from baseline at week 26. Secondary efficacy endpoints will include additional measures of change in visual acuity and reductions in retinal thickness from baseline. Safety measures will be monitored over the 26-week observation period and will include the incidence of adverse events and serious adverse events, including cataracts and increases in IOP.
Regulatory Approval Pathway of CLS-1001
If our single pivotal Phase 3 clinical trial is successful, we intend to seek regulatory approval of CLS-1001 by utilizing Section 505(b)(2) of the FDCA. As part of our NDA submission under Section 505(b)(2),
100
we intend to rely on the results from our ongoing Phase 1/2 clinical trial, our planned Phase 2 and single pivotal Phase 3 clinical trials conducted under our existing IND for CLS-TA, as well as the FDAs previous findings of safety and efficacy for TA and an analysis of available data from clinical literature.
Based on our discussions with the FDA, we believe this single pivotal Phase 3 clinical trial will be sufficient to support our NDA filing for macular edema associated with non-infectious uveitis pursuant to Section 505(b)(2). We also intend to base any foreign marketing applications, in part, on data obtained through these trials.
Orphan Drug Application for CLS-1001
We have applied for orphan drug designation from the FDA in the United States, and intend to apply for orphan drug designation from the European Medicines Agency in the European Union for CLS-1001 for treatment of non-infectious uveitis. Orphan drug designation for this indication would make us eligible for seven years of marketing exclusivity in the United States and 10 years of marketing exclusivity in the European Union, if we receive the first marketing approval of TA for macular edema associated with non-infectious uveitis. Orphan drug designation would also provide us with certain tax incentives and user fee waivers. However, even if we are able to obtain orphan drug designation, it will not convey any advantage in, or shorten the duration of, the regulatory review and approval process for our marketing application.
CLS-1003 Program Targeting Macular Edema Associated with Retinal Vein Occlusion
We are developing CLS-1003 for treatment of macular edema associated with RVO, a sight-threatening disorder resulting from the blockage of a retinal vein. CLS-1003 consists of an SCS injection of CLS-TA with our microinjector, for administration together with an intravitreal injection of an anti-VEGF drug. We plan to initiate a Phase 2 clinical trial in approximately 40 patients in the second half of 2014, with data expected in the second half of 2015. We believe that CLS-1003 may provide faster onset of therapeutic effect compared to currently used intravitreal anti-VEGF injections alone, while also reducing the frequency of required intravitreal anti-VEGF treatments from 30 days to 90 days. In addition, we believe that the side effect profile of CLS-1003 will be similar to that of current intravitreal anti-VEGF injections alone.
Market Opportunity for Treatment of Macular Edema Associated with RVO
RVO is a sight-threatening disorder resulting from a blockage of one of the veins carrying blood out of the retina. RVO is estimated to affect more than 16 million adults worldwide, according to a 2010 study published in the journal Ophthalmology, and we estimate RVO affects 500,000 adults in the United States annually. In RVO, the blockage of a retinal vein can lead to poor blood circulation, low oxygen, and sometimes inflammation. A blocked vein will leak its contents of blood and fluid. Bleeding within the retina and swelling from fluid can create macular edema.
Limitations of Currently Available Therapies for Macular Edema Associated with RVO
There are three primary treatments currently used for macular edema caused by RVO: intravitreal injections of anti-VEGF medications, intravitreal corticosteroid injections and laser surgery. The current standard treatment for macular edema associated with RVO involves intravitreal injections of anti-VEGF drugs, such as Lucentis, Eylea or Avastin. Lucentis and Eylea are indicated for monthly administration and Avastin is used in a similar fashion, but off-label. These monthly treatments are required throughout the
101
course of the disease, which could last for years. Anti-VEGF drugs are effective in significantly improving vision in approximately 30% to 40% of patients with macular edema associated with RVO, and have limited side effects.
Corticosteroid treatment, specifically TA injected intravitreally, was previously evaluated in a series of randomized, multi-center clinical trials, called the SCORE studies, conducted by the National Eye Institute. In these studies, approximately 20% of patients with macular edema associated with RVO had meaningful gains in visual acuity after one year with a dosing frequency of one intravitreal injection of TA every four months. However, several side effects were observed, including cataracts and elevated IOP. Because of these side effects, intravitreal administration of corticosteroids, such as TA, is not the preferred therapy, even though it has been observed to be effective in reducing macular edema associated with RVO. Another therapy, Ozurdex, an extended release corticosteroid implanted in the vitreous, has also been approved by the FDA for the treatment of RVO, but has also been associated with increased IOP in 25% of patients, conjunctival hemorrhages in 22% of patients and cataracts in 5% of patients.
Before the introduction of anti-VEGF drugs, laser surgery was the leading therapy for treating macular edema associated with RVO. Laser surgery can be used to help control bleeding and swelling, which can reduce the loss of sight, but cannot improve vision. Laser surgery, however, cannot be used long term because it permanently damages the retina.
Benefits of CLS-1003
We believe that SCS administration of CLS-TA, by addressing the inflammatory aspect of RVO, in combination with intravitreal anti-VEGF treatment, addressing the vascular aspect of RVO, may result in faster onset of therapeutic effect compared to currently used intravitreal anti-VEGF treatment alone. Based on the SCORE studies described above and our findings in preclinical studies, we believe that each SCS injection of CLS-TA may provide a duration of effect longer than anti-VEGF therapy alone, while also potentially reducing the frequency of necessary anti-VEGF treatments from 30 days to 90 days, due to the benefits of both corticosteroid and anti-VEGF treatment. In addition, we believe that the side effect profile of CLS-1003 will be similar to that of current intravitreal anti-VEGF treatments alone, as SCS injections of CLS-TA should allow the corticosteroid to remain substantially localized in the retina and choroid without introducing the side effects that are commonly observed with other routes of administration of corticosteroids.
Planned Clinical Trials
In support of our planned clinical development program for CLS-1003, we are in the process of completing a toxicology study in rabbits with the SCS injection of CLS-TA together with the intravitreal injection of the anti-VEGF drug Eylea. Depending on the outcome of this study, we intend to initiate a Phase 2 randomized, multi-center, double-masked clinical trial of CLS-1003 in the second half of 2014 under our existing IND for CLS-TA.
Based on our ongoing toxicology study and our clinical and preclinical experience with SCS administration of TA in our CLS-1001 program, we anticipate being able to proceed directly into a Phase 2 clinical trial for CLS-1003. The goal of the Phase 2 clinical trial will be to demonstrate that patients treated with CLS-TA administered into the SCS together with Eylea administered intravitreally may require less frequent treatments than monotherapy of Eylea administered intravitreally.
102
We expect to enroll approximately 40 patients at 10 sites in the United States for the Phase 2 clinical trial. All patients will start by receiving one intravitreal injection of 2.0 mg of Eylea, in a total volume of 50 microliters, and will then be randomized on a 1:1 basis to receive an SCS injection of either 4.0 mg of our CLS-TA, in a total volume of 100 microliters, or a sham procedure in the same visit. After randomization, patients will be seen in the clinic once per month for three months. Patients in the CLS-TA treatment arm will receive additional intravitreal injections of Eylea at the subsequent visits one and two months after the initial injection if they continue to experience increases in macular edema or reductions in visual acuity. If they do not experience increases in macular edema or reductions in visual acuity at these subsequent visits, they will not receive additional intravitreal Eylea treatment. Patients in the control arm will receive monthly intravitreal Eylea injections, as specified on the Eylea label.
The primary objective of the trial will be to evaluate the safety and efficacy of a single SCS injection of CLS-TA together with the initial intravitreal injection of Eylea, compared to monthly intravitreal Eylea injections alone. The primary efficacy endpoints in the trial will include determining the number of required Eylea treatments in each arm, which we believe will provide an indication of whether concomitant therapy provides any advantage to the patient in reducing the number of required Eylea treatments. Secondary efficacy endpoints will include measures of change in visual acuity and reductions in retinal thickness from baseline. The safety endpoints will be the incidence of adverse events and serious adverse events, including increases in IOP.
Regulatory Approval Pathway
We intend to meet with the FDA following the completion of our Phase 2 clinical trial to discuss the details of the regulatory approval pathway for CLS-1003. If the results of our planned Phase 2 clinical trial are positive, we expect to be able to follow a 505(b)(2) regulatory approval pathway and to conduct one or two pivotal Phase 3 clinical trials in order to support an NDA submission for CLS-1003 in macular edema associated with RVO. In pursuing the 505(b)(2) regulatory pathway, we intend to rely on the results from our planned CLS-1003 clinical trials, the FDAs previous findings of safety and efficacy for TA, and peer-reviewed literature.
CLS-1002 Program Targeting Wet Age-Related Macular Degeneration
Under our CLS-1002 program, we intend to develop a treatment for wet AMD that, through SCS administration with our microinjector, could reduce the frequency of necessary treatments compared to the current standard of care. Wet AMD is a condition involving the abnormal formation and growth of new blood vessels in the choroid, their intrusion into the outer layers of the retina and leakage of blood and fluid into the retina. We have completed a Phase 1 clinical trial evaluating the safety and efficacy of SCS injection of Avastin, an anti-VEGF drug, in four patients with wet AMD. We are evaluating a number of compounds as SCS-injected therapies for the treatment of wet AMD, including compounds with anti-VEGF activity, and compounds with dual anti-VEGF and anti-PDGF activity, and expect to select a lead drug candidate for IND submission in 2015. We believe that CLS-1002 may show faster onset of therapeutic effect as compared to intravitreal injection, while potentially reducing the frequency of necessary treatment.
Market Opportunity for Treatment of Wet AMD
Wet AMD is a leading cause of severe vision loss and blindness in people over the age of 50 in the developed world. If untreated, the blood vessel growth and leakage associated with wet AMD can eventually lead to blindness. The majority of patients with wet AMD experience severe vision loss in the
103
affected eye within approximately two years after diagnosis of the disease. According to a study published in 2004 in the journal Ophthalmology, approximately 1.2 million people in the United States suffer from wet AMD. Based on estimates from AMD Alliance International, a non-profit organization focused on AMD awareness, and census growth data, we estimate there are approximately 230,000 new cases of wet AMD each year in the United States. Because the risk of developing wet AMD increases with age, we expect that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide.
Limitations of Currently Available Therapies for Wet AMD
The current standard of care for the treatment of wet AMD is administration by intravitreal injection of anti-VEGF drugs as a standalone therapy. The anti-VEGF drugs most commonly used include Lucentis and Eylea, both of which have been approved by the FDA for the treatment of wet AMD, and Avastin, which is used off-label for the disease.
Because anti-VEGF therapies inhibit abnormal blood vessel growth and leakage, they are effective in reducing the macular edema associated with wet AMD. Anti-VEGF therapies have demonstrated the ability to prevent further visual loss in approximately 90% of treated patients. A retrospective study published in 2012 in the journal Archives of Ophthalmology concluded that the prevalence of both legal blindness and moderate visual impairment in patients two years after being diagnosed with wet AMD had decreased substantially following the introduction of anti-VEGF therapy. However, because anti-VEGF drugs do not appear to cause any regression of the underlying neovascularization associated with wet AMD, the current standard of care requires regular injections, typically as often as seven times per year, and therapy may be required indefinitely. Further, while anti-VEGF treatment is effective at preventing vision loss, only 30% of patients improve their visual acuity by 15 letters or more. Anti-VEGF treatments have been associated with subretinal fibrosis, or the formation of excess connective tissue under the retina, as well as retinal scarring in some patients.
In addition to anti-VEGF therapies, anti-PDGF drugs are being developed as potential treatments for wet AMD. Because PDGF is a major factor in the formation and stabilization of blood vessel growth in the choroid, therapies inhibiting PDGF may also be effective in addressing the abnormal growth of new blood vessels associated with wet AMD. In clinical trials, an intravitreal injection of a PDGF inhibitor together with an intravitreal injection of Lucentis improved visual acuity in approximately 60% of patients with wet AMD compared to approximately 30% of patients receiving Lucentis alone. However, no anti-PDGF therapy has been approved by the FDA for the treatment of wet AMD. Even if approved, we expect that anti-PDGF therapy would also require regular injections indefinitely.
Even though anti-VEGF and anti-PDGF therapies may be effective in treating wet AMD, intravitreal administration of these drugs relies on the process of diffusion of the drug from the vitreous outward to the retina and, eventually, the choroid, which results in lower bioavailability and the need for frequent retreatment.
Benefits of CLS-1002
The compounds we are evaluating have anti-VEGF activity, and we believe these compounds will provide the clinically established advantages that currently used anti-VEGF drugs provide, especially the reduction in macular edema and improvements in visual outcomes. Some of the compounds we are evaluating have dual anti-VEGF and anti-PDGF activity. We believe that the anti-PDGF properties together
104
with anti-VEGF properties may provide superior visual outcomes to standalone anti-VEGF drugs. We believe that the SCS administration of drugs with anti-VEGF, or dual anti-VEGF and anti-PDGF, activity more directly to the neovascularization in the choroid through SCS injection will block the process of additional new vascular growth within the choroid before the vessels break into and create further damage through leakage into the retina. We believe that such SCS injection of treatment may, therefore, provide faster onset of therapeutic effect and delay vision loss for a longer duration of time than the current standard intravitreal administration and will require less frequent administration, potentially only once every 90 days.
Clinical and Preclinical Development of CLS-1002
We have completed the following clinical trial and preclinical studies as part of our CLS-1002 development program:
| a completed Phase 1 clinical trial in wet AMD patients evaluating the safety and tolerability of SCS injection of Avastin, an anti-VEGF drug, with our microinjector; |
| a completed preclinical efficacy study of a compound with dual anti-VEGF and anti-PDGF activity in a rabbit model of wet AMD; and |
| a completed preclinical safety study of SCS injection of compounds with dual anti-VEGF and anti-PDGF activity. |
Details of the trial and studies are summarized below.
Completed Phase 1 Clinical Trial with Avastin
In order to evaluate the safety and tolerability of SCS administration of Avastin, an anti-VEGF drug, in humans with our microinjector, we conducted a Phase 1, single-center, open-label clinical trial in 2012 at the Hospital of the Association to Prevent Blindness in Mexico. Because of its established safety profile and its prevalence as an off-label treatment for wet AMD, we selected Avastin as the therapy to be evaluated in this exploratory trial. Four patients with wet AMD were enrolled in the trial, each of whom was between the ages of 63 and 73. Each patient received a 2.5 mg dose of Avastin in a 100 microliter injection in one eye using a prototype of our microinjector. The trial was conducted in accordance with current U.S. good clinical practices.
Trial Design. Eligibility criteria included adult patients with choroidal neovascularization associated with wet AMD that had previously responded to Avastin treatment, had retinal thickness in the study eye of between 275 and 600 microns in the central subfield, and had specified levels of visual acuity. In addition, patients could not have received any anti-VEGF treatment within 60 days of screening or have had any expectation of receiving such treatment during their participation in the study other than the single Avastin injection.
Once eligibility was established, each patient received a single SCS injection of Avastin and then returned for a follow-up examination on the day after the injection. Thereafter, patients returned for five additional evaluations at approximately weeks 1, 2, 3, 4 and 8 following the injection. No additional treatments were administered during the course of the trial.
Endpoints. The trial was primarily a safety and tolerability study. The safety endpoints included incidence, intensity and type of adverse events, as well as changes from baseline in IOP. We also measured efficacy endpoints, including change from baseline in BCVA letter score.
105
Safety results. SCS injection of Avastin in the trial was observed to be generally well tolerated. No increases in IOP or serious or unexpected adverse events were reported in any of the patients. Two patients experienced hyperemia, or redness in the study eye, which was mild in severity, was determined to be unrelated to treatment in the trial and resolved within a day without other treatment.
Efficacy results. Two of the four patients achieved an improvement in BCVA letter score of at least 13 letters at the end of the eight-week trial following the SCS injection of Avastin. One of these patients improved by 16 letters within one day of treatment and maintained that level of improvement for the remainder of the trial. The second patient achieved an improvement of four letters by one week after treatment, which improved to 10 letters by week 3 after treatment and 13 letters by week 8. The other two patients in the trial maintained their BCVA letter score within four letters of their baseline at each measurement point in the trial. Overall, there was an average gain of nine letters in the four patients at the end of the eight-week observation period following the SCS injection of Avastin.
The trial was not designed to show any efficacy results with statistical significance and was conducted in an open-label, uncontrolled setting. While the data from this exploratory trial suggested potential improvement in visual acuity over eight weeks following SCS injection of Avastin, it is important to note that the results from this trial were observed in only four patients and might not be achieved by any other patient treated with a product candidate to be developed as part of our CLS-1002 program. Any later-stage trials intended to support an application for regulatory approval of a product candidate for this indication will need to show statistical significance in larger, well-controlled clinical trials.
Preclinical Efficacy Study of a Compound with Dual Anti-VEGF and Anti-PDGF Activity in a Rabbit Model of Wet AMD
We conducted a preclinical study assessing the effect on retinal leakage in a wet AMD rabbit model of a drug candidate with dual anti-VEGF and anti-PDGF activity administered by SCS injection. In this study, the treatment arm of three rabbits received an SCS injection of the drug and the control arm of three rabbits received an SCS injection of a vehicle without the active drug. After 28 days, retinal leakage was induced on the surface vessels of the inner retina in both arms and leakage was measured approximately two hours after this induction. The treatment arm showed 41% less retinal leakage than the vehicle arm. We believe this suggests that this dual anti-VEGF and anti-PDGF drug administered through the SCS may be effective in treating wet AMD by reducing leakage in the retina, and even in vessels in the inner retina, which is closest to the vitreous. We are continuing to evaluate this compound.
Preclinical Safety Study of SCS Injection of Compounds with Dual Anti-VEGF and Anti-PDGF Activity
We conducted a preclinical study assessing the safety of compounds with dual anti-VEGF and anti-PDGF activity administered by SCS injection. In this study, rabbits received an SCS injection of a number of compounds and were evaluated on days 1, 4 and 7. Overall, the compounds were well tolerated with only mild or transient ocular effects observed.
Planned Clinical Development
Based on the results of our Phase 1 clinical trial in four wet AMD patients and our preclinical rabbit study, we believe that wet AMD may be effectively treated through SCS injection. We will continue to evaluate the SCS injection of a number of compounds with anti-VEGF and anti-PDGF activity to assess their potential for clinical development for the treatment of wet AMD. Once we select a lead compound for
106
clinical development, we expect to perform pharmacokinetic and toxicology studies as well as additional preclinical testing to support an IND filing by the end of 2015.
Future Potential Product Candidates
We believe that our SCS-focused approach has the potential to become more broadly used for the treatment of other back of the eye diseases, and we intend to develop additional product candidates for SCS injection based on the results of our current and planned clinical trials. In addition to uveitis, RVO and wet AMD, there are a number of ophthalmic conditions affecting the retina and choroid with unmet medical need for which SCS injection of therapy may be beneficial, including:
| Diabetic macular edema, or DME, a common ocular complication of diabetes that results in swelling in the macula and is the primary cause of vision loss associated with diabetes; |
| Polypoidal choroidal vasculopathy, or PCV, a disorder resulting from the abnormal growth of new blood vessels in the choroid adjacent to the macula. PCV is characterized by dilated and branching blood vessels in polyp like groups in the choroid that could lead to leakage; and |
| Geographic atrophy, an advanced form of AMD, is characterized by a loss of the layers of cells in the retina next to the choroid, eventually including the photoreceptor cells in the macula, leading to gradual irreversible loss of central vision and eventually blindness. |
According to the U.S. Centers for Disease Control and Prevention, or CDC, the number of Americans diagnosed with diabetes has increased from approximately 7.7 million in 1994 to approximately 21.0 million in 2010. All patients with diabetes are at risk of developing some form of diabetic eye disease. DME accounts for a majority of vision loss in patients with diabetic eye disease. According to a study published in the journal Diabetes Care in 2003, patients with diabetes have a 10% risk of developing clinically significant DME over a 10-year period. A study published in the journal Ophthalmology in 2009 found that over a 25-year period, approximately 17% of diabetics studied were diagnosed with DME. Based on this study and the current size of the U.S. diabetic population, we estimate the incidence of DME in the United States to exceed 400,000 new cases annually.
Currently, the only FDA-approved drug for the treatment of DME is the anti-VEGF drug Lucentis. Retinal specialists also use other anti-VEGF drugs off-label, such as Avastin, as well as corticosteroid therapies, primarily Kenalog and Triesence, and laser photocoagulation to treat DME. Laser photocoagulation is a procedure in which a laser is used to apply a burn or a pattern of burns to cauterize leaky blood vessels to reduce edema in the retina. Studies have shown that both anti-VEGF drugs and corticosteroids are effective in some DME patients. However, both anti-VEGF drugs and corticosteroids are limited by a need for multiple injections to maintain a therapeutic effect. This raises concerns, not only for patients, but also for caregivers who are affected by frequent doctor visits, as well as for healthcare providers who must monitor patients monthly. In addition, these therapies have safety concerns. Corticosteroids administered intravitreally have historically been associated with acceleration of cataract formation and significant increases in IOP, which may increase the risk of glaucoma. Laser photocoagulation can also have undesirable side effects, including partial loss of peripheral and night vision.
Our development program for DME will be modeled after our approach for addressing macular edema associated with RVO. We expect that any clinical trials we may conduct for this indication will be designed based on the results observed in our Phase 2 clinical trial of CLS-1003 in RVO patients.
107
Our Proprietary SCS Microinjector
Our drug candidates have been and will be specifically formulated to be injected with our microinjector into the SCS in order to spread around to the back of the eye. The single-use microinjector is designed to consistently administer drug into the SCS, in volumes similar to the amount of drug commonly used in an intravitreal injection. The microinjector will be packaged with two 30-gauge hollow microneedles of varying lengths, each less than 1.2 millimeters, to account for varying scleral thicknesses, within a custom-designed hub that optimizes insertion into the eye. Our microinjector can be used to inject a wide variety of drugs into the SCS. The microinjector is shown below.
The SCS microinjection is designed to be made perpendicular to the sclera, at a site similar to an intravitreal administration, under local anesthesia. Once drug is injected into the SCS, it spreads within the SCS to the back of the eye, where diseases manifest. The preparation and injection will require minimal training for the administering retinal specialist and can be accomplished in an in-office setting.
108
Background on Eye Disease
The human eye possesses focusing elements in the front, the cornea and lens, and a light-sensing element in the back, the retina. Light falls on the photoreceptors that are part of the retina, called rods and cones, and is converted into electrical energy, which travels via the optic nerve to the brain. The central portion of the retina is the macula, which is the region responsible for seeing color and the acute central vision necessary for activities such as reading, face recognition, watching television and driving. The brain processes the complex signals sent from the retina into vision. The following diagram illustrates the principal elements of the anatomy of a healthy eye, including a detailed cross-section of the back of the eye, which refers to the portion of the eye behind the lens.
Role of the Choroid in Retinal Disease
Eye disease can be caused by many factors and can affect both the front and back of the eye. In its most extreme cases, eye disease can result in either partial or total blindness. In the developed world, the major diseases that result in blindness are those affecting the retina. Millions of people live with varying degrees of irreversible vision loss because they have a degenerative eye disorder that affects the retina. In these conditions, the retina is damaged, affecting the retinas ability to send light signals to the brain. The choroid provides blood, oxygen and nourishment to the outer layers of the retina, but it is also thought to regulate retinal heat, to assist in the control of IOP and to absorb excess light so as to avoid reflection that can damage the retina.
The choroid can be subject to disorders that can lead to retinal damage and vision loss, including inflammatory disorders, vascular disorders and tumors. Our focus is on the first two categories of disorders. When the choroid and surrounding tissue become inflamed from an immune response, it can result in macular edema, or swelling in the macular region of the retina, which often results in distorted vision or even blindness. In addition, in the case of choroidal neovascularization, abnormal blood vessels forming from choroidal blood vessels may rupture and leak into the retina, also leading to macular edema.
109
Back of the Eye Diseases
Some of the more common diseases that originate or manifest in the retinal and choroidal areas of the eye include:
Uveitis
Uveitis is a group of ocular conditions that are characterized by inflammation that typically affects the choroid and surrounding tissues. Prolonged or severe inflammation in the back of the eye associated with uveitis can result in the breakdown of cells at the interface of the retina and choroid, leading to the leakage and accumulation of fluid in the macular region of the retina. This fluid build-up can cause macular edema, which can rapidly result in distortion of vision, and eventually blindness, given the maculas critical role in vision. Macular edema is the most frequent cause of visual impairment among patients with uveitis.
Uveitis is one of the most frequent causes of blindness in the developed world. Based on prevalence data published in the journal Ophthalmology in 2004 and United States census data for 2010, we estimate approximately 350,000 individuals in the United States suffer from some form of uveitis. Uveitis can be either infectious, caused by an immune response to fight an infection inside the eye, or non-infectious. Non-infectious uveitis accounts for approximately 80% of all uveitis cases.
Uveitis is commonly treated with corticosteroids. Corticosteroids administered through eye drops, although used to treat some uveitis patients, are generally ineffective in treating patients with macular edema associated with non-infectious uveitis. Corticosteroids administered orally or systemically can be effective in treating patients with macular edema associated with non-infectious uveitis, but their long-term use is associated with significant side effects. As a result of the shortcomings associated with these methods of administering corticosteroids, the most common method for treating macular edema associated with non-infectious uveitis is intravitreal injection or implant of a corticosteroid, such as TA, dexamethasone or fluocinolone acetonide.
Retinal Vein Occlusion
RVO is a sight-threatening visual disorder resulting from a blockage of one of the veins carrying blood out of the retina. In RVO, the blockage of a retinal vein can lead to poor blood circulation, low oxygen, and sometimes inflammation in the area that is normally drained by the affected vein. A blocked vein will leak its contents of blood and fluid. This leakage within the retina and the consequential swelling from fluid can cause macular edema. Persistent inadequately treated macular edema associated with RVO can blur vision, cause significant loss in visual acuity and eventually lead to blindness.
RVO is estimated to affect more than 16 million adults worldwide, according to a 2010 study published in the journal Ophthalmology. We estimate RVO affects 500,000 adults in the United States annually.
RVO can be treated and vision can be restored in most cases when treatment is administered relatively soon after initial diagnosis and aggressive treatment is obtained. One common method of reducing the macular edema associated with RVO is to use an anti-VEGF drug. Anti-VEGF drugs are effective in drying the leaking fluid and, therefore, they are useful in eye conditions where edema is a complication of the disease. An added challenge of RVO is inflammation that arises in response to the vascular damage and further contributes to the swelling by causing even more fluid to accumulate in the retina. Since inflammation also plays a role in vein occlusion, corticosteroids may provide an added advantage in the reduction of macular edema associated with RVO because they block the inflammatory pathways and also act to stabilize membranes.
110
Age-related Macular Degeneration
AMD is a chronic, progressive disease of the macula that results in the loss of central vision. The most common symptoms are a central blurred or blank spot, distortion of objects or simply blurred vision. Peripheral vision usually remains intact. The disease typically affects patients initially in one eye, with a high likelihood of it occurring in the second eye over time. Because AMD is strongly correlated with aging, the disease may recur, notwithstanding treatment, as the aging process continues.
There are two forms of AMD, dry AMD and wet AMD. Dry AMD is the most common form, representing approximately 85% to 90% of all AMD cases. However, dry AMD cases can develop into wet AMD, and wet AMD accounts for 90% of the severe vision loss associated with AMD.
Wet AMD occurs when new blood vessels in the choroid intrude into the retinal layers. This is referred to as choroidal neovascularization. Abnormal new blood vessels tend to be fragile and often bleed and leak fluid into the macula. Untreated, blood vessel growth and associated leakage typically lead to retinal distortion and eventual retinal scarring, resulting in irreversible destruction of the macula and loss of vision. This visual loss occurs rapidly with a progressive course.
According to a study published in 2004 in the journal Ophthalmology, approximately 1.2 million people in the United States suffer from wet AMD. Based on estimates from AMD Alliance International and census growth data, we estimate there are approximately 230,000 new cases of wet AMD each year in the United States. Because the risk of developing wet AMD increases with age, we expect that the overall aging of the population will result in a significant increase in the number of wet AMD cases, both in the United States and worldwide.
The current standard of care for the treatment of wet AMD is administration by intravitreal injection of anti-VEGF drugs as a standalone therapy. Because anti-VEGF therapies inhibit abnormal blood vessel growth and leakage, they are effective in reducing the macular edema associated with wet AMD. Anti-VEGF treatments have been associated with subretinal fibrosis, or the formation of excess connective tissue under the retina, as well as retinal scarring in some patients. In addition to anti-VEGF therapies, anti-PDGF drugs are being developed as potential treatments for wet AMD. Even though anti-VEGF and anti-PDGF therapies may be effective in treating wet AMD, intravitreal administration of these drugs relies on the process of diffusion of the drug from the vitreous outward to the retina and, eventually, the choroid, which results in lower bioavailability and the need for frequent retreatment. Patients typically receive injections as often as seven times per year to manage this chronic disease.
Diabetic Macular Edema
DME is a complication of diabetic retinopathy, a disease affecting the blood vessels of the retina. Diabetic retinopathy results in multiple abnormalities in the retina, including retinal thickening, hemorrhages, impeded blood flow, excessive leakage of fluid from blood vessels and, in the final stages, abnormal blood vessel growth. When the blood vessel leakage causes swelling in the macula, it is referred to as DME. Poorly controlled blood glucose levels, high blood pressure, abnormal kidney function causing fluid retention, high cholesterol levels and other general systemic factors are risk factors associated with DME. The principal symptom of DME is a severe loss of central vision.
According to the CDC, the number of Americans diagnosed with diabetes has increased from approximately 7.7 million in 1994 to approximately 21.0 million in 2010. According to a study published in the journal Diabetes Care in 2003, patients with diabetes have a 10% risk of developing clinically
111
significant DME over a 10-year period. A study published in the journal Ophthalmology in 2009 found that over a 25-year period, approximately 17% of diabetics studied were diagnosed with DME. Based on this study and the current size of the U.S. diabetic population, we estimate the incidence of DME in the United States to exceed 400,000 new cases annually.
Currently, the only FDA-approved drug for the treatment of DME is the anti-VEGF drug Lucentis. Retinal specialists also use other anti-VEGF drugs off-label, such as Avastin, as well as corticosteroid therapies, primarily Kenalog and Triesence, and laser photocoagulation to treat DME. Studies have shown that both anti-VEGF drugs and corticosteroids are effective in some DME patients. However, both anti-VEGF drugs and corticosteroids administered intravitreally are limited by a need for frequent injections to maintain a therapeutic effect. In addition, these therapies have safety concerns. Corticosteroids administered intravitreally have historically been associated with acceleration of cataract formation and significant increases in IOP, which may increase the risk of glaucoma. Laser photocoagulation can also have undesirable side effects, including partial loss of peripheral and night vision.
Challenges of Ophthalmic Drug Administration
Administration of drugs to treat back of the eye diseases is a significant issue in ophthalmology. Due to the effectiveness of the blood/eye barrier, it is difficult for oral or other systemically administered drugs to reach the eye in sufficient quantities to have a beneficial effect without adverse side effects to other parts of the body. It is also difficult to provide localized delivery of drug to the individual tissues of the eye through common eye drop or intravitreal injection techniques.
There is a need for more localized drug delivery to the back of the eye in a manner that is safe, effective and practical for long-term use. While there have been many attempts to deliver drugs to the back of the eye, most do not achieve sufficient and consistent concentrations for the appropriate period of time. Currently, intravitreal injection remains as the standard for delivering drugs to the retina and choroid. We believe that our novel approach using SCS injection can address several of the shortcomings of current therapies.
Manufacturing
We do not have any manufacturing facilities. We utilize contract manufacturers to formulate and produce our drug candidates and to produce our microinjector components used for our clinical trials. We assemble our microinjector ourselves for our clinical trials. We procure the active pharmaceutical ingredient for our drugs from a third-party supplier. We expect to utilize third-party manufacturers to produce commercial quantities of our drugs and microinjector, if approved. We anticipate entering into commercial supply agreements with these or other manufacturers at a later date.
Commercialization
We intend to develop and, if approved, to commercialize our product candidates in the United States, and we may enter into distribution or licensing arrangements for commercialization rights for other regions. Our management team, who will lead the commercialization of our lead product candidates, has substantial experience in sales and marketing based on their participation in the commercialization of ophthalmic drugs at large pharmaceutical companies including Alcon, Allergan, CIBA Vision, ISTA and Novartis.
For marketing in the United States, we intend to hire a dedicated field sales force consisting of approximately 30 to 40 sales professionals to target the approximately 1,700 retinal specialists in the United States.
112
Competition
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidate that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.
With respect to CLS-TA, we face competition from other commercially available forms of TA and other injectable and implantable corticosteroids. Bristol-Myers Squibb markets TA under the brand name Kenalog. Kenalog is indicated only for intramuscular or intraarticular injection, although it is commonly used off-label for intraocular inflammation. There are also a number of generic equivalents of Kenalog. In addition, Alcons injectable TA, Triesence, is approved in the United States for the treatment of uveitis and other inflammatory conditions unresponsive to topical corticosteroids, although it is not indicated for the treatment of macular edema associated with uveitis or RVO or DME. Ozurdex, marketed by Allergan, is a bioerodable extended release implant that delivers the corticosteroid dexamethasone and is approved for the treatment of macular edema following RVO and non-infectious uveitis in both the United States and in the European Union, and has been submitted to the FDA to treat DME. Bausch + Lomb markets Retisert, an intravitreal implant of the corticosteroid fluocinolone acetonide for the treatment of non-infectious uveitis. Alimera Sciences is developing Iluvien, an injectable form of fluocinolone acetonide, as a therapy for DME in the United States Iluvien has been approved in the European Union for the treatment of DME.
Our product candidates will also compete with anti-VEGF drugs, which are the current standard of care for RVO and wet AMD and have also been approved for DME. Genentechs products Lucentis and Avastin are both anti-VEGF antibodies. Lucentis is currently approved in the United States and European Union for the treatment of wet AMD and the treatment of macular edema following RVO. Lucentis is the only ophthalmic drug therapy approved to treat DME. Avastin is an anti-VEGF drug used by retinal specialists off-label in both the United States and in certain countries of the European Union in the treatment of numerous retinal diseases, but it is not indicated for ophthalmic use. Regenerons anti-VEGF product, Eylea, is approved for the treatment of wet AMD in the United States and in the European Union and has been submitted to the FDA for approval to treat DME and a form of RVO.
Ophthotechs drug candidate, Fovista, an anti-PDGF agent, is in Phase 3 clinical trials as a potential treatment for wet AMD to be administered together with an anti-VEGF drug. We are also aware of several other drug candidates in earlier stages of development as potential treatments for the diseases that we intend to target.
Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient recruitment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
113
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors may also obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of our product candidates, if approved for marketing, are likely to be their efficacy, safety, method of administration, convenience, price and the availability of coverage and reimbursement from government and other third-party payors.
Intellectual Property
Our success depends in part on our ability to obtain and maintain patent and other intellectual property and proprietary protection for our technologies and methods of accessing the SCS, drug candidates and formulations as well as patent and other intellectual property and proprietary protection for novel applications, uses, and technological innovations related to our drug candidates, proprietary delivery devices and core technologies. We also rely on trade secrets, know-how, and continuing technological innovation to develop and maintain our proprietary position.
Patents and Patent Applications
Our patent estate, on a worldwide basis, includes three granted U.S. patents broadly directed to methods of administering drugs into the SCS by injection and over 20 patent applications filed in the United States and other major markets relating to our SCS delivery technology, as well as the formulations of our current therapeutic drug candidates and delivery device. Subject to payment of required maintenance fees, annuities and other charges, our issued patents are expected to expire between 2027 and 2029, without taking into account possible patent term adjustments or extensions. Applications relating to SCS delivery technology and methods, our current therapeutic drug candidates and formulations, various therapeutic uses, including treatment of specific indications such as macular edema associated with non-infectious uveitis and RVO, wet AMD as well as DME and improvement of specified clinical parameters, are expected to expire between 2027 and 2034, without taking into account possible patent term adjustments or extensions.
The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patents term may, in certain cases, be extended by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review.
Our product candidates are protected against genericization through several levels of patents, including the patented approach of non-surgical administration into the SCS. In the case of CLS-TA injected into the SCS, an applicant who files a paragraph 4 ANDA or 505(b)(2) NDA certifying they may circumvent our patents must also demonstrate comparability of the proposed drug, which we believe may require a clinical trial in uveitic macular edema against our product, unless a biowaiver is obtained.
114
Third-Party Patent Filings
Numerous U.S. and foreign issued patents and patent applications owned by third parties exist in the fields in which we are developing products, including patents and applications related to surgical methods of accessing the SCS and certain formulations of TA. Because patent applications can take many years to issue, there may be applications unknown to us, which may later result in issued patents that our product candidates or proprietary technologies may infringe.
Under U.S. law, a person may be able to patent a discovery of a new way to use a previously known compound, even if such compound itself is patented, provided the newly discovered use is novel and nonobvious. Such a method-of-use patent, however, if valid, only protects the use of a claimed compound for the specified methods claimed in the patent. This type of patent does not prevent persons from using the compound for any previously known use of the compound. Further, this type of patent does not prevent persons from making and marketing the compound for an indication that is outside the scope of the patented method.
License Agreement with Emory and Georgia Tech
In July 2012, we entered into a license agreement with Emory University, or Emory, and the Georgia Tech Research Corporation, or GTRC, under which we received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using microinjector. The field of the license covers all ophthalmic uses of the microinjector for mammals and birds. Under this license agreement, we have agreed to direct all prosecution of intellectual property to the licensors patent counsel and have agreed to pay for all intellectual property expenses associated with the licensed patents.
Under this license agreement, we made an initial $30,000 upfront payment and a $35,000 milestone payment upon dosing of the first human patient in a clinical trial. This license agreement requires us to make a milestone payment upon the occurrence of a specified event relating to the commercialization of a drug developed using the licensed patents. Beginning on the third anniversary of this license agreement, we will be obligated to pay an annual license maintenance fee of $25,000, which will continue until the first commercial sale of a product covered by the licensed patents. Additionally, we will owe a low single-digit royalty on any worldwide net product sales related to the licensed patents, with minimum annual royalties of $15,000 after commercialization. The minimum annual royalty increases thereafter to $100,000.
We are solely responsible for the development and commercialization of products related to the licensed patients. We are obligated to provide Emory and GTRC a written report detailing our activities related to the development and commercialization of products twice a year.
Royalties are calculated based on net sales of products covered by a patent licensed under the agreement, and are due on each such product sold as long as the patent covering that particular product is valid and unexpired. Unless otherwise terminated pursuant to its termination provisions, this license agreement will expire upon the expiration of the last to expire of the licensed patents. We have the right to terminate this license agreement at any time upon 60 days written notice to Emory and GTRC. Emory and GTRC may also terminate this license agreement in the event of a material breach by us. This license agreement will immediately terminate if we challenge the validity or enforceability of any of the licensed patents in a court or other governmental agency of competent jurisdiction.
115
Trademarks, Trade Secrets and Know-How
Our trademark portfolio currently contains seven trademarks and trademark applications, consisting of two trademarks registered in the European Union, three pending U.S. trademark applications and two pending trademark applications in Canada. In addition to patent and trademark protection, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and employees. These and other agreements, such as invention assignment agreements, grant us ownership of technologies that are developed through a relationship with a third party.
Government Regulation
In the United States, the FDA regulates drug and device products under the FDCA and its implementing regulations. Our product candidates are subject to regulation as combination products, which means that they are composed of both a drug product and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different Centers within the FDA. A combination product, however, is assigned to a Center that will have primary jurisdiction over its regulation based on a determination of the combination products primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of our product candidates, the primary mode of action is attributable to the drug component of the product, which means that the FDAs Center for Drug Evaluation and Research has primary jurisdiction over the premarket development, review and approval of our product candidates. Accordingly, we plan to investigate our products through the IND framework and seek approval through the NDA pathway.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by FDA to approve applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA and the Department of Justice or other governmental entities.
Drugs
The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of our product candidates are governed by extensive regulation by governmental authorities in the United States and other countries. The FDA, under the Federal Food, Drug, and Cosmetic Act, or FDCA, regulates pharmaceutical products in the United States. The steps required before a drug may be approved for marketing in the United States generally include:
| preclinical laboratory tests and animal tests conducted under Good Laboratory Practices, or GLP; |
| the submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials commence; |
| adequate and well-controlled human clinical trials to establish the safety and efficacy of the product and conducted in accordance with Good Clinical Practices, or GCP; |
116
| the submission to the FDA of an NDA; |
| FDA acceptance, review and approval of the NDA; and |
| satisfactory completion of an FDA inspection of the manufacturing facilities at which the product is made to assess compliance with current Good Manufacturing Practices, or cGMPs. |
The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain. The FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.
Preclinical studies include laboratory evaluations of the product candidate, as well as animal studies to assess the potential safety and efficacy of the product candidate. The results of the preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of the IND, which must become effective before clinical trials may be commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the trials as outlined in the IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can proceed.
Each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at each of the sites at which the trial will be conducted. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution.
Clinical trials are typically conducted in three sequential phases prior to approval, but the phases may overlap. These phases generally include the following:
Phase 1. Phase 1 clinical trials represent the initial introduction of a product candidate into human subjects, frequently healthy volunteers. In Phase 1, the product candidate is usually tested for safety, including adverse effects, dosage tolerance, absorption, distribution, metabolism, excretion and pharmacodynamics.
Phase 2. Phase 2 clinical trials usually involve studies in a limited patient population to (1) evaluate the efficacy of the product candidate for specific indications, (2) determine dosage tolerance and optimal dosage and (3) identify possible adverse effects and safety risks.
Phase 3. If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase 2 clinical trials, the clinical trial program will be expanded to Phase 3 clinical trials to further demonstrate clinical efficacy, optimal dosage and safety within an expanded patient population at geographically dispersed clinical trial sites.
Phase 4 clinical trials are conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA in the form of post-market requirements or commitments. Failure to promptly conduct any required Phase 4 clinical trials could result in withdrawal of approval.
The results of preclinical studies and clinical trials, together with detailed information on the manufacture, composition and quality of the product, are submitted to the FDA in the form of an NDA, requesting approval to market the product. The application must be accompanied by a significant user fee payment. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval and require additional preclinical, clinical or other studies.
117
Review of Application
Once an NDA has been accepted for filing, which occurs, if at all, 60 days after submission, the FDA sets a user fee goal date that informs the applicant of the specific date by which the FDA intends to complete its review. This is typically 10 months from the date of submission for drugs that are not new molecular entities, such as our product candidates. The review process is often extended by FDA requests for additional information or clarification. The FDA reviews NDAs to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the products identity, strength, quality and purity. Before approving an NDA, the FDA may inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facility complies with cGMPs and may also inspect clinical trial sites for integrity of the data supporting safety and efficacy. The device component of our products will also be subject to review as part of the NDA review process and its manufacturers subject to inspection for compliance with device cGMPs embodied in the Quality System Regulation, or QSR. During the approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS, and the FDA will not approve the application without an approved REMS, if required. A REMS can substantially increase the costs of obtaining approval. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to risk, benefit and interpretation of clinical trial data. The FDA may delay approval of an NDA if applicable regulatory criteria are not satisfied and/or the FDA requires additional testing or information. The FDA may require post-marketing testing and surveillance to monitor safety or efficacy of a product. FDA will issue either an approval of the NDA or a Complete Response Letter, detailing the deficiencies and information required for reconsideration of the application.
Post-Approval Requirements
Approved drugs that are manufactured or distributed in the United States are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims and some manufacturing and supplier changes are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for products and the establishments at which such products are manufactured, as well as new application fees for certain supplemental applications.
The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the products safety and effectiveness after commercialization. The FDA may also require a REMS, which could involve requirements for, among other things, a medication guide, special training for prescribers and dispensers, and patient registries.
In addition, entities involved in the manufacture and distribution of approved devices or drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. The FDA has promulgated specific requirements for drug cGMPs, device cGMPs embodied in the QSR and combination product cGMPs that, for drug/device combination products, specify the requirements within the drug cGMPs and the QSR with which manufacturers must comply. Changes to the manufacturing
118
process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:
| restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; |
| fines, warning letters or holds on post-approval clinical trials; |
| refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; |
| product seizure or detention, or refusal to permit the import or export of products; or |
| injunctions or the imposition of civil or criminal penalties. |
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.
The Hatch-Waxman Amendments
Our regulatory strategy is to pursue development of our drugs for suprachoroidal delivery as Section 505(b)(2) NDAs under the FDCA. As an alternative path to FDA approval for modifications to formulations or uses of drugs previously approved by the FDA, an applicant may submit an NDA under 505(b)(2) of the FDCA. 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on FDAs previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.
Orange Book Listing
In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicants product. Upon approval of an NDA,
119
each of the patents listed in the application for the drug is then published in the FDAs Approved Drug Products with Therapeutic Equivalence Evaluations, known as the Orange Book. Any applicant who files an Abbreviated New Drug Application, or ANDA, seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify, for each patent listed in the Orange Book for the referenced drug, to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the date on which such patent expires or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a section viii statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent.
If the reference NDA holder and patent owners assert a patent challenge directed to one of the Orange Book listed patents within 45 days of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30 months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant.
The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired as described in further detail below.
Non-Patent Exclusivity
In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug.
A drug, including one approved under a 505(b)(2) application, may obtain a three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, the FDA can accept an application and begin the review process during the three-year exclusivity period.
Orphan Drugs
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than 200,000 individuals in the United States. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan drugs are eligible for certain incentives, including tax credits for qualified clinical testing. In addition, an NDA for a product that has received orphan drug designation is not subject to a prescription drug user fee unless the application includes an indication other than the rare disease or condition for which the drug was designated.
120
If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same active moiety for the same indication for seven years, except in limited circumstances, such as another drugs showing of clinical superiority over the drug with orphan exclusivity. Competitors, however, may receive approval of different active moieties for the same indication or obtain approval for the same active moiety for a different indication. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same active moiety for the same indication before we do, unless we are able to demonstrate that our product is clinically superior.
We intend to seek orphan drug designation and exclusivity for CLS-1001 for the treatment of non-infectious uveitis in the United States and Europe, and we may seek designation for other products in the future, but we cannot guarantee that we will obtain orphan drug designation for any products in any jurisdiction. Even if we are able to obtain orphan drug designation for a product, we cannot be sure that such product will be approved, or that we will be able to obtain orphan drug exclusivity upon approval, if ever.
Foreign Regulation
In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union and other geographies, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.
Federal and State Fraud and Abuse, Data Privacy and Security and Transparency Laws
In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws restrict our business practices. These laws include, without limitation, anti-kickback and false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to
121
induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statutes intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated.
Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes any request or demand for money or property presented to the U.S. government. The civil False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil False Claims Act. Several pharmaceutical, device and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies marketing of products for unapproved, and thus non-covered, uses.
The government may further prosecute conduct constituting a false claim under the criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil False Claims Act, requires proof of intent to submit a false claim.
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
122
Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.
Under HIPAA, the U.S. Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information used or disclosed by covered entities including health care providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA regulations include civil and criminal penalties. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. New laws governing privacy may be adopted in the future as well. Failure to comply with privacy requirements could result in civil or criminal penalties, which could have a materially adverse effect on our business.
Additionally, there has been a recent trend of increased federal and state regulation of payments and transfers of value provided to healthcare professionals and/or entities. On February 8, 2013, the Centers for Medicare & Medicaid Services, or CMS, released its final rule implementing section 6002 of the Affordable Care Act known as the Physician Payment Sunshine Act that imposes new annual reporting requirements on manufacturers of drugs, devices, biologicals and medical supplies for payments and other transfers of value provided by them, directly or indirectly, to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their family members. A manufacturers failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year, and up to an aggregate of $1 million per year for knowing failures. The period between August 1, 2013 and December 31, 2013 was the first reporting period, for which manufacturers were required to report aggregate payment data to CMS by March 31, 2014. Manufacturers also will be required to CMS report detailed payment and transfers of value data and submit legal attestation to the completeness and accuracy of such data during Phase 2 of the program, which began on June 1, 2014 and will extend until June 30, 2014. Thereafter, manufacturers must submit reports by the 90th day of each subsequent calendar year. Any failure to comply could result in significant fines and penalties. Certain states also mandate implementation of commercial compliance programs, impose restrictions on device manufacturer marketing practices or require tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, it is possible that some of our current or future business activities, including certain sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such laws. Given the heightening compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions, increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country,
123
we may be subject to similar foreign laws, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.
Coverage and Reimbursement
We believe that physicians who use our product candidates, if approved, will be reimbursed by third-party payors for both the SCS injection using our microinjector and for the drug itself. We intend to seek a specific Current Procedural Terminology, or CPT, code as established and maintained by the American Medical Association, or AMA, for the SCS injection of pharmacologic agents using our microinjector, and a separate Healthcare Common Procedure Coding System, or HCPCS, code as maintained by the Centers for Medicare and Medicaid Services, or CMS, for the drug itself. We believe that separate CPT and HCPCS codes will help payors differentiate our drug candidates from other drugs currently on the market administered through intravitreal injections, although we can provide no assurance that the AMA or CMS will approve the creation of such new codes applicable to our products.
Our strategy will include efforts to engage physician societies and encourage third-party payors to establish coverage, coding and payment that will facilitate access to our product candidates and microinjector as we expand our commercialization efforts in the United States. Our success in these efforts depends in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage for and establish adequate reimbursement levels for the procedures during which our product candidates are administered and for the drugs themselves. Failure by physicians, hospitals, ambulatory surgery centers, and other users of our products to obtain sufficient coverage and reimbursement from healthcare payors for the procedures administering our product candidates or for the product candidates themselves, or adverse changes in government and private third-party payors policies would have a material adverse effect on our business, financial condition, results of operations and future growth prospects.
In the U.S., third-party payors continue to implement initiatives that restrict the use of certain technologies to those that meet certain clinical evidentiary requirements. Failure to obtain favorable coverage policies could have a material adverse effect on our business and operations.
In addition to uncertainties surrounding coverage policies, third-party payors from time to time update reimbursement amounts and also revise the methodologies used to determine reimbursement amounts. This includes annual updates to payments to ambulatory surgery centers, hospitals and physicians for the procedure performed administering our products, which could directly impact the demand for any of our product candidates that may be approved. An example of payment updates is the Medicare program updates to physician payments, which is done on an annual basis using a prescribed statutory formula. In the past, when the application of the formula resulted in lower payment, Congress has passed interim legislation to prevent the reductions. Most recently, the Protecting Access to Medicare Act of 2014, signed into law in April 2014, provided for a 0.5% change from 2013 payment rates under the Medicare Physician Fee Schedule through 2014 and a 0% update from January 1 until April 1, 2015. If Congress fails to intervene to prevent the negative update factor in future years, the resulting decrease in payment may adversely affect our revenues and results of operations. Any changes in coverage and reimbursement that further restricts coverage of our products or lowers reimbursement for procedures using our products could materially affect our business.
124
Healthcare Reform
Current and future legislative proposals to further reform healthcare or reduce healthcare costs may result in lower reimbursement for our products, or for the procedures associated with the use of our products, or limit coverage of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce our revenues from the sale of our products. However, we believe that the shift away from fee-for-service agreements to capitated payment models supports the value of our products, as we believe that our products reduce longitudinal resource utilization, which can be cost saving-for both payors and providers.
For example, implementation of the Affordable Care Act has the potential to substantially change healthcare financing and delivery by both governmental and private insurers, and significantly impact the pharmaceutical and medical device industries.
The Affordable Care Act imposed, among other things, a new federal excise tax on the sale of certain medical devices, established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, and provided incentives to programs that increase the federal governments comparative effectiveness research. In addition, the Affordable Care Act implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August 2, 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislations automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and will remain in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.
The Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions
125
requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts.
Employees
As of March 31, 2014, we had 17 employees, all of whom are located in the United States. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.
Facilities
Our principal offices occupy approximately 8,800 square feet of leased office space in Alpharetta, Georgia, pursuant to a lease agreement that expires in September 2014. We also lease approximately 6,600 square feet of space in Durham, North Carolina for our clinical development and regulatory functions under a lease agreement that expires in May 2015. We believe that our current facilities are suitable and adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.
Legal Proceedings
We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition.
126
Directors and Executive Officers
The following table sets forth information concerning our directors, executive officers and other key employees, including their ages as of May 31, 2014:
Name |
Age | Position | ||||
Executive Officers: |
||||||
Daniel H. White |
47 | President, Chief Executive Officer and Director | ||||
Charles A. Deignan |
49 | Chief Financial Officer | ||||
Glenn Noronha, Ph.D. |
49 | Executive Vice President, Research and Development | ||||
Other Key Employees: |
||||||
Rafael V. Andino |
49 | Vice President, Product Development | ||||
Stephen H. Lang |
57 | Vice President, Commercial Operations | ||||
Non-Management Directors: |
||||||
Christy L. Shaffer, Ph.D |
56 | Chairman of the Board of Directors | ||||
Clay B. Thorp |
45 | Director | ||||
William D. Humphries |
47 | Director | ||||
Mark R. Prausnitz, Ph.D. |
48 | Director | ||||
Gerald D. Cagle., Ph.D. |
69 | Director |
Executive Officers
Daniel H. White
Mr. White is the founder of our company and has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in May 2011. From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009. From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company. In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology. Previously, he was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma. Mr. White holds an M.B.A. degree from Wake Forest University, a B.S. degree in Molecular Biology from Auburn University. Our board of directors believes that Mr. Whites leadership of our company since its inception, extensive entrepreneurial experience, knowledge of our company as founder and experience with biotechnology companies prior to founding our company allow him to make valuable contributions to the board.
Charles A. Deignan
Mr. Deignan has served as our Chief Financial Officer since January 2012. From 2009 to December 2011, Mr. Deignan was Vice President of Finance and Administration for Salutria Pharmaceuticals. Previously, from 1999 to 2009, Mr. Deignan served in a number of roles with AtheroGenics, Inc., a publicly held biopharmaceutical company, including as its Vice President of Finance and Administration. Prior to that, he held management positions at AAIPharma, Inc. and Schering-Plough. Mr. Deignan received his B.S. degree in Business Administration from Boston University.
127
Glenn Noronha, Ph.D.
Dr. Noronha has served as our Executive Vice President, Research and Development since August 2013. From August 2012 to May 2013, he served as Vice President, Research and Development at Sucampo Pharma Americas, LLC, a pharmaceutical company. From July 2011 to July 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development. From 2008 to July 2011, Dr. Noronha was Global Project Head for Retinal Development at Alcon Laboratories, Inc., a Novartis company. From 2002 to 2008, Dr. Noronha held several positions at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs. Previously, from 2000 to 2002, he was a research scientist and project leader for Medtronic MiniMed, Inc. Dr. Noronha received his Ph.D. degree from Loyola University of Chicago and was a post-doctoral fellow at the University of California at Irvine.
Other Key Employees
Rafael V. Andino
Mr. Andino has served as our Vice President, Product Development since February 2013. Since June 2013, Mr. Andino has also served as an adjunct professor of biomedical engineering at the Georgia Institute of Technology. From January 2009 to February 2013, he served as Director of Research and Development for Bard Medical, a division of C.R. Bard, Inc., a publicly traded company. In 1999, Mr. Andino founded, and until 2008 served as President and Chief Executive Officer of Biofisica, Inc., a biotechnology company that developed technology to expedite wound healing and regeneration of connective tissue in humans. Prior to founding Biofisica, from 1995 to 2005 Mr. Andino was a mechanical engineer, research and development director and senior project manager for CIBA Vision, a Novartis company. He has also worked for the global technology companies E.I. Dupont de Nemours, General Electric and IBM. Mr. Andino received his Bachelors degree in Mechanical Engineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and an M.B.A. degree from Mercer University.
Stephen H. Lang
Mr. Lang has served as our Vice President, Commercial Operations since March 2013. From 2006 to June 2012, Mr. Lang served as Vice President of Sales for ISTA Pharmaceuticals, Inc., an ophthalmic product company acquired by Bausch + Lomb in 2012. Previously, Mr. Lang held leadership roles in sales and marketing, serving with Novartis Ophthalmics, Inc. from 1995 to 2003, including as its Senior Vice President of U.S. Sales from 2002 to 2003. Mr. Lang began his career with Allergan, Inc. where he served for more than 16 years in various positions, including sales, marketing, national accounts and global business development. He earned his B.B.A. degree in Management from Georgia Southern University.
Non-Management Directors
Christy L. Shaffer, Ph.D.
Dr. Shaffer has served as a director of our company and as the chairman of our board of directors since January 2012. Since 2011, Dr. Shaffer has served as a Venture Partner with Hatteras Venture Partners, an investment firm, and as Managing Director of Hatteras Discovery, which invests in early-stage companies in the life sciences industry sector. From 1995 to March 2010, Dr. Shaffer served in increasing leadership positions at Inspire Pharmaceuticals, a publicly held biopharmaceutical company, beginning as the
128
companys first full-time employee and Director of Clinical Operations and eventually being appointed as Chief Executive Officer and a director of the company in 1999, as its President in 2005 and a member of its Development Committee in 2009. Prior to Inspire, she was a clinical research scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co. Dr. Shaffer currently serves in leadership roles on several non-profit boards, including as chair of the Morehead Planetarium and Science Centers advisory board, on the Board of Trustees for the Cystic Fibrosis Foundation, and as chair of the board of CFF Therapeutic, Inc. Dr. Shaffer is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessees Health Science Center in Memphis, Tennessee. She completed post-doctoral training at The Chicago Medical School as well as the University of North Carolina at Chapel Hill. In September 2008, the Securities and Exchange Commission approved a non-monetary settlement of its investigation relating to Inspire Pharmaceuticals disclosures in its periodic reports relating to a clinical trial. The Commission also approved a settlement with Dr. Shaffer, as Inspires President and Chief Executive Officer and a member of its board of directors, under which she consented to a cease and desist order against future violations of Section 13(a) of the Exchange Act and Rules 12b-20 and 13a-13 thereunder. Dr. Shaffer did not admit or deny any findings in the order, and the order did not include any monetary payments or other sanctions or otherwise affect her future employment status, nor did it prohibit Dr. Shaffer from serving in any capacity on public company boards of directors. Our board of directors believes that Dr. Shaffers clinical background as a scientist and her leadership experience as chief executive of a public company in the biopharmaceutical industry provides her with the qualifications and skills to serve as a director of our company.
Clay B. Thorp
Mr. Thorp has served as a director of our company since January 2012. In 2001, Mr. Thorp co-founded and has since served as General Partner of Hatteras Venture Partners, an investment firm, where he leads investments in a range of life science companies in the biopharmaceutical, medical device, diagnostics and research informatics sectors. Previously, he was instrumental in the founding of several life sciences companies, including serving as co-founder, Chief Executive Officer and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired by Symyx Technologies in 2005, co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc., co-founder and head of corporate development for Novalon Pharmaceutical Corporation, which was sold to Karo Bio in 2000, and co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Mr. Thorp holds a Masters of Public Policy degree from Harvard University and a B.A. degree in Mathematics and History from the University of North Carolina at Chapel Hill. Our board of directors believes that Mr. Thorps experience as an entrepreneur and an investor in life sciences companies provides him with the qualifications and skills to serve as a director of our company.
William D. Humphries
Mr. Humphries has served as a director of our company since January 2012. Mr. Humphries has served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company, since March 2012. From 2006 to March 2012, he served in a number of leadership positions with Stiefel Laboratories, Inc., a dermatology pharmaceutical company, including as its Chief Commercial Officer and then as its President beginning in 2008. Stiefel was acquired by GlaxoSmithKline in 2009. After the acquisition, Mr. Humphries served as the President of Dermatology for Stiefel from 2009 until March 2012. Before Stiefel, Mr. Humphries served in executive roles in sales
129
and marketing, business development, and international marketing for Allergan, Inc., concluding as vice president of its U.S. skincare business. Mr. Humphries has served on the board of ZARS Pharma, the GlaxoSmithKline Portfolio Investment Board and the GlaxoSmithKline Ophthalmology Board. Mr. Humphries received his M.B.A. degree from Pepperdine University and a B.A. degree from Bucknell University. Our board of directors believes that Mr. Humphries experience as pharmaceutical company executive provides him with the qualifications and skills to serve as a director of our company.
Mark R. Prausnitz, Ph.D.
Dr. Prausnitz is a co-founder of our company and has served on our board of directors since August 2011. He has served on the faculty at the Georgia Institute of Technology since 1995 and currently holds the rank of Regents Professor of Chemical and Biomolecular Engineering. His research interests focus on biophysical methods of drug delivery, which employ microfabricated devices, microneedles, ultrasound, lasers, electric fields and other physical means to control the transport of drugs, proteins, genes and vaccines into and within the body. Previously, from 1988 to 1989, Dr. Prausnitz worked at Alza Corporation carrying out research on transdermal drug delivery systems and from 1994 to 1995 at ORBIS International, teaching biomedical engineering in developing country hospitals. Dr. Prausnitz earned his B.S. degree from Stanford University and a Ph.D. degree from the Massachusetts Institute of Technology, both in Chemical Engineering. Our board of directors believes that Dr. Prausnitzs scientific and academic background provides him with the qualifications and skills to serve as a director of our company.
Gerald D. Cagle, Ph.D.
Dr. Cagle has served on our board of directors since July 2013. Dr. Cagle has served as Chief Operating Officer at Cognoptix, lnc., a biotechnology company focused on the diagnosis of Alzheimers disease, since December 2008. He also is Senior Advisor and Head of Business Development for GrayBug, LLC, a platform drug delivery company. Previously, Dr. Cagle served as Senior Vice President of Research & Development at Alcon Laboratories lnc. from 1997 to 2008, assuming the responsibility of Chief Scientific Officer in 2006. He currently serves on the board of directors of Aerie Pharmaceuticals, Inc., a publicly held biopharmaceutical company. Dr. Cagle has also served on the Wilmer Eye Institute Advisory Council and is a member of the ARVO Foundation Board of Governors. Dr. Cagle received his B.S. degree from Wayland College and earned M.S. and Ph.D. degrees from the University of North Texas. Our board of directors believes that Dr. Cagles scientific background and experience provides him with the qualifications and skills to serve as a director of our company.
Board Composition
Our board of directors currently consists of six members. Each director is currently elected to the board for a one-year term, to serve until the election and qualification of successor directors at the annual meeting of stockholders, or until the directors earlier removal, resignation or death.
Our directors were elected to and currently serve on the board pursuant to a voting agreement among us and several of our largest stockholders. This agreement will terminate upon the completion of this offering, after which there will be no further contractual obligations regarding the election of our directors.
In accordance with our amended and restated certificate of incorporation, which will be in effect upon the closing of this offering, our board of directors will be divided into three classes, each of which will consist, as nearly as possible, of one-third of the total number of directors constituting our entire board and
130
which will serve staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows:
| Class I, which will consist of and , and their term will expire at our first annual meeting of stockholders to be held after the completion of this offering; |
| Class II, which will consist of and , and their term will expire at our second annual meeting of stockholders to be held after the completion of this offering; and |
| Class III, which will consist of and , and their term will expire at our third annual meeting of stockholders to be held after the completion of this offering. |
Our amended and restated bylaws, which will become effective upon completion of this offering, will provide that the authorized number of directors may be changed only by resolution approved by a majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors.
The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.
Director Independence
Our board of directors has undertaken a review of the independence of the directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our board of directors has determined that Drs. Shaffer and Cagle and Messrs. Humphries and Thorp, representing four of our six directors, are independent directors as defined under NASDAQ rules.
Committees of the Board of Directors
Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has the composition and responsibilities described below. From time to time, the board may establish other committees to facilitate the management of our business.
Audit Committee
Our audit committee reviews our internal accounting procedures and consults with and reviews the services provided by our independent registered public accountants. Our audit committee consists of three directors, , and , and our board of directors has determined that each of them is independent within the meaning of the applicable stock exchange listing requirements and the independence requirements contemplated by Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. is the chairman of the audit committee and our board of directors has determined that is an audit committee financial expert as defined by SEC rules and regulations. Our board of directors has determined that the composition of our audit committee meets the criteria for independence under, and the functioning of our audit committee complies with, the applicable requirements of the Sarbanes-Oxley Act, applicable stock exchange listing requirements and
131
SEC rules and regulations. We intend to continue to evaluate the requirements applicable to us and we intend to comply with the future requirements to the extent that they become applicable to our audit committee. The principal duties and responsibilities of our audit committee include:
| appointing and retaining an independent registered public accounting firm to serve as independent auditor to audit our financial statements, overseeing the independent auditors work and determining the independent auditors compensation; |
| approving in advance all audit services and non-audit services to be provided to us by our independent auditor; |
| establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls, auditing or compliance matters, as well as for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters; |
| reviewing and discussing with management and our independent auditor the results of the annual audit and the independent auditors review of our quarterly financial statements; and |
| conferring with management and our independent auditor about the scope, adequacy and effectiveness of our internal accounting controls, the objectivity of our financial reporting and our accounting policies and practices. |
Compensation Committee
Our compensation committee reviews and determines the compensation of all our executive officers. Our compensation committee consists of directors, , each of whom is a non-employee member of our board of directors as defined in Rule 16b-3 under the Exchange Act. is the chairman of the compensation committee. Our board of directors has determined that the composition of our compensation committee satisfies the applicable independence requirements under, and the functioning of our compensation committee complies with the applicable requirements of, stock exchange listing rules and SEC rules and regulations. We intend to continue to evaluate and intend to comply with all future requirements applicable to our compensation committee. The principal duties and responsibilities of our compensation committee include:
| establishing and approving, and making recommendations to the board of directors regarding, performance goals and objectives relevant to the compensation of our chief executive officer, evaluating the performance of our chief executive officer in light of those goals and objectives and setting, or recommending to the full board of directors for approval, the chief executive officers compensation, including incentive-based and equity-based compensation, based on that evaluation; |
| setting the compensation of our other executive officers, based in part on recommendations of the chief executive officer; |
| exercising administrative authority under our stock plans and employee benefit plans; |
| establishing policies and making recommendations to our board of directors regarding director compensation; |
| reviewing and discussing with management the compensation discussion and analysis that we may be required from time to time to include in SEC filings; and |
132
| preparing a compensation committee report on executive compensation as may be required from time to time to be included in our annual proxy statements or annual reports on Form 10-K filed with the SEC. |
Nominating and Corporate Governance Committee
The nominating and corporate governance committee consists of directors, . is the chairman of the nominating and corporate governance committee. Our board of directors has determined that the composition of our nominating and corporate governance committee satisfies the applicable independence requirements under, and the functioning of our nominating and corporate governance committee complies with the applicable requirements of, stock exchange listing standards and SEC rules and regulations. We will continue to evaluate and will comply with all future requirements applicable to our nominating and corporate governance committee. The nominating and corporate governance committees responsibilities include:
| assessing the need for new directors and identifying individuals qualified to become directors; |
| recommending to the board of directors the persons to be nominated for election as directors and to each of the boards committees; |
| assessing individual director performance, participation and qualifications; |
| developing and recommending to the board corporate governance principles; |
| monitoring the effectiveness of the board and the quality of the relationship between management and the board; and |
| overseeing an annual evaluation of the boards performance. |
Code of Business Conduct and Ethics for Employees, Executive Officers and Directors
Effective upon completion of this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and directors. Following the completion of this offering, the Code of Conduct will be available on our website at www.clearsidebio.com. The nominating and corporate governance committee of our board of directors will be responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website.
Compensation Committee Interlocks and Insider Participation
None of our directors who currently serve as members of our compensation committee is, or has at any time during the past year been, one of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our board of directors or compensation committee.
Non-Employee Director Compensation
We have not historically paid cash retainers or other compensation with respect to service on our board of directors, except for reimbursement of direct expenses incurred in connection with attending meetings of
133
the board or committees. In January 2012, we awarded an option to purchase 50,000 shares of our common stock to Mr. Humphries at an exercise price of $0.07 per share. In October 2013, we awarded an option to purchase 50,000 shares of our common stock to Mr. Humphries at an exercise price of $0.18 per share. In June 2013, in connection with his appointment to our board of directors, we awarded an option to purchase 100,000 shares of our common stock to Dr. Cagle at an exercise price of $0.18 per share. Other than Mr. Humphries and Mr. Cagle, none of our non-employee directors serving as of December 31, 2013 held any options to purchase our common stock.
The following table sets forth information regarding compensation earned for service on our board of directors during the year ended December 31, 2013 by our non-employee directors. Mr. White, our President and Chief Executive Officer, is also a director but does not receive any additional compensation for his service as director. Mr. Whites compensation as an executive officer is set forth below under Executive Compensation Summary Compensation Table.
Name |
Stock Awards ($) |
Option Awards ($)(1) |
||||||
Gerald D. Cagle, Ph.D. |
| 44,900 | (2) | |||||
William D. Humphries |
| 29,800 | (3) | |||||
Mark R. Prausnitz, Ph.D. |
| (4) | | |||||
Christy L. Shaffer, Ph.D. |
| | ||||||
Clay B. Thorp |
| |
(1) | This column reflects the full grant date fair value for options granted during the year as measured pursuant to ASC Topic 718 as stock-based compensation in our consolidated financial statements. Unlike the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting but assumes that the director will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note 11 to our audited consolidated financial statements included in this prospectus. |
(2) | As of December 31, 2013, Dr. Cagle held an option to purchase 100,000 shares of common stock, which vests in 16 equal quarterly installments at the end of each calendar quarter beginning September 30, 2013 and is subject to full acceleration of vesting upon a change of control of our company. |
(3) | As of December 31, 2013, Mr. Humphries held options to purchase 100,000 shares of common stock, of which 50,000 shares were vested and the remainder vests in eight equal quarterly installments at the end of each calendar quarter beginning March 31, 2014 and are subject to full acceleration of vesting upon a change of control of our company. |
(4) | As a founder of our company, Dr. Prausnitz acquired 617,500 shares of common stock from us in August 2011, which shares are subject to a right of repurchase in favor of us through June 30, 2014. As of December 31, 2013, there were 77,188 shares not yet vested. |
We expect that our board of directors will adopt a director compensation policy for non-employee directors to be effective following the completion of this offering.
134
Our named executive officers for the year ended December 31, 2013 include our principal executive officer and our two other executive officers:
| Daniel H. White, our President and Chief Executive Officer; |
| Charles A. Deignan, our Chief Financial Officer; and |
| Glenn Noronha, Ph.D., our Executive Vice President of Research and Development. |
No other individuals served as executive officers of our company at any point during 2013.
2013 Summary Compensation Table
The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the year ended December 31, 2013.
Name and Principal Position |
Salary ($)(1) |
Option Awards ($)(2) |
Non-Equity Incentive Plan Compensation ($) |
All Other Compensation ($) |
Total ($) | |||||||||||
Daniel H. White |
256,771 | 102,225 | (3) | | ||||||||||||
President and Chief Executive Officer |
||||||||||||||||
Charles A. Deignan |
179,740 | 68,025 | (3) | | ||||||||||||
Chief Financial Officer |
||||||||||||||||
Glenn Noronha, Ph.D. |
108,333 | 105,250 | (3) | 48,809 | (5) | |||||||||||
Executive Vice President, Research and Development(4) |
(1) | Salary amounts represent actual amounts paid during 2013. See Narrative to Summary Compensation TableAnnual Base Salary for a description of adjustments to base salaries made during the year. |
(2) | The amounts reflect the full grant date fair value for awards granted during 2013. The grant date fair value was computed in accordance with ASC Topic 718, Compensation Stock Compensation. Unlike the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in note 11 to our financial statements included in this prospectus. |
(3) | Final amounts payable with respect to 2013 performance have not yet been determined. See below under Narrative to Summary Compensation Table Annual Bonus. |
(4) | Dr. Noronha became an executive officer of our company in August 2013, and amounts represent compensation earned since that date. |
(5) | Amount represents relocation allowance plus associated tax gross-up. |
Narrative to Summary Compensation Table
We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as
135
compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives.
The compensation committee of our board of directors has historically determined our executives compensation. Our compensation committee typically reviews and discusses managements proposed compensation with the chief executive officer for all executives other than the chief executive officer. Based on those discussions and its discretion, the compensation committee then recommends the compensation for each executive officer. Our compensation committee, without members of management present, discusses and ultimately approves the compensation of our executive officers. To date, our compensation committee has not engaged a compensation consultant or adopted a peer group of companies for purposes of determining executive compensation.
Annual Base Salary
Our named executive officers base salaries are reviewed periodically by our board of directors, and adjustments may be made upon the recommendations of the compensation committee. In 2012, we entered into an employment agreement with Mr. White under which his annual base salary was established at $250,000. In February 2013, our compensation committee recommended, and our board of directors approved, an increase in Mr. Whites annual base salary to $258,125. At the same time, our compensation committee recommended, and our board of directors approved, an increase in Mr. Deignans base salary from $175,000 to $180,688. In May 2014, the board of directors approved a further increase in Mr. Deignans annual base salary to $210,000. Dr. Noronhas annual base salary of $260,000 was approved by our board of directors in connection with the commencement of his employment with us in August 2013.
Annual Bonus
We seek to motivate and reward our executives for achievements relative to our corporate goals and expectations for each fiscal year. Each named executive officer has a target bonus opportunity, defined as a percentage of his annual salary. For 2013 and 2014, the target bonus was and is as follows:
Name |
Target Bonus (% of Salary) | |
Daniel H. White |
25 | |
Charles A. Deignan |
20 | |
Glenn Noronha, Ph.D. |
20 |
To reinforce the importance of integrated and collaborative leadership, our executives bonuses have historically been solely based on company performance, and we did not include an individual performance component. For 2013, 40% of each executive officers target bonus was attributable to the commencement of our Phase 1/2 clinical trial for CLS-1001, 30% was attributable to our further drug and product development efforts and 30% was attributable to our capital raising activities. Our compensation committee has not yet made its final determinations with respect to the level of achievement of each of these goals, and therefore the final bonus amounts have not yet been determined. Such bonus amounts, once determined, will be reflected in the Non-Equity Incentive Plan Compensation column of the Summary Compensation Table above.
136
Long-Term Incentives
Our 2011 Stock Incentive Plan authorizes us to make grants to eligible recipients of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units and other stock-based awards. All of our awards under this plan have been in the form of stock options.
We typically grant stock options at the start of employment to each executive and our other employees. Through 2013, we have not maintained a practice of granting additional equity on an annual basis, but we have retained discretion to provide additional targeted grants in appropriate circumstances.
We award stock options on the date the compensation committee approves the grant. We set the option exercise price and grant date fair value based on our per-share valuation on the date of grant.
In February 2013, our compensation committee awarded options to Messrs. White and Deignan to purchase 128,000 shares and 52,000 shares, respectively. Each of these options has an exercise price of $0.18 per share. In August 2013, in connection with the commencement of Dr. Noronhas employment with us, our board of directors approved the grant of an option to purchase 125,000 shares of our common stock with an exercise price of $0.18 per share. In November 2013, our board of directors approved additional options grants to Messrs. White and Deignan and Dr. Noronha to purchase 75,000 shares, 75,000 shares and 50,000 shares, respectively.
Employment Arrangements and Potential Payments upon Termination of Employment
In September 2012, we entered into an employment agreement with Mr. White under which he serves as our President and Chief Executive Officer. The agreement is renewable for one-year terms beginning in September 2014, unless either we or Dr. White give written notice of non-renewal at least 60 days prior to the end of the term. Under this agreement, Mr. White is eligible to receive severance benefits in specified circumstances.
In the event that we terminate Mr. White without cause, he resigns for good reason or we elect not to renew the term of the employment agreement, then, upon execution and effectiveness of a settlement agreement and release of claims in a form acceptable to us, Mr. White will be entitled to receive (a) an amount equal to nine months of his annual base salary, less applicable deductions, payable in accordance with our normal payroll schedule, (b) reimbursement of the cost of health insurance premiums for 12 months or, if shorter, until he obtains reasonably comparable health insurance coverage.
The following definitions have been adopted in Mr. Whites employment agreement:
| cause means that our board of directors, without Mr. White, has determined that any of the following occurred: (a) Mr. Whites material breach of the employment agreement, his failure to diligently and properly perform his duties or his failure to achieve the objectives specified by the board of directors, and any such breach or failure has not been cured within 30 days after written notice thereof, (b) his misappropriation or unauthorized use of our property or breach of his agreements with us relating to confidentiality, intellectual property rights, non-competition or non-solicitation, (c) his material failure to comply with our company policies or directives of our board of directors, and any such failure has not been cured within 30 days after written notice thereof, provided that the failure to comply with company policies relating to harassment, unlawful discrimination, retaliation or workplace violence do not require notice or permit a cure period, (d) his use of illegal drugs or any illegal substance, or his use of alcohol in any manner that materially interferes with the performance of his duties to the company, (e) any dishonest or illegal action by |
137
him, or any action determined to be materially detrimental to the interest and well-being of our company, including harm to our reputation, (f) his failure to fully disclose any material conflict of interest that he may have in a transaction between us and a third party, which conflict is materially detrimental to our interest and well-being, or (g) any adverse action or omission by him that would be required to be disclosed under securities laws or which would limit our ability to sell securities or would disqualify us from an exemption otherwise available to us; and |
| good reason means the existence of any of the following without Mr. Whites prior consent: (a) any substantial reduction or diminution of his duties and responsibilities or salary, (b) any material breach of the employment agreement by us, or (c) a relocation of his place of employment by more than 50 miles from the location of our principal office, in each case after notice to us within 90 days following the initial existence of the event and after we have had the opportunity to but have not cured the event for 30 days following such notice, and the executive terminates his employment with us no later than two years after the initial existence of the event. |
Outstanding Equity Awards at End of 2013
The following table provides information about outstanding stock options held by each of our executive officers at December 31, 2013. All of these options were granted under our 2011 Stock Incentive Plan.
Option Awards | Stock Awards | |||||||||||||||||||||
Name |
Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable |
Option Exercise Price ($) |
Option Expiration Date |
Number of Shares or Units of Stock That Have Not Vested (#) |
Market Value of Shares or Units of Stock That Have Not Vested ($)(8) |
||||||||||||||||
Daniel H. White |
| 128,000 | (1) | 0.18 | 02/28/2023 | 118,750 | (4) | 78,375 | ||||||||||||||
75,000 | (3) | 0.18 | 11/24/2023 | |||||||||||||||||||
Charles A. Deignan |
| 52,000 | (1) | 0.18 | 02/28/2023 | 20,833 | (5) | 13,750 | ||||||||||||||
75,000 | (3) | 0.18 | 11/24/2023 | 38,750 | (6) | 25,575 | ||||||||||||||||
17,188 | (7) | 11,344 | ||||||||||||||||||||
Glenn Noronha, Ph.D. |
| 125,000 | (2) | 0.18 | 08/06/2023 | |||||||||||||||||
50,000 | (3) | 0.18 | 11/24/2023 |
(1) | The unvested shares underlying this option vest as to 25% of the shares on March 1, 2014, with the remainder vesting in 36 equal monthly installments thereafter, subject to the officers continued service through each applicable vesting date. The option is subject to full acceleration of vesting following a change of control if the option is assumed or a substantially equivalent award is substituted, but the officers employment is terminated without cause within 12 months following the change of control. |
(2) | The unvested shares underlying this option vest as to 25% of the shares on August 1, 2014, with the remainder vesting in 36 equal monthly installments thereafter, subject to the officers continued service through each applicable vesting date. The option is subject to full acceleration of vesting (a) upon a change of control if the option is not assumed or a substantially equivalent award is not substituted by the acquiring or succeeding entity or (b) following a change of control if the option is assumed or a substantially equivalent award is substituted, but the officers employment is terminated without cause within 12 months following the change of control. |
138
(3) | The unvested shares underlying this option vest as to 25% of the shares on December 13, 2014, with the remainder vesting in 36 equal monthly installments thereafter, subject to the officers continued service through each applicable vesting date. The option is subject to full acceleration of vesting (a) upon a change of control if the option is not assumed or a substantially equivalent award is not substituted by the acquiring or succeeding entity or (b) following a change of control if the option is assumed or a substantially equivalent award is substituted, but the officers employment is terminated without cause or for good reason within 12 months following the change of control. |
(4) | These restricted shares will vest in equal monthly installments through June 30, 2014. These restricted shares are subject to full acceleration of vesting upon a change of control or in the event the officers employment is terminated without cause. |
(5) | These restricted shares will vest in equal monthly installments through January 31, 2016. These restricted shares are subject to full acceleration of vesting (a) upon a change of control if the option is not assumed or a substantially equivalent award is not substituted by the acquiring or succeeding entity or (b) following a change of control if the option is assumed or a substantially equivalent award is substituted, but the officers employment is terminated without cause or for good reason within 12 months following the change of control. |
(6) | These restricted shares will vest in equal monthly installments through July 1, 2016. These restricted shares are subject to full acceleration of vesting (a) upon a change of control if the option is not assumed or a substantially equivalent award is not substituted by the acquiring or succeeding entity or (b) following a change of control if the option is assumed or a substantially equivalent award is substituted, but the officers employment is terminated without cause or for good reason within 12 months following the change of control. |
(7) | These restricted shares will vest in equal monthly installments through September 30, 2016. These restricted shares are subject to full acceleration of vesting (a) upon a change of control if the option is not assumed or a substantially equivalent award is not substituted by the acquiring or succeeding entity or (b) following a change of control if the option is assumed or a substantially equivalent award is substituted, but the officers employment is terminated without cause or for good reason within 12 months following the change of control. |
(8) | Based on the valuation of our common stock of $0.66 per share as of December 31, 2013. |
Stock Option Exercises and Stock Vested During 2013
The following table shows information regarding options exercised and stock awards vested during the year ended December 31, 2013 with respect to our named executive officers.
Option Awards | Stock Awards | |||||||||||||||
Name |
Number of Shares Acquired on Exercise (#) |
Value Realized on Exercise ($) |
Number of Shares Acquired on Vesting (#) |
Value Realized on Vesting ($) |
||||||||||||
Daniel H. White |
| | 237,500 | 137,750 | (2) | |||||||||||
Charles A. Deignan |
46,875 | 27,655 | (1) | 1,354 | (3) | 799 | (4) |
(1) | The aggregate dollar amount represents the amount by which the aggregate fair value of the shares of our common stock on the date of exercise, as calculated using an assumed per share value of $0.66, which is the assumed fair value as of the date of exercise, exceeds the aggregate exercise price of the option, as calculated using the per share exercise price of $0.07. |
139
(2) | For shares that vested during the first six months of 2013, we have determined the value realized by Mr. White using an assumed value of $0.50 per share. For shares vested during the last six months of 2013, we have determined the value of such shares using an assumed value of $0.66 per share. |
(3) | Mr. Deignan acquired shares of stock pursuant to the early exercise of stock options, which stock was subject to a right of repurchase in favor of us. The number of shares acquired on vesting represents the number of such shares for which our rights of repurchase lapsed during the year. |
(4) | Represents the difference between the estimated value of the shares for which our repurchase right lapsed and the exercise price of $0.07 per share paid by Mr. Deignan in respect of such shares upon the early exercise of the options. The assumed value of such shares upon vesting was $0.66 per share. |
Pension Benefits
Our named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan sponsored by us during 2013.
Nonqualified Deferred Compensation
Our named executive officers did not participate in, or otherwise receive any benefits under, any nonqualified deferred compensation plan sponsored by us during 2013.
Health and Welfare Benefits
We maintain a defined contribution employee retirement plan for our employees. Our 401(k) plan is intended to qualify as a tax-qualified plan under Section 401 of the Internal Revenue Code so that contributions to our 401(k) plan, and income earned on such contributions, are not taxable to participants until withdrawn or distributed from the 401(k) plan. Our 401(k) plan provides that each participant may contribute a portion of his or her pre-tax compensation, up to a statutory limit, which is $17,500 for 2014. Participants who are at least 50 years old can also make catch-up contributions, which in 2014 may be up to an additional $5,500 above the statutory limit. Under our 401(k) plan, each employee is fully vested in his or her deferred salary contributions. Employee contributions are held and invested by the plans trustee, subject to participants ability to give investment directions by following specified procedures. We do not currently make discretionary contributions or matching contributions to our 401(k) plan.
Except for the benefits described above under Narrative to Summary Compensation Table Other Compensation, we do not provide perquisites or personal benefits to our named executive officers. We do, however, pay the premiums for medical, dental and term life insurance for all of our employees, including our named executive officers.
Equity Incentive Plans
2014 Equity Incentive Plan
We expect that our board of directors will adopt, and our stockholders will approve, prior to the completion of this offering our 2014 Equity Incentive Plan, or our 2014 plan. We do not expect to issue equity awards under our 2014 plan until after the completion of this offering. No awards have been granted and no shares of our common stock have been issued under our 2014 plan. Our 2014 plan will provide for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code, or the Code, to our employees and our parent and subsidiary corporations employees, and for the grant of
140
nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to our employees, including officers, consultants and directors. Our 2014 plan will also provide for the grant of performance cash awards to our employees, consultants and directors.
Authorized Shares
The maximum number of shares of our common stock that may be issued under our 2014 plan is shares. The number of shares of our common stock reserved for issuance under our 2014 plan will automatically increase on January 1 of each year, for a period of 10 years, from January 1, 2015 continuing through January 1, 2024, by % of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by our board of directors. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options under the 2014 plan is .
Shares issued under our 2014 plan may be authorized but unissued or reacquired shares of our common stock. Shares subject to stock awards granted under our 2014 plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under our 2014 plan. Additionally, shares issued pursuant to stock awards under our 2014 plan that we repurchase or that are forfeited, as well as shares reacquired by us as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under our 2014 plan.
Administration
Our board of directors, or a duly authorized committee thereof, has the authority to administer our 2014 plan. Our board of directors has delegated its authority to administer our 2014 plan to our compensation committee under the terms of the compensation committees charter. Our board of directors may also delegate to one or more of our officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares of our common stock to be subject to such stock awards. Subject to the terms of our 2014 plan, the administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share of our common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under our 2014 plan.
The administrator has the power to modify outstanding awards under our 2014 plan. Subject to the terms of our 2014 plan, the administrator has the authority to reprice any outstanding option or stock appreciation right, cancel and re-grant any outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant.
Section 162(m) Limits
No participant may be granted stock awards covering more than shares of our common stock under our 2014 plan during any calendar year pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise price or strike price of at least 100% of the fair market value of our common stock on the date of grant. Additionally, no participant
141
may be granted in a calendar year a performance stock award covering more than shares of our common stock or a performance cash award having a maximum value in excess of $ under our 2014 plan. These limitations enable us to grant awards that will be exempt from the $1,000,000 limitation on the income tax deductibility of compensation paid per covered executive officer imposed by Section 162(m) of the Code.
Performance Awards
Our 2014 plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not subject to the $1,000,000 limitation on the income tax deductibility of compensation paid per covered executive officer imposed by Section 162(m) of the Code. To enable us to grant performance-based awards that will qualify, our compensation committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of specified pre-established performance goals during a designated performance period.
Corporate Transactions
Our 2014 plan provides that in the event of a specified corporate transaction, including without limitation a consolidation, merger, or similar transaction involving our company, the sale, lease or other disposition of all or substantially all of the assets of our company or the consolidated assets of our company and our subsidiaries, or a sale or disposition of at least 50% of the outstanding capital stock of our company, the administrator will determine how to treat each outstanding stock award. The administrator may:
| arrange for the assumption, continuation or substitution of a stock award by a successor corporation; |
| arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation; |
| accelerate the vesting of the stock award and provide for its termination prior to the effective time of the corporate transaction; |
| arrange for the lapse, in whole or in part, of any reacquisition or repurchase right held by us; or |
| cancel the stock award prior to the transaction in exchange for a cash payment, which may be reduced by the exercise price payable in connection with the stock award. |
The administrator is not obligated to treat all stock awards or portions of stock awards, even those that are of the same type, in the same manner. The administrator may take different actions with respect to the vested and unvested portions of a stock award.
Change in Control
The administrator may provide, in an individual award agreement or in any other written agreement between us and the participant, that the stock award will be subject to additional acceleration of vesting and exercisability in the event of a change in control. In the absence of such a provision, no such acceleration of the stock award will occur.
Plan Amendment or Termination
Our board has the authority to amend, suspend, or terminate our 2014 plan, provided that such action does not materially impair the existing rights of any participant without such participants written consent. No incentive stock options may be granted after the tenth anniversary of the date our board of directors adopts our 2014 plan.
142
2011 Stock Incentive Plan
Our board of directors adopted, and our stockholders approved, the 2011 Stock Incentive Plan, or the 2011 plan, in November 2011. Our 2011 plan was amended by our board of directors and our stockholders in December 2011. Our 2011 plan provides for the grant of incentive stock options within the meaning of Section 422 of the Code to our employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock units and other stock-based awards to our officers, directors, employees, consultants and advisers.
Authorized Shares
There are 2,240,508 shares of our common stock reserved for issuance under our 2011 plan. As of March 31, 2014, 396,354 shares of our common stock have been issued upon the exercise of options granted under our 2011 plan and options to purchase 1,657,159 shares of our common stock were outstanding at a weighted average exercise price of $0.16 per share. Effective upon the completion of this offering, no further options or stock awards may be granted under our 2011 plan, but all outstanding stock awards will continue to be governed by their existing terms.
Administration
Our board of directors, or a committee thereof appointed by our board of directors, administers our 2011 plan and the option and stock awards granted under it. Our board of directors delegated its authority to administer our 2011 plan to our compensation committee.
Corporate Transactions
Our 2011 plan provides that, in the event of a specified change of control transaction, including without limitation a dissolution, merger, consolidation or reorganization of our company with one or more other entities in which our company is not the surviving entity, a sale of substantially all of the assets of our company, or any transaction which results in the disposition of at least a majority of the voting power or value of the securities of our company, the board may take any one or more of the following actions with respect to awards other than restricted stock awards:
| the assumption or substitution of the options by a successor corporation; |
| the termination of the options immediately prior to the change of control transaction; |
| provide that the options become exercisable, realizable or derivable, or that restrictions applicable to options shall lapse; |
| the purchase of outstanding options for an amount of cash that could have been received upon the exercise of the options or the conversion of the options into a right to receive liquidation proceeds; or |
| any combination of the foregoing. |
With respect to restricted stock awards, upon the occurrence of a change of control transaction involving the liquidation or dissolution of our company, all restrictions and conditions on all restricted stock awards then outstanding shall automatically be deemed terminated or satisfied. With respect to a change of control transaction not involving the liquidation or dissolution of our company, all of our repurchase or other rights under each outstanding restricted stock award shall inure to the benefit of our successor.
143
Limitations on Liability and Indemnification Matters
Upon completion of this offering, our amended and restated certificate of incorporation will contain provisions that limit the liability of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for:
| any breach of the directors duty of loyalty to the corporation or its stockholders; |
| any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
| unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or |
| any transaction from which the director derived an improper personal benefit. |
This limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.
Our amended and restated certificate of incorporation and our amended and restated bylaws will provide that we are required to indemnify our directors to the fullest extent permitted by Delaware law. Our amended and restated bylaws will also provide that, upon satisfaction of certain conditions, we are required to advance expenses incurred by a director in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. Our amended and restated bylaws will also provide our board of directors with discretion to indemnify our officers and employees when determined appropriate by the board. We have entered into and expect to continue to enter into agreements to indemnify our directors, and we also expect to enter into agreements to indemnify our officers, as determined by the board of directors. With certain exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors. We also maintain customary directors and officers liability insurance.
The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholders investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in claims for indemnification.
144